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Abstract 
The aim of this project was to develop methods for the preparation of fluorine analogues of 
natural products. The incorporation of fluorine into bioactive organic compounds enhances 
bioactivity and the replacement of either a hydrogen atom or oxygen atom with fluorine atom 
is sterically favoured since their atomic sizes are similar. Three classes of fluorine-containing 
compounds were synthesized, i.e. prenylated benzophenones, geranylated benzophenones and 
4-phenylcoumarins. 
Prenylated benzophenones are compounds with interesting activities such as anticancer, anti-
inflammation, anti-HIV, cholesterol regulatory, cytotoxic and antimicrobial activity. 
Fluorine-containing prenylated benzophenones were prepared by an improved synthetic route 
which includes the application of Friedel-Crafts acylation and electrophilic aromatic 
substitution reactions. The analogues of benzophenones that were synthesized in this study 
include monoprenylated, diprenylated, triprenylated and tetraprenylated benzophenones with 
a fluorine substituent in either the ortho-, meta- or para-position of the benzene ring. Among 
the analogues of benzophenones synthesized were (3-fluorophenyl)[2,4,6-trihydroxy-3-(3-
methyl-2-butenyl)phenyl]methanone (monoprenylated), (3-fluorophenyl)[2,4,6-trihydroxy-
3,5-bis(3-methyl-2-butenyl)phenyl]methanone (diprenylated), (3-fluorophenyl)[2,4,6-tris(3-
methylbut-2-enyloxy)phenyl]methanone (triprenylated) and (3-fluorophenyl)[2-hydroxy-3,5-
bis(3-methylbut-2-enyl)-4,6-bis(3-methylbut-2-enyloxy)phenyl]methanone (tetraprenylated). 
Similar types of 4-fluoro analogues of benzophenones were synthesized which includes C- 
and O-prenylated benzophenones. Geranylated benzophenones were also synthesized in this 
study including monogeranylated, digeranylated, trigeranylated and tetrageranylated 
benzophenones. The prenylation reaction of a 2-fluorobenzophenone using prenyl bromide 
and DBU was not successful, but when K2CO3 was used instead of DBU, the reaction was 
successful. 
Coumarins belong to a class of phenolic compounds characterized by a benzene ring fused to 
a pyrone ring. Many coumarins exhibit biological activities such as antibacterial, anti-
inflammatory, anti-oxidant, anticoagulant, anti-tumour, hepatoprotective, anti-carcinogenic, 
anti-viral and anti-thrombotic activities. In this study, fluorinated 4-phenylcoumarins 
(fluorine-substituted neoflavones) were synthesized by the Pechmann reaction. Fluorine-
substituted 4-aryl β-ketoesters were successfully synthesized by a newly developed method 
ii | P a g e  
 
and subjected to Pechmann reactions using resorcinol and phloroglucinol as starting materials 
to form 7-hydroxyneoflavones and 5,7-dihydroxyneoflavones, respectively. 
Some of the synthesized fluorinated prenylated benzophenones and fluorinated neoflavones 
were assayed for HIV activity at a concentration of 10 µg.mL-1 but did not show any activity 
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CHAPTER 1. INTRODUCTION 
1.1 Microbes as cause of infectious diseases 
Microbes can be defined as tiny living organisms that efficiently reproduce and spread 
quickly. Microbes are too small to be seen by the naked eye which makes them difficult to 
control. They are abundant on earth and they live everywhere, in air, water, rock and soil. 
Microbes can survive harsh conditions such as living under freezing conditions, at high 
temperatures, aerobic and anaerobic conditions. Microbes belong to one of four major 
groups: 
1. Fungi, e.g. Candida albicans, which causes some yeast infections. 
2. Bacteria, e.g. Staphylococcus aureus, which causes some staph infections. 
3. Viruses, e.g. Hemophilus influenzae, which causes flu 
4. Parasites, e.g. Plasmodium falciparum, which causes malaria. 
 
Infectious diseases have been a major challenge to human survival as they remain among 
the top causes of death and disability globally.1 Infectious diseases were not known to be 
caused by microbes until the development of a better microscopic magnification by van 
Leeuwenhoek in 1670’s, who was the first to identify bacteria. Thereafter, there had been a 
number of suspicions of infectious diseases (e.g. smallpox) that could not be proven to be 
associated with microbes at that time. More than a century later, Bassi managed to prove 
that some diseases (infectious diseases) were caused by microorganisms.2 A decade later in 
1876, Koch isolated Bacillus anthracis (first bacterium isolation).2 Identification of 
infectious diseases and isolation of microbes has been ongoing. 
1.2 Antibiotics 
1.2.1  Definition of antibiotics 
Antimicrobials including antibiotics are chemical compounds that kill or inhibit the growth 
of microorganisms by different kinds of action. Antibiotics used to be defined as chemical 
compounds produced by microorganisms that have the ability to kill or inhibit the growth 
of the other microorganisms even in small concentrations.3 Hutter4 and coworkers defined 
antibiotics as the products of secondary metabolites with an incidental action on growth 
processes even in high dilution. 
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Antimicrobial agents from different chemical classes may have the same mode of action, 
e.g. penicillin and cephalosporin both inhibit the synthesis of bacterial cell wall. 
Antimicrobials can affect the metabolism, RNA, DNA; can affect respiratory electron 
transport chain and thus depriving the cell of the energy currency (ATP); can inhibit the 
cell wall synthesis and cell membrane synthesis, thus affect its permeability. In this 
research, however, antimicrobials are classified on the basis of their chemical structure as 
well as their bioactivities.3 
Due to the steady increase in the rate of bacterial drug-resistance and the lack of new 
effective antimicrobial drugs appearing from pharmaceutical development worldwide,5 
there is a need to identify new targets for antimicrobial action and strategies to overcome 
antimicrobial resistance. 
1.2.2 Discovery of antibiotics 
Since the discovery of antimicrobial agents, there has been a substantial reduction in the 
threat posed by infectious diseases. The history of antibiotic agents started in 1907, when 
Ehrlich successfully developed the first example of a purely synthetic antimicrobial drug, 
the “magic bullet”, Salvarsan (1.1) (Figure 1.1), an arsenic containing drug.6 Although it 
was not active against a wide range of bacterial infections, it did show activity against the 
protozoal disease sleeping sickness, and the spirochaete disease of syphilis. The drug was 
used until 1945 when penicillin came into the market. In 1928, Alexander Fleming 
discovered the effect of penicillin (1.2) as an antimicrobial agent from fungus Penicillium 
notatum, but it was not known that it could be used as a therapeutic agent. Penicillin was 
not used as a therapeutic agent until 1940s, when Florey and Chain managed to isolate 
penicillin under mild conditions and was used to treat bacterial infections during the 
Second World War.7 While Fleming was working on penicillin in the 1930s, Gerhard 
Domagk, a German doctor, publicized the discovery of a synthetic sulfur-containing 
compound (Prontosil) with antibacterial properties. Prontosil (1.3) is a member of the 
sulfonamides or sulfa drugs and is the first of a long series of synthetic antibiotics.8 
Prontosil was used to combat urinary tract infections, pneumonia and other conditions. 
Sulfa drugs are now used as effective antibiotics for the treatment of a wide range of 
infectious conditions. 
 

























Figure 1.1: Structure of salvarsan, penicillin and prontosil. 
 
The discovery of penicillin drew attention to nature as a source of biologically active 
agents. As a result, microorganisms were investigated as a source of useful pharmaceutical 
compounds. Many new antibiotics were then discovered, including sulfonamides, β-
lactams, aminoglycosides, chloramphenicol, cephalosporins, tetracyclines, macrolides, 
lincosamides, streptogramins, glycopeptides, rifamycin, nitroimidazole, quinolone and 
trimethoprim (1968) (Table 1.1).9 More than thirty years later, oxazolidinones, 
lipopeptides and glycylcylinones were introduced. The search for new and more effective 
antimicrobials has been successful since the discovery of penicillin and more than 350 
antimicrobial drugs have reached the market. 
Table 1.1: History of antibacterial drug introduction and approval. 
 
Year Introduced     Class of Drugs 
1935                         Sulfonamides 
1941                         β-Lactams 
1944                         Aminoglycosides 
1949                         Chloramphenicol 
1950                         Tetracyclines  
1952                         Macrolides, Lincosamides, Streptogramins 
1956                         Glycopepdides 
1957                         Rifamycins 
1959                         Nitromidiazoles 
1962                         Quinolones 
1968                         Trimethoprim 
2000                         Oxazolidinones 
2003                         Lipopeptides 
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1.3 Resistance to antimicrobial agents 
The battle of treating microbial infections has been increasingly complicated by the ability 
of microbes to develop resistance to the existing antimicrobial drugs. The development of 
resistance to antimicrobial drugs starts almost as soon as the drug is deployed. 
Antimicrobial agent resistance is the ability for microbes to grow in the presence of the 
drug that would normally kill or inhibit their growth. Ever since antimicrobial resistance 
emerged, there has been pressure to develop more antimicrobial drugs with a broad 
spectrum of activity, high level of efficacy, and that are environmentally friendly.10 
 
The emergence of antimicrobial drug resistance is as a result of both natural causes and 
societal pressure. Resistance due to natural causes arises from random genetic mutation 
that microbes can undergo. The societal pressure is associated with both overuse and 
misuse of antimicrobial drugs in both human medicine and agriculture. This can be due to 
the lack of instruction, carelessness or ignorance of humans. Due to these factors, the 
number of infections by the bacteria that are resistant to at least one of the drugs that are 
commonly used for treatment has gone up to about 70%. It is also documented that some 
of these microbes are resistant to all recommended antimicrobial drugs and can only be 
treated with potentially toxic drugs.11 
1.3.1 Mechanisms of antibacterial agent resistance 
Bacteria may develop resistance to antibacterial agents through a variety of mechanisms. 
Antibiotic resistance occurs when a microorganism’s cellular physiology and the structure 
of the microorganism changes due to alterations in its usual genetic makeup leading to the 
protection of the bacteria from the action of an antibiotic drug, and the mechanism is called 
microbial resistance.12,13 There are four main ways in which microorganisms may acquire 
the ability to resist the effect of antimicrobial agents (Figure 1.2): 
 Extrusion of the antibiotic agent (active efflux) before it can damage the 
microorganism. 
 Alteration in the drug target for antibiotic action: mutations in the target, 
production of alternative targets or protection of the target, thus leading to the 
ineffectiveness of the drug. 
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 Inactivation of the antibiotic drug. This is where the microorganism produces drug-
inactivating enzymes that chemically modify the drug and make it ineffective. 
 Changed access: alteration in the bacterial outer membrane, making it hard for a 
drug to bind to the exterior of the microorganism. 
Microbes have increased their resistant ability to antimicrobials to an extent that they may 
acquire more than one resistant mechanism for one class of antibiotics (Table 1.2). For 
example, sulfonamides and trimethoprim may either bypass their metabolic inhibition-
reaction or be made insufficient for their target sites due to the overproduction of antibiotic 
target sites by microbes. 
 
Figure 1.2: Mechanisms of antibiotic resistance in bacteria.14 
 
Generally bacteria are frequently referred to as being resistant to antibiotics, but the 
biochemical meaning of resistance is rarely considered. Even the bacteria that are referred 
to be the most resistant can be killed by sufficiently high concentration of antibiotics. 
However, high doses of antibiotics cannot always be used because it may exceed the level 
that the human body can tolerate. For example, most strains of Streptococcus pneumonia 
are inhibited by a minimum concentration of 0.01 mg/L of benzylpenicillin which the body 
can manage, whereas for Escherichia coli a minimum of 60 mg/L is required, which 
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exceeds the level the human body can tolerate. This resistance is called ‘clinical 
resistance’.15 
Microorganisms may develop resistance to a certain antimicrobial drug as soon as it is 
applied. This can be due to the above-mentioned mechanisms resulting from genetic 
mutations, the acquisition of resistance genes from the other microorganisms via gene 
transfer or the combination of both phenomena. Antimicrobial resistance in bacteria may 
be an inherent trait of an organism that renders it naturally resistant or be acquired by 
means of mutation in its own DNA or acquisition of resistance-conferring DNA from 
another source.12 
Table 1.2: Some modes of resistance to some antibiotics.14 
 
Antibiotic Mode of resistance 
 
 
Chloramphenicol Reduced uptake into cell 
 
 





Eliminates or reduces binding of antibiotic to 




Enzymatic cleavage or modification to 
inactivate antibiotic molecule  
 
Sulfonamides, Trimethoprim Metabolic bypass of inhibited reaction 
 
 
Sulfonamides, Trimethoprim Overproduction of antibiotic target (titration) 
   
Resistance of some bacteria to antibiotics may be inherent. For example, bacteria may lack 
the target site for the antibacterial molecule or a transportation system for antibacterial 
drug for an active efflux mechanism which is inherited for generations. Gram-negative 
bacteria have cell wall that is covered with an outer membrane that establishes a 
permeability barrier against some antimicrobial drugs.16 
Mutational resistance is a spontaneous event that occurs regardless of whether an 
antimicrobial is present or not. Mutational resistance in bacteria occurs when a strain 
changes its DNA bases, which leads to the change in RNA and in turn to the change in the 
proteins produced. Chromosomal mutations can lead to a change in cell proteins that is 
responsible for the structure of the site of action of the antimicrobial.12 A bacterium 
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acquiring such a mutation is at a huge advantage as it withstands the antimicrobials while 
the susceptible cells are being killed. 
The strive to develop new antibiotics has never stops due to the ability of microbes to 
develop resistance to existing antibiotics.17 
1.4 Fluorine in pharmaceuticals 
Halogen-containing compounds are limited in nature, especially fluorinated natural 
products. However, the introduction of fluorine into a biologically active compound 
imparts a variety of properties such as enhanced binding interaction, metabolic stability, 
reaction selectivity and changes in physical and chemical properties. No fluorine-
containing drug had been developed before 1957. Since then, over 150 fluorine-containing 
drugs have come onto the market, accounting for about 20% of all pharmaceuticals.18 The 
increasing prevalence and success of fluorine-containing pharmaceuticals has stimulated 
further interest into the synthesis of such compounds. There is a limited number of 
fluorination methods available. This is because of the dangers of using fluorine gas usually 
associated with these chemical reactions.19 
It has been reported that fluorinated pharmaceuticals are among  the top-selling drugs on 
the market and these include Prozac® (anti-depressant drug), Lipitor® (cholesterol-
lowering drug), Ciprobay® (antibacterial drug) and Xeloda® (anti-cancer agent) as shown 
in figure 1.3.19 It was further reported that the introduction of fluorine or fluoroalkyl 
groups into these compounds had improved their binding affinity and the inhibitory ability. 
Kirk et al.20 and Hagmann21 reviewed the different ways of incorporating fluorine and/or 
fluoroalkyl groups into organic molecules. 
 





































R R  
Figure 1.3: Some examples of top-selling fluorinated pharmaceuticals. 
 
Due to the shortage of drugs on the market, it is crucial that new biologically active 
compounds including fluorinated ones are developed. An overview of fluorine in organic 
compounds will be given in Chapter 2. 
1.5  Prenylated/geranylated benzophenones 
Prenylated benzophenones and geranylated benzophenones are natural products with 
interesting biological activities. Those activities include anticancer, anti-HIV, cholesterol 
regulatory, cytotoxic, anti-inflammatory and antimicrobial activity. The benzophenone 
class (Figure 1.4) is one of the big classes of organic compounds and often serve as 
precursors for synthesis. In this context, the focus will be on the prenylated and 
geranylated benzophenones which are naturally occurring and have been reported from 
various plant species.22, 23 
O
Benzophenone  
Figure 1.4: General structure of benzophenone. 
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Among prenylated benzophenones, the position or/and the number of the prenyl groups 
may affect the biological activity of the compounds. Some details about prenylated 
benzophenones will be covered in Chapter 3. 
1.6  Coumarins 
Coumarins constitute an important class of naturally occurring compounds. The first 
coumarin was isolated from the tonka bean (Dipteryx odorata) by Vogel and Guibourt in 
1820. To date, more than 1300 coumarins have been identified from natural sources.22,24 
Many more have been synthesized via numerous methods including the Pechmann 
condensation,25 Perkin reaction,26 Knoevenagel condensation,27 Reformatsky reaction,28 
Wittig reaction29 and Baylis-Hillman reaction.30 In addition, coumarins have been reported 
to possess antibacterial,31 anti-inflammatory,32 anti-oxidant,33 anticoagulant34, anti-tumor35, 
hepatoprotective, anti-carcinogenic, anti-viral and anti-thrombotic activities.36 
O O
Coumarin  
Figure 1.5: General structure of coumarin. 
 
Coumarins are characterized by a benzene ring fused with a pyrone ring as shown in figure 
1.5 and are structurally diverse and can be roughly classified into five major groups 
depending on the position of the substituent/s (explained in Chapter 4). The type and 
position of the substituent/s in the coumarin structure have huge impact on the biological 
activities, physical and chemical properties. 
1.7 Aims of the project 
Our research group specializes in Natural Product Chemistry. In one of the projects on 
phytochemistry of South African Hypericum species, bioactive prenylated benzophenones 
and pyrones have been isolated.37 Incorporating fluorine into these structures might change 
the activities of the compounds. 
In this research, the aim was to develop methods to prepare fluorine-containing prenylated 
benzophenones and 4-phenylcoumarins (Figure 1.6). Although some prenylated and 
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geranylated benzophenones have been synthesized in the laboratory, none of them contain 
fluorine.  
The main objectives of this investigation were: 
 To develop methods for the synthesis of fluorine-containing analogues of 
prenylated and geranylated benzophenones. 
 To improve the methods for synthesizing fluorinated 4-phenylcoumarins. 































Figure 1.6: Compounds proposed to be synthesized. 
 
1.8 Structure of this Thesis 
This thesis consists of five chapters including this chapter, Chapter 1 (introductory 
chapter). Chapter 2 explores the nature of fluorine and its effect on organic molecules. 
Chapter 3 examines the synthesis of fluorinated prenylated benzophenones. It also reviews 
bioactive prenylated benzophenones and their synthesis. Chapter 4 covers the synthesis of 
4-phenylcoumarins. This chapter also reviews the biological activities of 4-
phenylcoumarins as well as the synthetic methods that have been used to synthesize 4-
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CHAPTER 2.    AN OVERVIEW OF FLUORINE IN ORGANIC 
COMPOUNDS 
2.1 Background on fluorine and fluorinated compounds 
Many of the current pharmaceuticals on the international market are fluorinated 
compounds. Fluorine is the 13th most abundant element in earth’s crust. South Africa is the 
third largest producer of fluorspar (CaF2, the mineral that is the main source of fluorine) in 
the world. Elemental fluorine was first isolated by Moissan in 1886 and is an extremely 
dangerous yellow-green gas.20 Fluorine is the most electronegative element in the periodic 
table leading to high polarization of the C–F covalent bond which results in the shortening 
of the bond length and an increase in the bond strength, as shown in Table 2.1. Replacing 
hydrogen with fluorine in organic molecules has a small steric effect since their van der 
Waals radii are not too different (Table 2.1).38 In a C-F bond, the fluorine atom has three 
lone pairs, which are electrostatically held tightly to the nucleus and, therefore, are non-
reactive. 
Table 2.1: Properties of some selected elements and when bonded to carbon.39, 40 
 H F O N C Cl Br 
Van der Waals radius 
(Å) 
1.20 1.47 1.52 1.55 1.70 1.75 1.85 
Pauling 
electronegativity 
2.1 4.0 3.5 3.0 2.5 3.2 2.8 
Length of single bond 
to carbon (Å) 
1.09 1.40 1.43 1.47 1.52 1.77 1.97 
Strength of bond to 
carbon (kcal.mol-1) 
98 105 84 70 83 77 66 
 
The electron pull by fluorine in a C-F bond of an organic compound has a large electronic 
effect on the neighbouring atoms. For example, the electron-withdrawing ability of 
fluorine increases the acidity of organic acids as shown by the pKa values in Table 2.2. The 
substitution of the first hydrogen with fluorine changes the pKa value by 2.2, for the 
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second and the third substitution the change in the pKa values is 1.4 and 1.0, respectively. 
The pKa values for the chlorinated analogues indicate that the pulling effect of chlorine is 
less pronounced than that of fluorine.41 
Table 2.2: Acidity of acetic acid and its fluorinated and chlorinated analogues.41 









The incorporation of a fluorine atom into a molecule enhances the acidity of the hydrogens 
bonded to the same carbon as fluorine. The nature of the highly polarized C-F bond results 
in the presence of a low-energy σ* antibonding orbital located behind the carbon atom in 
the plane of C-F bond. This vacant σ* antibonding orbital can accept the electron density 
from the neighboring σ-bonds, π-bonds or lone pairs (hyperconjugation effect). This effect 
increases the acidity of the protons on the adjacent carbons.39, 42 
2.2 Naturally occurring fluoroorganic compounds 
More than 4000 halogenated natural products have been isolated but less than 1% of these 
are fluorinated natural products. The rarity of the naturally occurring fluoroorganic 
compounds is in contrast to the high abundance of fluorine in the earth’s crust.43 The main 
reason for this phenomenon is that fluorine exists predominantly in insoluble forms such as 
calcium fluorspar (CaF2), cryolite (Na3AlF6) and fluorapatite [Ca5(PO4)3F], which hinder 
the uptake of this element by bioorganisms.20 Fluorine has a very high redox potential and 
its ionic form is highly hydrated, making it a very poor nucleophile and therefore inhibits 
C–F bond formation in nature.44 
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To the best of my knowledge, only 30 naturally occurring fluoroorganic compounds have 
been identified. Fluoroacetic acid (2.1) was the first naturally occurring fluoroorganic 
compound to be isolated (Figure 2.1). It was first extracted in 1943 by Marais from the 
South African “gifblaar shrub” (Dichapetalum cymosum),45 a plant that is known to be 
highly toxic to cattle and sheep in South Africa.46 Fluoroacetic acid can be a good mimic 
of acetic acid which has a crucial role in the Krebs cycle (cellular metabolism). 
Fluoroacetate combines with coenzyme A (CoA) to form fluoroacetyl-CoA which reacts 
with citrate synthase to form fluorocitrate. Fluorocitrate binds irreversibly to aconitase, 
thus halting the Krebs cycle which results in the accumulation of citrate in the blood, 
thereby depriving the cells of energy.47 
The antibiotic nucleocidin (2.2) was first isolated in 1957 from the bacterial culture 
Streptomyces calvus.48 The structure of 2.2 was elucidated in 1968 and was confirmed by 
total synthesis.49 Fluorothreonine (2.3) is an amino acid derivative that was isolated from 
Streptomyces cattleya in 1986. This bacterium also produces fluoroacetate and the 
antibiotic thienamycin.50 5-Fluorouracil analogue 2.4 was extracted from a marine sponge 
Phakellia fusca by a Chinese research group in 2003 and it was found to be active against 
cancer cells. 10-Fluorodecanoic acid (2.5), 18-fluorooleic acid (2.6) and several other 
fluorinated fatty acids were extracted from the seeds of the Sierra Leone shrub 





































Figure 2.1: Some examples of naturally occurring fluoroorganic compounds. 
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2.3 Fluorination of organic compounds 
Synthetic methods in fluoroorganic chemistry have made massive progress since Borodin 
reported the first synthesis of a fluoroorganic compound in 186353 and Swarts published 
the fluorination of polychloroalkenes in 1892 using mercury fluoride, zinc fluoride or 
antimony trifluoride.54 The scope of fluorination reactions with elemental fluorine started 
to expand in 1960s when elemental fluorine was diluted with inert gases such as argon or 
nitrogen and the process was commercialized.55 Fluorination of uracil (2.7) using 
elemental fluorine in an inert gas to form 5-fluorouracil (2.8) is one of the earliest 
examples of the use of F2:N2 gas mixture (Scheme 2.1). Another typical example is 





































Scheme 2.1: Synthesis of 5-fluorouracil (2.8)56 and α-fluoroketone steroid (2.10).57 
 
2.3.1 Electrophilic fluorination of organic compounds 
The success of fluorination with elemental fluorine resulted in the development of 
electrophilic fluorination, in which a nucleophile attacks electrophilic fluorine of the 
fluorinating agent.55 Fluoroxytrifluoromethane is one of the early reagents and was 
developed by Barton in 1968 in his research on fluorination of biologically active 
compounds such as steroids,58 as illustrated in Scheme 2.2 (CF3OF was used to fluorinate 
2.11 to form α-fluorocholestane 2.12). Acetyl hypofluorite (CH3COOF) was developed by 
Rozen in 198159 and has been used in many fluorination reactions such as the fluorination 
of lithium enolates60 (Scheme 2.2) and aromatic fluorination. The success of this reagent in 
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electrophilic fluorination resulted in the introduction of other electrophilic fluorinating 
agents such as xenon difluoride, perchloryl fluoride and many more, but most of these are 


















Scheme 2.2: Examples of O-F electrophilic fluorination reactions. 
 
Subsequently, electrophilic fluorinating reagents that are relatively stable and convenient 
to handle have been developed and are now commercially available (Figure 2.2). Those 
reagents containing a N-F moiety such as N-fluoropyridinium triflate (2.13) were 
developed by Umemoto,61,62 N-fluorobenzenesulfonimide (NFSI) (2.14) were developed 
by Differding,63 Selectfluor® or F-TEDA-BF4 (2.15) were synthesized by Banks and co-
workers,64 and many more. There have been extensive developments on these fluorinating 
agents such as an increase in their fluorinating ability, selectivity and stability. That is 
achieved by varying the substituents of the structure, e.g. the fluorinating ability of 2.13 
increases with a decrease in electron density at the N+-F site, which is accomplished by 



















Figure 2.2: Examples of N-F electrophilic fluorinating agents. 
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These fluorinating reagents have become very popular with various applications, including 
fluorination of aromatic rings, carbon-metal bonds, steroids, carbanions, nucleosides, enol 
esters and other related substrates. For example, fluorination of the enol Corey lactone 
prostaglandin intermediate 2.16 with an activated analogue of 2.13 yielded 2.17 (Scheme 
2.3).20 Methodologies for introduction of fluorine have improved to a stage where 
enantioselective fluorination is possible. These fluorinating reagents have been modified to 
react under mild conditions to minimize loss of chirality. The first enantioselective reaction 
of Selectfluor® was reported by Togni, the reaction of β-keto ester 2.18 in the presence of 
2.15 and transition metal catalyst to yield 2.19.65, 66 NFSI (2.14) has recently been reported 







































Scheme 2.3: Examples of N-F electrophilic fluorination reactions. 
 
2.3.2 Nucleophilic fluorination of organic compounds 
Fluorination of organic compounds does not rely only on electrophilic fluorination but can 
also be done by nucleophilic fluorination. Fluoride is regarded as a poor nucleophile since 
it strongly solvates in protic solvents and forms tight ion pairs in most aprotic solvents. 
Hydrogen fluoride (HF) is one of the nucleophilic fluorinating agents that have been 
widely used in organofluorination. However, HF is corrosive and highly reactive, and thus 
hard to handle and has poor selectivity. These problems were overcome by the introduction 
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of amines, e.g. pyridiniumpoly(hydrogen fluoride) (PPHF), which generally reduces the 
nucleophilicity. An example of the application of PPHF is the opening of an epoxide ring 














Figure 2.3: Examples of nucleophilic fluorinating agents. 
 
Until the 1970s, the fluorinating agents used were extremely reactive which limited the 
widespread use of organofluorination in ordinary laboratory equipment. In 1975 Middleton 
reported the first preparation of diethylaminosulfur trifluoride (DAST) which has been 
proven to be a valuable versatile fluorinating reagent.69 This breakthrough led to the 
introduction of other fluorinating reagents that are selective, stable and compatible with 
laboratory equipment. Among those reagents was bis(2-methoxyethyl)aminosulfur 
trifluoride (Deoxofluor®) which was reported by Lat in the late 1990s.70,71 These reagents 
are commercially available and are reported to fluorinate organic compounds such as 
ketones, aldehydes and alcohols selectively.19 DAST and Deoxofluor® react with ketones 
to form difluoroalkyl compounds (2.23 and 2.24) as illustrated in Scheme 2.4.72 The 
development of these user-friendly fluorinating reagents (electrophilic and nucleophilic) 























Scheme 2.4: Examples of N-F electrophilic fluorination reactions. 
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2.4 Fluorine-containing drugs 
Incorporation of fluorine into bioactive organocompounds has a profound impact on 
improving the biological activities. The journey of developing fluorine-containing drugs 
started in 1954 when Fried and Sabo reported the improvement of the therapeutic index of 
cortisol (an anti-inflammatory drug) by the incorporation of fluorine in the 9α position 
(Figure 2.4).73 Since then, more than 150 fluorinated drugs have come onto the market and 
those compounds constitute 20% of all drugs on the market.21 Of the top 30 best-selling 







Figure 2.4: The first fluorinated pharmaceutical developed. 
 
2.4.1 Best-selling fluorinated pharmaceutical products 
Fluorine-containing drugs are among the best selling drugs in the pharmaceutical industry 
(Figure 2.5). Among all pharmaceutical products on the market worldwide, Lipitor® has 
the biggest sales. It holds the most prominent position in the blockbuster league with sales 
of more than 5.9 billion dollars in 2011.74 Lipitor® (Atorvastatin) belongs to the ‘statin’ 
class of drugs and is prescribed to lower the amount of biosynthetic cholesterol. Advair 
Discus® (also called fluticasone propionate) is an anti-inflammatory steroidal drug used to 
treat various conditions (inflammation associated with psoriasis and dermatosis), 
depending on how it is administered.75 It is at fourth position relative to all 
pharmaceuticals and the second relative to the fluorinated drugs with sales of 3.6 billion 
dollars per year. Prevacid® (lansoprazole) is currently at the fifth position relative to all 
pharmaceuticals and the third relative to the fluorinated drugs with 3.3 billion dollars per 
year. It is the most successful drug in the class of antacids.76 Lexapro® (Escitaloppram, 
Cipralex) is the most important drug for treating anxiety and depression.77 This drug is 
currently sitting at position 11 of all drugs and fourth relative to fluorinated drugs with 2.4 
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billion dollars sales. The fifth drug in the fluorinated drug’s league is Crestor® 










































Figure 2.5: The top 5 of the best-selling fluorinated pharmaceutical in USA in 2011. 
 
2.4.2  Some fluorinated drugs 
2.4.2.1 Cholesterol regulators 
There are numerous cholesterol-lowering drugs that have reached the market. Some of 
them are fluorine-containing compounds such as Lipitor® (2.25) and Lescol® (2.26) 
(Figure 2.6). Both Lipitor® and Lescol® belong to the drug class known as statins and they 
lower the level of cholesterol in the blood which prevents hypercholesterolemia and related 
diseases. These cholesterol lowering agents act through the inhibition of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme found in liver tissues that 
are responsible for the production of cholesterol in the body.79, 80 
 















Figure 2.6: Chemical structure of Lipitor® (2.25) and Lescol® (2.26). 
 
2.4.2.2 Anticancer agents 
Cancer has always been a major public health problem in both developed and developing 
countries.81 Galocitabine® (2.27) and Gemcitabine® (2.28) are among the top anticancer 
drugs that are in the market (Figure 2.7).20 These drugs bind to the ribonucleotide 
reductase (RNR) and inactivate this RNR irreversibly.82 This enzyme is responsible for the 
























Figure 2.7: Chemical structure of Galocitabine® (2.27) and Gemcitabine® (2.28). 
 
2.4.2.3 Antimicrobial agents (DNA inhibitors)  
Quinolones are among the most important drugs in the anti-infective chemotherapy field. 
A variety of quinolone derivatives have been introduced into the market since 1962 and 
each derivative has its own biological activity,83 which resulted in a significant 
improvement in antimicrobial activity and spectrum. The introduction of norfloxacin, 
fluoroquinolones resulted in a drastic change in the landscape of antibacterial 
chemotherapy.84 Although fluoroquinolones are reported to have clinically important 
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activity against Gram-positive bacterial pathogens, their activity is relatively moderate. In 
addition, due to the extensive use of fluoroquinolones, some pathogens became resistant. 
Due to this resistance phenomenon, new quinolones to enhance the antibacterial activity of 
this class, including gatifloxacin (2.29), gemifloxacin (2.30), sitafloxacin (2.31), 











































2.32 2.33  
Figure 2.8: Examples of fluorinated quinolones with antimicrobial activities. 
 
The target of quinolones in microbial cells are the bacterial topoisomerase IV and DNA 
gyrase, enzymes responsible for regulation of super coiling and decatenation of bacteria 
DNA.86 Before the introduction of quinolones, there were other compounds used in 
chemotherapy such as nalidixic acid with similar activity but they had a limited activity 
and poor systemic distribution, and were used mainly for Gram-negative urinary tract 
infections. Fluoroquinolones (norfloxacin, ciprofloxacin and ofloxacin) were introduced as 
a next generation of quinolones with an enhanced activity against Gram-negative bacteria 
which actively act on DNA topoisomerase. Moxifloxacin and levofloxacin are new 
fluoroquinolones with highly improved activity against many Gram-positive and Gram-
negative bacteria. Since levofloxacin and moxifloxacin are effective against chlamydia, 
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legionella and mycoplasma are therefore used for treatment of atypical pneumonia. 
Ciprofloxacin is widely used mainly for upper tract urinary infections and exacerbations of 
chronic bronchitis, both in hospital and ambulatory settings. 
2.5 Summary 
This review clearly shows that the incorporation of fluorine into bioactive organic 
compounds enhances bioactivity. This is due to the special nature of fluorine which 
imparts a variety of properties to certain medicines such as the enhancement of binding 
interactions, metabolic stability and selectivity, thus increase their bioactivities. It is also 
shown that the replacement of either a hydrogen atom or oxygen atom with fluorine atom 
is sterically favored since their atomic sizes are similar. Natural products have always been 
a good source for bioactive compounds. This study aims to synthesize a library of 
compounds consisting of fluorinated natural products therapy combining the potential for 
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CHAPTER 3. PRENYLATED BENZOPHENONES 
3.1  Introduction 
Benzophenones form a big class of organic compounds. The benzophenone structure is 
characterized by two benzene rings linked by a carbonyl carbon (Figure 3.1). Each ring 
may have different substituents and that gives the uniqueness to each compound. This 
study will narrow its focus to prenylated benzophenones. 
Prenylated benzophenones are mostly naturally occurring compounds and have shown 
interesting biological activities. Although these compounds have been synthesized 
previously, fluorine-containing prenylated benzophenones have not been reported. This 
study aims to develop methods for the synthesis of fluorine-containing prenylated 
benzophenones. In the next two Sections the biological activities and synthesis of 
prenylated benzophenones are reviewed. The results obtained in our synthesis of fluorine-
containing prenylated benzophenones are discussed in Section 3.4 and the last Section 





Figure 3.1: General structure of substituted benzophenone. 
 
3.2 Bioactive prenylated/geranylated benzophenones 
Prenylated benzophenones and geranylated benzophenones are a group of compounds that 
have various biological activities such as anticancer, anti-inflammation, anti-HIV, 
cholesterol regulatory, cytotoxic and antimicrobial activity.37 Most prenylated and 
geranylated benzophenones that are reported in the literature were isolated from plants. 
3.2.1 Anticancer activity 
Cancer has always been a major public health problem in both developed and developing 
countries and it remains among the leading causes of death worldwide.81 There are 
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anticancer agents that are on the market such as galocitabine®,20 but the death rate caused 
by cancer has been increasing. In 2012 alone, more than 8 million deaths due to cancer 
were reported and the most common causes of cancers are liver, lung, colorectal, stomach 
and breast cancers.87  
Natural products have been the most successful leads for the development of new 
chemotherapeutic agents.88 Among the prenylated compounds that have the potential for 
treating cancer are garciniaphenone (3.1) and 7-epiclusianone (3.2), isolated from the fruits 







3.1 3.2  
Figure 3.2: Chemical structure of garciniaphenone (3.1) and 7-epiclusianone (3.2). 
 
These prenylated benzophenones showed antiproliferative activity on human cancer cells, 
including the drug-resistant breast (NCI-ADR), kidney (786-0), melanoma (UACC-62), 
lung/non-small cells (NCI460), ovarian (OVCAR 03), prostate (PC03), breast (MCF-7), 
lung (NCI-460) and tongue (CRL-1624 and CRL-1623) cancer cells. Both garciniaphenone 
(3.1) and 7-epiclusianone (3.2) have shown a multiple proliferation inhibitory effects in 
vitro.89 
3.2.2 Anti-inflammatory activity 
Steroidal and non-steroidal anti-inflammatory drugs are well known and commonly used 
drugs for reducing or eliminating pain and many of these drugs such as glucocorticoids 
alleviate inflammation by binding to glucocorticoid receptors.90 Non-steroidal anti-
inflammatory drugs (NSAIDs) reduce pain by preventing the synthesis of prostaglandins 
which create inflammation. NSAIDs counteract the cyclooxygenase (COX) enzyme 
stopping it from synthesizing prostaglandins. NSAIDs containing a carboxy group in their 
chemical structures such as salicylic acid and aspirin® are reported to inhibit both COX-1 
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and COX-2 non-selectively.91 These drugs are also known to have analgesic and 
antipyretic (fever-reducing) activities. 
Prenylated benzophenone derivatives have shown anti-inflammation activity.92 
Guttiferones O (3.3) and P (3.4) were isolated from Garcinia solomonensis and are 
inhibitors of mitogen-activated protein kinase-2 (MAPKAPK-2) (Figure 3.3). This enzyme 
(MAPKAPK-2) is a member of the MAPK family of protein kinases, which is 
phosphorylated and activated by p38 in retort to stress, cytokines and chemotactic factors. 
This activity is known to play an important role in regulating cellular activities such as 
gene expression, differentiation, mitosis and cell survival, which could be useful in the 














Figure 3.3: Chemical structure of guttiferones O (3.3) and P (3.4).23 
 
3.2.3 Cholesterol regulator 
The liver has X-receptors which are powerful tools in the human body to regulate 
cholesterol. Liver X receptors (LXR) are members of a superfamily of nuclear hormone 
receptors and are implicated in cholesterol homeostasis.94,95 Oxysterols have been 
identified as endogenous ligands for these receptors.96-98 Liver X receptors chelate with the 
retinoid X receptors (RXRs) to form heterodimers, to regulate the quantity of genes 
involved in cholesterol and fatty acid metabolism.99 
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There are cholesterol-lowering drugs that have reached the market. One of them is a 
fluorinated compound, Lipitor®. As a result of the demand of the cholesterol-lowering 
drugs on the market, a number of potential cholesterol-lowering prenylated compounds 
have been reported, such as guttiferone I (3.5). This polyprenylated benzophenone 3.5 was 









Figure 3.4: Chemical structure of guttiferone I. 
 
3.2.4 Anti-HIV activity 
It has been 30 years since the establishment of the human immunodeficiency virus (HIV) 
as the causative agent of the acquired immunodeficiency syndrome (AIDS).101, 102 Millions 
of deaths caused by AIDS are reported annually which pose an ongoing threat to humans. 
Despite the impressive research on AIDS worldwide, the fight is not yet over because no 
drug has thus far been discovered which can cure the AIDS disease completely. However, 
there are drugs that inhibit human immunodeficiency virus (anti-HIV drugs) on the market. 
3'-Azido-3'-deoxythymidine (AZT)103 was the first anti-HIV drug approved by the Food 
and Drug Administration (FDA) and is still the most useful therapeutic agent.104,105 There 
are other important anti-HIV drugs that are used especially in cases of AZT-resistance such 
as zalcitabine, didanosine and stavudine.106,107,108 
Natural products that have shown anti-HIV activity include the prenylated benzophenones, 
guttiferones A-E which were isolated from three different genera, Garcinia, Symphonia 
and Clusia.109 Polyprenylated benzophenones, guttiferone F (3.6) isolated from 
Allanblackia stuhlmannii110 and vismiaphenone D (3.7) extracted from Vismia 
cayennensis,111 were reported to exhibit anti-HIV activity (Figure 3.5). 
 














Figure 3.5: Chemical structure of guttiferone F (3.6) and vismiaphenone D (3.7). 
 
3.2.5 Antimicrobial and cytotoxic activity 
Microbial organisms pose a huge threat to human beings, and have led to the deaths of 
millions of people. As a result, a number of antimicrobial drugs have been discovered, for 
example imipenem and penicillin. Both imipenem and penicillin belong to the β-lactam 
class of antimicrobial agents, which are widely used because of their high effectiveness, 
minimal side effects, low cost and easy delivery.  
Ever since antimicrobial agents were discovered, there has been an ongoing effort to 
develop more drugs with a broad spectrum antimicrobial activity, high level of efficacy, 
and that are environmentally friendly. In addition, micro-organisms develop resistance 
since they mutate rapidly and so the antimicrobials that are currently in use often have to 
be replaced. Prenylated benzophenones such as 3-geranyl-2,4,6-trihydroxybenzophenone 
(3.8) and 4-geranyloxy-2,6-dihydroxybenzophenone (3.9) have potential for the treatment 
of microbial infections (Figure 3.6). Compound 3.9 was isolated from the ethanol extract 
of Tovomita longifolia112 and has shown antimicrobial and cytotoxic activity.113 Compound 
3.8 was isolated from the chloroform extract of the same plant, but was also extracted from 
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From the short review above it is clear that many prenylated/geranylated benzophenones 
exhibit biological activities. 
3.3 A brief review of the synthesis of prenylated/geranylated 
benzophenones 
Most of the prenylated benzophenones reported in the literature have been isolated from 
plants and limited synthetic routes towards the synthesis of these compounds have been 
reported in the literature. Amongst the few synthetic routes found in the literature, the key 
reactions include acylation, C-prenylation and O-prenylation reactions. The most popular 
acylation is the Friedel-Crafts acylation reaction. In this project, the Friedel-Crafts reaction 
was applied to synthesize benzophenones. However, there are other reactions routes to 
prepare benzophenones reported in the literature. These reactions have been conducted 
under different conditions including different catalysts and solvents and some examples of 
these reactions are shown in detail below. In the subsequent Sections Friedel-Crafts 
acylation reactions, C- and O-prenylation reactions and the synthesis of prenylated 
acylphloroglucinols are reviewed. 
3.3.1  General methods to synthesize benzophenones 
Benzophenones are important intermediates for the preparation of fine chemicals such as 
agrochemicals, pharmaceuticals and fragrances. This Section will show different synthetic 
routes (that do not involve Friedel-Crafts acylation) to synthesize benzophenones. One of 
these synthetic routes is the formal [3+3] cyclization of 1,3-bis(silyl enol ether) 3.10 with 
2-methyl-1,1,3,3-tetraethoxypropane (3.11) to form 5-methyl-2-hydroxy benzophenone 
(3.12) as reported by Langer et al.116 They firstly synthesized 3.11 by a three-step reaction 
from propanal as shown in Scheme 3.1. The TiCl4-mediated condensation of bis(acetal) 
3.11 with 3.10 (readily prepared from benzoylacetone) afforded 3.12. 
 

































Scheme 3.1: Synthesis of 2-hydroxy-5-methylbenzophenone (3.12).116 
 
Wang et al.117 reported the synthesis of multi-substituted benzophenones by a regiospecific 
[5C+1C] annulation reaction of α-alkenoyl ketene S,S-acetal 3.13 with acetophenone 
(3.14) (Scheme 3.2). They developed two routes to synthesize 3.16, one is a direct 
synthesis of benzophenone and the other one is via the formation of cyclohexenone 3.15. 
This reaction starts with the Michael addition of the enol anion of acetophenone, followed 
by the intramolecular Michael addition to form 3.15. Cyclohexenone 3.15 was treated with 
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Rhodium catalysts were also used to synthesize benzophenones. Darses et al.118 reported 
the synthesis of benzophenone 3.19 from aryl aldehyde 3.17 and potassium 
benzyltrifluoroborate (3.18) (Scheme 3.3). They used a stable form of the phosphonium 
salt of tri-t-butylphosphane-rhodium catalyst system in a dioxane-acetone solvent system 










dioxane/acetone3.17 3.18 99%  
Scheme 3.3: Synthesis of (4-methoxyphenyl)(1-methyphenyl)methanone (3.19). 
 
Peterson et al.119 have synthesized a hexafluorobenzophenone (3.23) from 1-bromo-2,4,5-
trifluorobenzene (3.20) and 2,4,5-trifluorobenzaldehyde (3.21) by a Grignard reaction as 
shown in Scheme 3.4. The Grignard derivative of 3.20 was reacted with a benzaldehyde to 
afford the corresponding benzyl alcohol 3.22. Oxidation of the benzyl alcohol with 
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Scheme 3.4: Synthesis of bis(2,4,5-trifluorophenyl)methanone (3.23).119 
 
Storm and Andersson121 reported the synthesis of unsymmetrically substituted-
benzophenone 3.30 by using an intermediate iron complex (Scheme 3.5). Their first and 
key step was to synthesize η6-2-chlorotoluene-η5-cyclopentadienyl iron (3.24) which was 
oxidized in an aqueous solution of potassium permanganate to form a carboxylic acid-iron 
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complex 3.25. This acid was then converted into the methyl ester-iron complex 3.26, 
which underwent a nucleophilic aromatic substitution by a phenol nucleophile to form 
diaryl ether 3.27. The ester functionality of 3.27 was hydrolyzed to a carboxylic acid 
before it was subjected to an intramolecular Friedel-Crafts acylation to yield a xanthone 
complex 3.28. After a ring opening of 3.28 with an oxygen nucleophile, the benzophenone 
complex 3.29 was obtained and with a cyanide nucleophilic substitution in the presence of 
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Scheme 3.5: Synthesis of 3-methoxy-2-(2-methoxybenzoyl)benzonitrile (3.30).121 
 
3.3.2 Friedel-Crafts acylation reactions to synthesize benzophenones 
The Friedel-Crafts acylation reaction is the conventional reaction to synthesize aromatic 
ketones. This reaction takes place between aromatic compounds and acid chlorides in the 
presence of strong Lewis acids such as TiCl4, AlCl3, SnCl4 or FeCl3.122,123 However, Jong 
and co-workers reported a Friedel-Crafts acylation reaction that proceeds in the absence of 
Lewis acids.124 In their reactions, indium metal was used as a catalyst instead of a Lewis 
acid, and the reaction was run either neat or in dioxane as a solvent (Scheme 3.6). In the 
reaction between 1,3,5-trimethoxybenzene and benzoyl chloride (3.31), they reported a 
91% yield of 2,4,6-trimethoxybenzophenone (3.32). 
 













 Scheme 3.6: Friedel-Crafts acylation in the absence of a Lewis acid. 
 
Synthesis of 2,4,6-trihydroxybenzophenone (3.33) is another example of the application of 
a Friedel-Crafts acylation reaction, whereby phloroglucinol reacts with benzoyl chloride 
(Scheme 3.7).125 This reaction was performed in the presence of AlCl3 in nitrobenzene and 












Scheme 3.7: Synthesis of 2,4,6-trihydroxybenzophenone (3.33). 
 
These acylation reactions are also applicable to the heterocyclic acid chlorides such as 2-
chloronicotinoyl chloride (3.34) as reported by Marakos et al. (Scheme 3.8).126 This acid 
chloride 3.34 reacted with phloroglucinol in 1,2-dichloroethane in the presence of AlCl3 















Scheme 3.8: Synthesis of nicotinoylphloroglucinol (3.35). 
 
Mondal et al.127 reported the synthesis of 2,4,6-trihydroxybenzophenone (3.33) in two 
successful steps (Scheme 3.9). The first step was the Friedel-Crafts acylation of 1,3,5-
trimethoxybenzene with benzoyl chloride (3.31) in the presence of AlCl3 in DCM. The 
resulting 2,4,6-trimethoxybenzophenone (3.32) was subjected to the demethylation 
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reaction in a BBr3-mediated reaction. Both these reactions were run under dry conditions 














96% 92%3.31  
Scheme 3.9: Synthesis of 2,4,6-trihydroxybenzophenone (3.33).127 
 
3.3.3 Prenylation reactions 
The presence of a prenyl group affects the bioactivity of a compound as it influences the 
physicochemical properties such as lipophilicity and three-dimensional properties. These 
properties eventually control the interaction with the biological targets. The biological 
activities can be achieved depending on the length and the position of the prenyl group. 
For example, some relationship between presence, the length and the position of the prenyl 
group and the biological activity such as antitumor,128 anti-inflammation,129 PKC 
modulation130 and human lymphocyte proliferation131 have been observed. There are many 
bioactive prenylated compounds that are reported in the literature, most of them were 
isolated from living organisms. In this Section, however, we will focus on the synthesis of 
prenylated compounds as our main interest is on the prenylation of organic compounds. 
Normally, the prenylation of organic compounds takes place on carbon (C-prenylation) or 
oxygen (O-prenylation). 
3.3.3.1 C-prenylation reactions 
C-Prenylation reactions refer to reactions where the prenyl group is incorporated in the 
organic compound on a carbon atom. This implies the formation of a carbon-carbon bond. 
Normally, these reactions take place between aromatic compounds and halogenated 
prenyls and are therefore electrophilic aromatic substitution reactions. Barron et al.132 
reported the alkylation of flavonols with the use of microwave radiation. Basabe et al.133 
have applied the same conditions to prenylate chrysin (3.36) to afford a prenylated 
derivative of chrysin (3.37) (Scheme 3.10). They optimized their yield by using 10 equiv. 
of tetramethylammonium hydroxide and 6 successive 30 s microwave irradiations (90 W). 
This prenylation reaction had a poor selectivity as it yielded only 15% of 3.37, the rest of 
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Me4NOH, Et 4NI, MW (90 W)




R1, R2 =  H or geranyl  
Scheme 3.10: Synthesis of 6-C-geranylchrysin (3.37). 
 
Basabe et al.133 also reported the synthesis of 3-geranyl-2,4,6-trihydroxyacetophenone and 
3,5-digeranyl-2,4,6-trihydroxyacetophenone (3.39) by the prenylation of the acetophenone 
3.38 (Scheme 3.11). This reaction was run in a NaOH medium with 0.5 equiv. of geranyl 













Scheme 3.11: Synthesis of 3,5-digeranyl-2,4,6-trihydroxyacetophenone (3.39). 
 
C-prenylation reactions are not restricted to the use of organic solvents as Nuhant et al.134 
reported the synthesis of polyprenylated phlorogucinol by regioselective prenylation in an 
aqueous medium (Scheme 3.12). When the prenylation reaction was run in a potassium 
hydroxide medium, monoprenylated 3.40, diprenylated 3.41 and 3.42 and triprenylated 
phloroglucinol 3.43 were formed. 
 




















Scheme 3.12: Prenylation of phloroglucinol in aqueous medium. 
 
The formation of the gem-substituted phloroglucinols 3.42 and 3.43 resulted in the loss of 
the aromaticity of the ring. The aromaticity of the bis(enol acetate) 3.44 was reinstated by a 
tin(IV) chloride-mediated deprenylation reaction to form a biprenylated phloroglucinol 











Scheme 3.13: Synthesis of 3,5-diacetoxy-2,6-bis(3-methylbut-2-enyl)phenol (3.45). 
 
The yield of a monoprenylated phloroglucinol was increased by the use of the classic 
ortho-lithiation method. Firstly, tris-MOM ether 3.46 was synthesized from phloroglucinol 
which was then prenylated in the presence of butyl lithium in THF to afford 3.47. The 
cleavage of the MOM ether with CSA in methanol resulted in the formation of geranyl 
phloroglucinol 3.48. 
 

















Scheme 3.14: Synthesis of 2-(3,7-dimethylocta-2,6-dienyl)benzene-1,3,5-triol (3.48). 
 
3.3.3.2 O-prenylation reactions 
O-Prenylation reactions involve the use of a base. The most commonly used base in these 
reactions is potassium carbonate in acetone (Scheme 3.15). But other bases such as 
tetramethylammonium hydroxide (Scheme 3.10) and potassium hydroxide are also used. 
The selective prenylation of a phenol and a dihydroxyxanthone (3.50) in a K2CO3-
mediated reaction was reported to successfully produce corresponding monoprenylated 














Scheme 3.15: Oxyprenylation reactions using K2CO3. 
 
3.3.4  Synthesis of prenylated acylphloroglucinols 
Smith37 reported the synthesis of prenylated benzophenone 3.54 by Friedel-Crafts 
acylation of phloroglucinol followed by a C-prenylation (Scheme 3.16). She started her 
synthesis with the benzoylation of phloroglucinol, followed by the selective protection of 
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benzoyl phloroglucinol (3.33). Prenylation of the protected benzophenone in the presence 
of K2CO3, CuI and dibenzo-18-crown-6 formed the O-prenylated benzophenone 3.52, 
which underwent a Claisen/Cope rearrangement when heated in N,N-dimethylaniline to 
form the C-prenylated benzophenone 3.53. Compound 3.53 was subjected to a 






























Scheme 3.16: Synthesis of 2,4,6-trihydroxy-3-prenylbenzophenone (3.54).37 
 
Lee et al.125 also reported the synthesis of 2,4,6-trihydroxy-3-prenylbenzophenone (3.54) 
from phloroglucinol (Scheme 3.17). They synthesized benzoyl phloroglucinol from the 
benzoylation of phloroglucinol in the presence of aluminium trichloride. DBU was used as 














Scheme 3.17: Synthesis of 2,4,6-trihydroxy-3-prenylbenzophenone (3.54).125 
 
Delpech et al.137 reported the synthesis of 2,4,6-trihydroxy-3-prenylbenzophenone (3.54) 
by prenylation with the prenyl sulfonium salt. Trimethoxybenzophenone 3.32 was 
synthesized from the benzoylation of trimethoxybenzene. Demethylation of 3.32 with 
boron tribromide resulted in the formation of trihydroxybenzophenone 3.33. Prenyl 
sulfonium salt (3.55) was prepared by sulfonation of prenol in presence of the 
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trifluoroacetic acid followed by anion exchange with tetrafluoroboric acid. Lastly, the 
trihydroxybenzophenone was prenylated with the prenyl sulfonium salt in the presence of 










































Scheme 3.18: Use of sulfonium salt of prenol in the synthesis of prenylated benzophenone 
(3.54).137 
 
The review above has shown that prenylated benzophenones are natural compounds and 
exhibit biological activities such as anticancer, anti-inflammatory, anti-HIV and 
antimicrobial activity. It also showed reactions for the synthesis of benzophenones, the 
most popular reaction being Friedel-Crafts acylation. Prenylation reactions (O-prenylation 
and C-prenylation) were also explored but these reactions often result in the formation of 
more than one product. 
3.4 Results and discussion 
3.4.1 Introduction 
The aim of this research was to develop methods for the synthesis of fluorine-substituted 
benzophenones. The structures of the targeted benzophenones were based on bioactive 
benzophenones isolated from plants of the Hypericum family, viz. geranyl-2,4,6-
trihydroxybenzophenone (3.8), 4-geranyloxy-2,6-dihydroxybenzophenone (3.9) and 
vismiaphenone D (3.7) (Figure 3.7). Benzophenone 3.8 was isolated from Hypericum 
roeperianum37 and Garcinia vieillardii and exhibits inhibitory effect against 
Mycobacterium smegmatis (IC50 = 50 µg/mL) and other microbes.114,115 Compound 3.9 
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was isolated from Tovomita longifolia112 and has a higher activity against Staphylococcus 
aureus and Mycobacterium smegmatis (IC50 = 12.5 µg/mL), and is also cytotoxic to human 
cancer cells such as SF-268 (IC50 = 2.0 µg/mL), H-460 (IC50 = 4.4 µg/mL), and MCF-7 
(IC50 = 4.8 µg/mL).113 The diprenylated benzophenone, vismiaphenone D (3.7) was 
extracted from Vismia cayennensis and was reported to exhibit HIV-inhibitory activity in 






















Figure 3.7: Some examples of biologically active prenylated benzophenones. 
 
We envisaged synthesizing a library of compounds based on the structure in Figure 3.8. 
Although a number of acylated phloroglucinols have been synthesized, the synthesis of 
















 = H or prenyl or geranyl  
Figure 3.8: Proposed benzophenone derivatives to be synthesized. 
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Scheme 3.19: Retrosynthesis of prenylated benzophenone. 
 
The retrosynthetic analysis in Scheme 3.19 outlines the synthetic approach for the 
preparation of the prenylated benzophenones. It was envisaged that the benzophenones 
(3.33) could be formed by the acylation of phloroglucinol. The hydroxy groups on the 
aromatic ring are ortho directing and the C-C prenylation of benzophenone by electrophilic 
aromatic substitution is feasible to form C-prenylated benzophenones such as 3.8. On the 
other hand, benzophenones 3.33 could be O-prenylated to form O-prenylated 
benzophenones such as 3.9. 
3.4.1.2 Synthetic route to prenylated benzophenones 
In Scheme 3.20, the proposed syntheses of benzophenones containing fluorine and/or 
prenyl substituent are outlined. The first step of this synthesis is the methylation of 
phloroglucinol to form 1,3,5-trimethoxybenzene. The second reaction is a Friedel-Crafts 
acylation reaction whereby 1,3,5-trimethoxybenzene is reacted with a fluorinated benzoyl 
chloride to form a fluorinated phenyl(2,4,6-trimethoxyphenyl)methanone 3.32. 
Phenyl(2,4,6-trimethoxyphenyl)methanone is demethylated to form fluorinated benzoyl 
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phloroglucinol 3.33, which is prenylated by electrophilic aromatic substitution to yield C-





































orR = H  or
 
Scheme 3.20: General scheme for the synthesis of fluorinated prenylated benzophenones. 
 
3.4.2 Synthesis of 1,3,5-trimethoxybenzene 
A key step in the synthesis of the required compounds is the preparation of an acylated 
phloroglucinol. Phloroglucinol is an electron-rich aromatic compound and Friedel-Crafts 
reactions result in a mixture of O-acylated, C-acylated and polyacylated products. 
Therefore, it was desired to use the methylated derivative of phloroglucinol as starting 
material for the acylation step, similar to the approach of Delpech et al.137 Methylation of 
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phloroglucinol resulted not only in the required product (93%) (Scheme 3.21), but a side 












Scheme 3.21: Mechanism for the synthesis of 1,3,5-trimethoxybenzene. 
 
The mechanism for the conversion of phloroglucinol into 1,3,5-trimethoxybenzene 
(Scheme 3.21) is a SN2 reaction where the base removes the hydroxy proton of 
phloroglucinol to form a nucleophile. Nucleophilic attack on the carbon of the 
iodomethane results in the formation of 1,3,5-trimethoxybenzene. 1,3,5-
Trimethoxybenzene is electron rich and it can react with excess iodomethane to form 
1,3,5-trimethoxy-2-methylbenzene (3.56) (Scheme 3.22). The electron-rich benzene ring 
attacks on the partially positive carbon of iodomethane to form an arenium ion 

















Scheme 3.22: Mechanism for the synthesis of 1,3,5-trimethoxy-2-methylbenzene (3.56). 
 
The structure of 1,3,5-trimethoxybenzene and 3.56 was confirmed by NMR and IR 
spectrometry and HRMS. In the 1H NMR spectrum of 1,3,5-trimethoxybenzene only two 
singlet peaks (δH 6.08 and δH 3.78 with a relative integration of 1:3) were observed. The 
13C NMR spectrum of 1,3,5-trimethoxybenzene showed three peaks, an upfield peak at δC 
55.4 due to the methoxy carbons, and aromatic carbons at δC 93.1 and δC 161.7. HRMS 
confirmed the molecular formula of the compound. 
The structure of 1,3,5-trimethoxy-2-methylbenzene was verified by the 1H NMR spectrum 
in which the methyl protons appear as a singlet at δH 2.00. The 13C NMR spectrum also 
confirmed the structure by the presence of a methyl carbon at δC 7.8, C-1 at δC 106.9,  C-2 
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and C-6 at δC 158.8 and C-4 at δC 160.0. HRMS also confirmed the molecular formula by 
showing a good agreement between the observed mass and the calculated mass. 
3.4.3 Synthesis of phenyl(2,4,6-trimethoxyphenyl)methanone (3.32) 
The second step of the reaction sequence was the Friedel-Crafts acylation reaction. This is 
an electrophilic aromatic substitution whereby an aromatic hydrogen of 1,3,5-
trimethoxybenzene is replaced with an acyl group in the presence of the Lewis acid. This 
reaction was carried out in dichloromethane with aluminum trichloride (AlCl3) to give 3.32 












Scheme 3.23: Synthesis of phenyl(2,4,6-trimethoxyphenyl)methanone (3.32). 
 
The carbonyl group of benzoyl chloride was activated with aluminium trichloride which 
extracts chlorine leaving a highly electrophilic acylium ion. As a result, it is attacked by a 
nucleophile (1,3,5-trimethoxybenzene) giving an arenium ion intermediate as shown in 
Scheme 3.24. This arenium ion is stabilized through resonance with the lone pairs of 
electrons of the methoxy groups. Deprotonation of the arenium ion results in the formation 




















Scheme 3.24: Proposed mechanism for the formation of phenyl(2,4,6-trimethoxyphenyl) 
methanone (3.32). 
 
The structure of phenyl(2,4,6-trimethoxyphenyl)methanone (3.32), as well as phenyl(2,4,6-
trimethoxy-3-methylphenyl)methanone (3.57), were verified by standard techniques, 
including NMR, IR and HRMS. 
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The 1H NMR spectrum of 3.32 (Plate 1) reveals that the ortho and the para protons of the 
phenyl ring are more deshielded (δH 7.82 and δH 7.50, respectively) than the meta protons 
(δH 7.39). This can be attributed to resonance interaction between the carbonyl groups and 
the aromatic ring (Scheme 3.25). In addition, the ortho protons experience a great negative 
inductive effect than the para protons from the carbonyl group and as a result H-9 and H-
13 resonate further downfield than H-11. The protons on the methoxy substituted ring are 

























Scheme 3.25: Resonance forms for phenyl(2,4,6-trimethoxyphenyl)methanone (3.32). 
 
The 13C NMR spectrum of 3.32 (Plate 1) revealed a ketone carbonyl peak at δC 195.2, also 
confirmed by the HMBC and DEPT-135 spectra. Two quaternary carbon peaks at δC 159.0 
and δC 162.7 were assigned to the aromatic carbons bonded to the methoxy groups (C-2, 
C-4 and C-6). It also showed all the remaining aromatic carbons in the aromatic region (δC 
128-133) including the quaternary carbons (C-1 and C-8 at δC 111.3 and δC 138.5, 
respectively). The methoxy carbons appeared upfield at δC 55.7 and δC 56.1 and with the 
use of an HSQC spectrum and taking into account the relative intensity of the signals in the 
13C spectrum, they were assigned as 4-OCH3 and 2,6-OCH3, respectively. 
The elucidation of the structure of phenyl(2,4,6-trimethoxyphenyl)methanone was also 
confirmed by the appearance of a strong carbonyl band at 1660 cm-1 in the IR spectrum. 
The aromatic and alkyl C-H bond stretching appeared at 3053 cm-1 and 2949 cm-1, 
respectively. 
The structure of phenyl(2,4,6-trimethoxyphenyl)methanone was also confirmed by the 
high-resolution mass spectrum (HRMS) which shows good agreement between the 
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calculated mass for the sodium adduct of 295.0946 (C16H16O4Na) and a pseudo-molecular 
ion peak at m/z 295.0945 [M+Na]+. 
3.4.4 Synthesis of phenyl(2,4,6-trimethoxy-3-methylphenyl)methanone 
(3.57) 
Phenyl(2,4,6-trimethoxy-3-methylphenyl)methanone (3.57) was synthesized using the 
Friedel-Crafts acylation reaction (Scheme 3.26). The reaction mechanism is similar to the 



















Scheme 3.26: Reaction for the formation of phenyl(2,4,6-trimethoxy-3-methylphenyl) 
methanone (3.57). 
 
The 1H and 13C NMR spectra of phenyl(2,4,6-trimethoxy-3-methylphenyl)methanone 
(3.57) revealed the peaks that are similar to those of 3.32 except for additional upfield 
peaks (Plate 2). One of the new peaks is due to the methyl group (3-CH3) which appears 
further upfield at δH 2.11 in the 1H NMR spectrum and integrates for three protons. An 
HSQC spectrum revealed that this methyl group correlates with the upfield peak in the 13C 
NMR spectrum at δC 8.4. The methoxy groups (2-OCH3 and 6-OCH3) are no longer in the 
same environment and as a result they resonate with different frequencies, δH 3.62 and δH 
3.72 in the 1H NMR spectrum and at δC 62.0 and δC 56.0 in the 13C NMR spectrum, 
respectively. The DEPT-135, HSQC, HMBC, IR and mass spectra were also carried out to 
confirm the structure. 
3.4.5 Synthesis of fluorinated phenyl(2,4,6-trimethoxyphenyl) 
methanone (3.58-3.60) 
Since the application of the Friedel-Crafts acylation reaction (reaction of 1,3,5-
trimethoxybenzene with benzoyl chloride) in the second step of the reaction sequence was 
successful, the same reaction was then performed with the fluorinated benzoyl chlorides as 
shown in Scheme 3.27. The same reaction conditions were used and distinct colour 
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changes were observed during the reaction. The reaction of 2-fluorobenzoyl chloride was 











































Scheme 3.27: Reaction of 1,3,5-trimethoxybenzene with fluorinated benzoyl chloride. 
 
The formation of (2-fluorophenyl)(2,4,6-trimethoxyphenyl)methanone (3.58) was 
successful as confirmed by the 1H NMR spectrum (Plate 3). The methoxy protons are more 
shielded and as a result they resonate upfield, 2,6-OCH3 and 4-OCH3 appearing at δH 3.67 
and δH 3.83, respectively. The methoxy groups are electron donating which causes the 
aromatic protons (H-3 and H-5) to resonate upfield (δH 6.12) relative to the protons in the 
monofluorinated aromatic ring. The ortho (H-13) and para (H-11) are the most deshielded 
protons (δH 7.75 and δH 7.43, respectively) in the ring because of the mesomeric effect 
caused by the carbonyl group (as shown in Scheme 3.25). In addition to the mesomeric 
effect, H-13 experiences a greater negative inductive effect from the carbonyl group than 
H-11 as a result H-13 is shifted further downfield. The meta protons (H-10 and H-12) were 
the most shielded protons in the fluorinated benzene ring, at δH 7.01 and δH 7.15, 
respectively. Coupling was observed in the spectra in Table 3.1 and the coupling constants 
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Table 3.1: Aromatic region of the 1H NMR spectra of the fluorinated benzophenones. 













F 3.60   
 
The 13C NMR spectrum of (2-fluorophenyl)(2,4,6-trimethoxyphenyl)methanone (Plate 3) 
also supports the structure with a carbonyl carbon peak at δC 190.7. As a result of the high 
electronegativity of fluorine, the fluorine-containing carbon (C-9) resonates downfield at 
δC 160.4 relative to C-13 which resonates at δC 131.4 (∆δ = 30 ppm). The carbon peaks in 
this ring were all split due to coupling to the fluorine. The magnitude of the 19F,13C 
coupling constants depend on the number of bonds between the fluorine and the carbon, 
for example the ipso carbon (C-9) has 1J = 256.5 Hz (one-bond coupling with fluorine). 
The J-values decrease as the number of bonds increase as shown in Table 3.2. 
The structure of (2-fluorophenyl)(2,4,6-trimethoxyphenyl)methanone (3.58) was also 
confirmed by the high-resolution mass data which shows a good agreement between the 
calculated mass for the sodium adduct of 313.0852 (C16H15O4FNa) and an observed 
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Protons and carbons of the fluorinated aromatic rings 




δC    127.9 




δC    161.7 
d, J = 256.5 
δH    7.01 dd 
J = 11.4,8.5 
…………. 
δC  116.3 
d,  J = 22.8 
δH  7.43  
m 
…………. 
δC   133.8 
d, J = 9.1 
δH   7.15    t 
J = 7.7 
………… 
δC   123.8 
d, J = 3.9 
δH   7.75  dd 
J = 7.7, 7.6 
…………. 
δC   131.4 




δC   140.6 
d,   J = 6.2 
δH   7.51  dt 
J = 9.3, 1.8 
………….. 
δC   115.9 




δC    162.8 
d, J = 246.6 
δH   7.37  
m 
…………. 
δC     119.7 
d, J = 21.5 
δH   7.21  td 
J = 8.2, 2.8 
…………. 
δC    129.8 
d, J = 7.5 
δH 7.60 dt 
J = 8.2, 1.8 
…………. 
δC    125.1 




δC  134.9   s 
δH 7.85 dd 
J = 8.6, 5.7 
…………. 
δC     132.0 
d, J = 9.4 
δH  7.07  dd 
J = 9.2, 8.6 
………….. 
δC  115.3 




δC    165.8 
d, J=154.8 
δH  7.07  dd 
J = 9.2, 8.6 
………….. 
δC  115.3 
d, J = 22.0 
δH 7.85 dd 
J = 8.6, 5.7 
…………. 
δC    132.0 
d, J = 9.4 
 
The Friedel-Crafts acylation was also applied to synthesize (3-fluorophenyl)(2,4,6-
trimethoxyphenyl)methanone (3.59) and (4-fluorophenyl)(2,4,6-
trimethoxyphenyl)methanone (3.60) where 3-fluorobenzoyl chloride and 4-fluorobenzoyl 
chloride were used, respectively, to react with 1,3,5-trimethoxybenzene. These reactions 
were highly successful and gave good yields of up to 95% as shown in Table 3.4. The 1H 
NMR spectra of these benzophenone derivatives showed interesting proton splittings as a 
result of the position of the fluorine (shown in Table 3.1). In general, the coupling constant 
for 1H to the neighboring 19F is always bigger than the coupling constant between 1H and 
the neighboring 1H on the related position. For example, for the 2-fluoro substituted 
derivative (3.58), the ortho coupling constants (J values) for H-10 to 9-F and H-11 are 11.4 
Hz and 8.5 Hz, respectively as shown in Table 3.2. 
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Table 3.3: Splitting observed in the 19F NMR spectra due to 1H, 19F coupling. 




















The 19F NMR spectra were run for all the fluorinated benzophenones to verify the position 
of fluorine in each structure. Because of its ability to couple with the neighboring carbons, 
the splitting varies from the ortho, meta and para substituted fluorine as shown in Table 
3.3. 
Table 3.4: Percentage yields and physical properties of the synthesized 
benzophenones. 
 3.32 3.57 3.58 3.59 3.60 
Yield 90% 92% 94% 95% 95% 
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All the synthesized fluorinated benzophenones were fully characterized by other 
techniques such as IR, HRMS and melting points. Their IR spectra look similar to that of 
phenyl(2,4,6-trimethoxyphenyl)methanone (3.32) as they all show strong carbonyl peaks 
within a carbonyl range (1600 - 1700 cm-1). The melting point for the para-substituted 
benzophenone (3.60) was the highest (155 °C - 157 °C), followed by the ortho-substituted 
fluorine derivative 3.58 (127 °C - 129 °C).   
The results discussed above show that the Friedel-Crafts reaction can be applied for the 
acylation of phloroglucinol derivatives to form benzophenones as it gave good yields (90% 
- 95%). AlCl3 has also proved to be a good Lewis acid for this type of acylation reaction. 
All benzophenone derivatives were obtained as colourless crystals. 
3.4.6 Synthesis of phenyl(2,4,6-trihydroxyphenyl)methanone (3.33) 
The third step was the demethylation of the methoxy groups of the aromatic ring using a 
strong Lewis acid (boron tribromide, BBr3).138,139 BBr3 has been used to cleave ethers and 
acetals that cannot be deprotected by the use of a normal acid.140 This use of BBr3 for aryl 
deprotection in this research was preferred over the other methods because the reaction 
proceeds under mild conditions. This reaction was carried out in dichloromethane at -78 °C 
with 5 equivalents of BBr3 added quickly to the solution of 3.32 (Scheme 3.28). The 
reaction was stirred at room temperature for 24 h, resulting in a complete demethylation. 
When the reaction was run for 10 h, the TLC showed some spots with higher Rf values 
which may be due to partially demethylated products. After isolation, NMR analysis 
revealed the existence of some methoxy peaks in the structure. With longer reaction time, 
the yield of these side products was decreased. After monitoring a few reactions, it was 
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The mechanism of demethylation of phenyl(2,4,6-trimethoxyphenyl)methanone (3.32) to 
form 3.33 is outlined in Scheme 3.29. The lone pair of the methoxy oxygen attacks the 
electrophilic boron atom in BBr3 to form an unstable zwitterion. The release of methyl 
bromide results in the formation of the dibromo(organo)borane which undergoes 
hydrolysis to form an unstable intermediate which cleaves off dibromo(hydroxy)borane to 














































Scheme 3.29: Proposed mechanism for the formation of phenyl(2,4,6-trihydroxyphenyl) 
methanone (3.33). 
 
The formation of the desired product was confirmed by NMR, IR and mass spectrometry. 
The 1H NMR spectrum of 3.33 revealed the disappearance of the methoxy proton peaks 
and the appearance of hydroxy proton peaks resonating downfield (shown in Plate 6). The 
ortho hydroxy protons are more deshielded, as they resonate at δH 10.08 and integrate for 
two protons, than the para-OH which resonate at δH 9.82 and integrates for one proton. 
The monosubstituted aromatic protons (H-9, H-10, H-11, H-12 and H-13) resonate 
between δH 7.42 and δH 7.63. The phloroglucinol protons (H-3 and H-5) appear as a singlet 
at δH 5.84 which integrates for two protons. 
With the support of DEPT-135, HSQC and HMBC spectra, the peaks in the 13C NMR 
spectrum were assigned. The absence of methoxy carbon peaks is evidence of the success 
of the demethylation reaction. C-3 and C-5 is the most shielded carbon and appeared at δC 
94.8 (Plate 6). The quaternary carbons adjacent to the carbonyl C-1 and C-8 resonate at δC 
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106.0 and δC 140.2, respectively. The monosubstituted aromatic carbons resonate within a 
range of δC 128-133 which is within the aromatic region. 
The structure of phenyl(2,4,6-trihydroxyphenyl)methanone (3.33) was also confirmed by 
HRMS. The IR spectrum showed a strong carbonyl band at 1625 cm-1 and a broad band for 
the phenol (O-H stretch) at 3621 cm-1. 
3.4.7 Synthesis of fluorinated phenyl(2,4,6-trihydroxyphenyl) 
methanone (3.61 - 3.63) 
The demethylation reaction with BBr3 was also applied to 3.58 - 3.60 to produce 3.61 - 
3.63 successfully as shown in Scheme 3.30. The success of these reactions was confirmed 
by NMR, IR and mass spectra. The 1H NMR spectra of these compounds revealed that the 
methoxy proton signals were absent and the appearance of the hydroxy proton signals 
resonating downfield as shown in Plates 7, 8 and 9. In the 13C NMR spectra, the methoxy 












































Scheme 3.30: Demethylation reactions to form fluorinated benzophenones. 
 
Demethylation of trimethoxybenzophenone derivatives (3.32, 3.58, 3.59 and 3.60) with 
BBr3 was successful with yields of about 98%. These results confirm that BBr3 is a good 
demethylating agent for the methyl ether system. 
 
53 | P a g e  
 
3.4.8 C-Prenylation reactions 





















3.33 62%  




The last step of the reaction consists of two types of prenylation, C- and O-prenylation. 
The method for the C-prenylation of benzophenones was an adaption of the method of Lee 
et al.125 (method A). During this electrophilic aromatic substitution, an aromatic proton is 
replaced by a prenyl group by using 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (Scheme 
3.31). This prenylation method was preferred over the other methods (discussed in the 
previous Sections) because it gives better yields and does not require harsh conditions. 
These reactions took place in THF at room temperature.  
DBU is a mild base which extracts an acidic phenolic proton from benzophenone 3.33 to 
form a phenolate ion intermediate which reacts freely with prenyl bromide via an SN2 
mechanism and re-aromatize to form the prenylated benzophenone 3.54 (Scheme 3.32). 
 
 
































Scheme 3.32: Proposed mechanism for the formation of phenyl[2,4,6-trihydroxy-3-(3-
methyl-2-butenyl)phenyl]methanone (3.54). 
 
NMR, IR and mass spectrometry were the key techniques used to confirm the structure of 
the product of the prenylation reaction. The 1H NMR spectrum of 3.54 revealed two 
upfield methyl peaks at δH 1.76 (doublet, J = 1.1 Hz) and δH 1.80 (singlet), corresponding 
to the cis-allylic methyl-protons (H-4'b) and trans-allylic protons (H-4b), respectively 
(Plate 10). A doublet peak, integrating for two hydrogens, appears at δH 3.36 (J = 7.0 Hz) 
and was assigned to H-1b. A vinylic proton peak (H-2b) appeared as a multiplet at δH 5.26. 
The replacement of aromatic hydrogen (H-3) with a prenyl group was also confirmed by 
the decrease of the integral from two to one proton as well as the upfield shift of the peak 
from δH 5.84 to δH 5.26. This shift is due to the addition of an electron-donating group to 
the aromatic ring which shields the aromatic proton. The aromatic protons of the 
monosubstituted ring appeared at δH 7.64 (H-9,13), δH 7.51 (H-10,12) and δH 7.58 (H-11). 
DEPT-135, HSQC and HMBC spectra were used for the assignment of 13C NMR peaks. In 
the 13C NMR spectrum (Plate 10) of 3.54 the prenyl carbons resonate upfield which is in 
agreement with the 1H NMR spectrum. The terminal allylic carbons, C-4b and C-4'b 
resonate at δC 17.9 and δC 25.8, respectively, whereas the olefinic carbons (C-2b and C-3b) 
resonate at δC 121.6 and δC 135.4, respectively. The peak appearing downfield at δC 197.7 
was assigned for the carbonyl carbon (C-7). The quaternary carbon (C-8) and hydroxy 
carbons (C-2, C-4 and C-6) were deshielded and appeared downfield at δC 140.0, δC 160.8, 
δC 162.6 and δC 159.4, respectively. 
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The IR spectrum confirmed the presence of the carbonyl group as shown by a strong band 
at 1625 cm-1 and the presence of hydroxy groups (O-H stretch band that appeared at 3621 
cm-1). The structure of 3.54 was also confirmed by the high-resolution mass data which 
shows good agreement between the calculated mass of 297.1127 (C18H17O4) and a 
molecular ion peak at m/z 297.1130 [M-H]-.  
3.4.8.2 Synthesis of fluorinated monoprenylated benzophenones 
(3.64-3.66) 
Method A 
After the prenylation of 3.33 was successfully performed, it was applied to the fluorinated 
benzophenones (3.61 - 3.63) as well. However, the reaction was not successful with the 2-
fluorobenzophenone 3.61 as shown in Scheme 3.33, with no product being observed. The 
reason for the difference in reactivity between 2-fluorobenzophenone and 3- and 4-
fluorobenzophenone is not clear to us. It might be that there is an interaction of the fluorine 
and the phenolate which reduces the nucleophilicity of the aromatic ring (Figure 3.9). 

























































Scheme 3.33: Prenylation reactions to form fluorinated prenylated benzophenones. 
 
 










Figure 3.9: Intramolecular hydrogen bonding of 2-fluorobenzophenones (3.61). 
 
Due to this hydrogen bonding, these ortho hydroxy groups contribute less of an inductive 
and mesomeric effect to the ring, which reduce the acidity of the hydroxy protons. Hence, 
DBU was no longer a strong enough base to abstract the hydroxy protons. However, the 
prenylation of 3-fluoro and 4-fluoro analogues was successful and NMR (Plate 11 and 12), 
IR and mass spectra confirmed the structures of the products. 













































Figure 3.10: Chemical structures of diprenylated benzophenones (3.67, 3.68 and 3.69). 
 
Method B 
When the prenylation reaction was given more time in the presence of DBU (1.5 eq) and 
prenyl bromide (2.2 eq) (as in method A), diprenylation was observed. This reaction was 
run at 35 °C for 48 h for optimum yields (46-48%) (Figure 3.10). The rest of the reaction 
mixture consists of monoprenylated product and non-reacted starting material. The NMR 
and mass spectra results for these compounds were analysed to confirm their structure. 
The 1H NMR spectra of these compounds revealed the absence of C-3 and C-5, the 
aromatic protons of the hydroxy-substituted ring. The prenyl protons appeared upfield with 
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their integration double that of the monoprenylated compounds (3.54, 3.65 and 3.66). The 
aromatic protons of the fluorine/ hydrogen-substituted ring were not disturbed and their 
resonances were similar to those of the monoprenylated benzophenones (3.54, 3.65 and 
3.66). 
DEPT-135 spectra confirmed that C-3 and C-5 were quaternary carbon which proved that 
the aromatic protons were indeed substituted by the prenyl groups. HSQC and HMBC 
spectra showed that C-3 and C-5 had no protons bonded to them. The resonances of these 
carbons (C-3 and C-5) were shifted downfield from δC 96 to δC 106, showing the 
quaternary nature of these carbons. The carbonyl carbons, fluorine and hydroxy substituted 
carbons appeared downfield in the 13C NMR spectra (Plates 13, 14 and 15). 






















Scheme 3.34: Geranylation reactions to form geranylated benzophenones. 
 
Method C 
The reaction conditions in this method are the same as in method A but with geranyl 
bromide replacing prenyl bromide. This reaction was run at 35 °C for 24 h to give a yield 
of 40%-44% (Scheme 3.34). After purification, the product was obtained as an orange 
semi-solid. 
 The 1H NMR spectrum of 3.8 showed the disappearance of one of the aromatic protons 
(H-3) of the geranylated ring leaving only one aromatic proton (H-5) on this ring. The 
appearance of the geranyl protons confirms the incorporation of geranyl. Geranyl protons 
including the terminal allylic protons (H-4'b, H-8b and H-8'b), non-terminal allylic protons 
(H-1b, H-4b and H-5b) and olefinic protons (H-2b and H-6b) are shown in the 1H NMR 
spectrum (Plate 16). The DEPT-135, HSQC and HMBC spectra were used to assign the 
signals in the 13C NMR spectrum. 
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The IR spectrum confirmed the existence of the carbonyl group as shown by a strong band 
at 1656 cm-1, while an aromatic C-H stretch band at 3073 cm-1and O-H stretch bands at 
3533 cm-1 were apparent. The structure of 3.8 was also confirmed by HRMS which shows 
a good agreement between the calculated mass of 389.1729 (C23H26O4 Na) and a pseudo-
molecular ion peak at m/z 389.1721 [M+Na]+.  
3.4.8.5 Synthesis of fluorinated monogeranylated benzophenones 
(3.70, 3.71 and 3.72) 
The geranylation of fluorinated benzophenones 3.62 and 3.63 was successful (Scheme 
3.35). As was found with the prenylation reactions, the geranylation of the O-fluorinated 
benzophenone 3.61 was unsuccessful. The structures of the products of these reactions 
were confirmed by NMR, IR and mass spectrometry. 1H NMR and 13C NMR spectra 
revealed the presence of all components of each structure such as geranyl resonances and 
also for both aromatic rings (Plate 17 and 18). The IR spectra revealed the presence of the 




























































Scheme 3.35: Geranylation of fluorinated benzophenones. 
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3.4.8.6 Synthesis of fluorinated digeranylated benzophenone (3.73 
and 3.74) 
Method D 
The double geranylation reactions to yield 3.73 and 3.74 involved an adaptation of method 
B (Figure 3.11). These reactions were run for 48 h in THF in the presence of DBU (1.5 eq) 
and geranyl bromide (2.2 eq) which yielded the desired products. The NMR, IR and mass 
spectra were used to confirm the structures of the products. 1H NMR spectra (Plate 19 and 
Plate 20) revealed the absence of the aromatic proton peaks (H-3 and H-5) of the hydroxy 
substituted aromatic ring which proved that the substitution took place in C-3 and C-5. The 
appearance of the geranyl protons resonating upfield confirmed the incorporation of the 
geranyl group. 13C NMR spectra revealed the presence of the geranyl carbons, carbonyl 





































Figure 3.11: Chemical structure of digeranylated benzophenones (3.73 and 3.74). 
  
The results above show that DBU is a good base to be used for C-prenylation and C-
geranylation reactions of trihydroxybenzophenones. DBU can selectively monoprenylate 
or diprenylate benzophenones depending on the reaction time (diprenylation reactions need 
longer reaction time). According to the results, the monoprenylation is favored with more 
than 60% yields whereas, for diprenylation, the yield is less than 48%. 
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3.4.9 O-prenylation reactions 
3.4.9.1 O-prenylation of C-prenylated benzophenones 
Method E 
The observations on the DBU-mediated reactions showed that the use of DBU restricts the 
prenylation to C-prenylation only. A harder base (K2CO3) was used to obtain O-prenylated 
benzophenones.136,144 These reactions were performed under reflux in acetone in the 
presence of the K2CO3 (4 eq) and prenyl bromide (3 eq) for 5 h (Scheme 3.36). Two 
products, (3-fluorophenyl)[2-hydroxy-3-(3-methylbut-2-enyl)-4,6-bis(3-methylbut-2-
enyloxy)phenyl]methanone (3.75) and (3-fluorophenyl)[2-hydroxy-3,5-bis(3-methylbut-2-
enyl)-4,6-bis(3-methylbut-2-enyloxy)phenyl]methanone (3.76), were obtained in this 
reaction and their NMR spectra are shown on Plate 21 and Plate 22, respectively. 
Compound 3.75 was the major product of this reaction and was obtained in 85% yield 
(relative yield) whereas 3.76 was formed in 15% yield. When this reaction was run in other 












































Scheme 3.36: O-prenylation of monoprenylated 3-fluorobenzophenone. 
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The base abstracts the hydroxy proton of the prenylated benzophenone to form a phenolate 
ion intermediate as shown in Scheme 3.37. This then acts as a nucleophile substituting the 




















Scheme 3.37: Proposed mechanism for O-prenylation of monoprenylated benzophenone. 
 
After the O-prenylation reaction was optimized, it was applied to a para-fluorinated 
benzophenone. Two products 3.77 and 3.78 were formed in this reaction (Scheme 3.38). 
The NMR spectra for compound 3.77 and 3.78 are shown on Plate 25 and Plate 26, 
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Method F 
The yield of 3.76 and 3.78 could be improved by subjecting biprenylated benzophenones 
(3.68 and 3.69) to the O-prenylation reaction (Scheme 3.39). This reaction was run in the 
presence of the base (K2CO3, 2.2 eq) and prenyl bromide (2.1 eq) in refluxing acetone for 2 
hours to give a quantitative conversion. This method was the best route to synthesize this 
kind of polyprenylated benzophenone. NMR, IR and MS were used to confirm the 
structures of 3.76 and 3.78. This alkylation reaction (method F) was also applied to 












Scheme 3.39: O-prenylation of fluorinated diprenylated-benzophenone. 
 
3.4.9.2 O-geranylation of C-geranylated benzophenones 
The O-alkylation reaction was not only restricted to prenyl groups but was extended to 
geranyl groups.145,146 Method E was adapted to synthesize multi-geranylated 
benzophenone (4-fluorophenyl)[2-hydroxy-3-(3,7-dimethylocta-2,6-dienyl)-4,6-bis(3,7-
dimethylocta-2,6-dienyloxy)phenyl]methanone (3.79) and (4-fluorophenyl)[2-hydroxy-
3,5-bis(3,7-dimethylocta-2,6-dienyl)-4,6-bis(3,7-dimethylocta-2,6-dienyloxy)phenyl] 
methanone (3.80) as shown in Scheme 3.40. The ratio of products 3.79 : 3.80 was found to 
be 6 : 1. NMR, IR and MS analysis confirmed the structures of these compounds. The 
NMR spectra for 3.79 and 3.80 are shown on Plate 29 and Plate 30, respectively. 
 




















































Scheme 3.40: O-geranylation of monogeranylated 4-fluorobenzophenone. 
3.4.9.3 Polyprenylation of benzophenones 
Method G 
The prenylation reaction was also applied to non-prenylated benzophenones to explore the 
mechanism of the carbonate base in these kinds of reactions. When (3-fluorophenyl)(2,4,6-
trihydroxyphenyl)methanone was subjected to this type of prenylation reaction, four 
prenylated benzophenones were isolated. A mixture of (3-fluorophenyl)(2,4,6-
trihydroxyphenyl)methanone (3.62) and prenyl bromide (4 eq) was refluxed in acetone in 
the presence of K2CO3 (4 eq) for 6 hours. After purification, it was found that two of these 
products (3.75 and 3.76) had already been synthesized by method E and method F. The 
other two products were the O-prenylated benzophenones, (3-fluorophenyl)[2-hydroxy-
4,6-bis(3-methylbut-2-enyloxy)phenyl]methanone (3.81) and (3-fluorophenyl)[2,4,6-tris(3-
methylbut-2-enyloxy)phenyl]methanone (3.82) as shown in Scheme 3.41. 
 










































Scheme 3.41: Prenylation of meta-fluorinated benzophenone. 
 
The results showed that every proton of the hydroxy-substituted ring of benzophenone can 
be substituted by prenyl in the presence of K2CO3. This reaction favoured 3.75 and 3.76 as 
each of them was produced in 35% yield, whereas the yields of 3.81 and 3.82 were only 
20% and 10%, respectively. The yield of 3.82 was the smallest as was expected, because of 
the hydrogen bonding that exists between the ortho-hydroxy hydrogen and the carbonyl 
oxygen as explained in Section 3.4.8.2, and hence, this hydroxy is less reactive. 
The 1H NMR spectrum of 3.81 showed two sets of non-equivalent prenyl protons, for 
example, the allylic protons H-1c resonate at δH 4.58 and H-1e resonates at δH 4.20. The 2-
OH peak appeared downfield at δH 12.37. The aromatic protons of the hydroxy substituted 
ring, H-3 and H-5, are no longer in the same environment and resonate as doublets at δH 
5.94 and δH 6.17, respectively. With the help of COSY, DEPT-135, HSQC and HMBC 
NMR spectra, the carbon signals in 13C NMR spectrum were assigned (Plate 23). The 
related compound (3.83) was synthesized from the para-fluorinated benzophenone as 
shown in Scheme 3.42. The NMR spectrum of 3.83 is shown in Plate 27. 
No hydroxy peaks were observed in the 1H NMR spectrum of 3.82 (Plate 24). Also, in the 
1H NMR spectrum, three prenyl groups were observed, two of which are in the same 
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environment. For example, the olefinic protons of the prenyl groups, H-2a resonates at δH 
5.20 and integrates for 2H whereas H-2c resonates at δH 5.53 and integrates for 1H. The 
appearance of an aromatic peak in the 1H NMR spectrum which integrates for two protons 
showed that only O-prenylation occurred. 
When these reaction conditions (method G) were applied to the para-fluorinated 
benzophenone (3.63), the products 3.77, 3.78, 3.83 and 3.84 were produced in relative 







































Scheme 3.42: Prenylation of para-fluorinated benzophenone. 
 
The 1H NMR spectrum of 3.84 was found to be similar to that of 3.77 since they both are 
triprenylated, two O-prenylation on the same position (4-O and 6-O) for both and one C-
prenylation on different positions (C-3 for 3.77 and C-5 for 3.84). The structure of 3.77 
was also confirmed by X-ray crystallography (Figure 3.12) which confirms the positions of 
the prenyl groups. An aromatic proton of the hydroxy substituted ring of 3.84 (H-3) 
appeared as a singlet at δH 6.38 as opposed to H-5 of 3.77 which resonate at δH 5.95. The 
protons of the C-substituted prenyl of 3.84 were found to be more deshielded than those of 
3.77, for example the allylic protons of 3.84 (H-1b) resonate at δH 4.01 while those of 3.77 
(H-1d) resonate at δH 3.33, H-2b resonate at δH 5.33, while H-2d resonate at δH 5.26. 
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Figure 3.12: Crystal structure of (4-fluorophenyl)[2-hydroxy-3-(3-methylbut-2-enyl)-
4,6-bis(3-methylbut-2-enyloxy)phenyl]methanone (3.77) 
3.4.9.4 Polygeranylation of benzophenones 
The alkylation reaction of para-fluorinated benzophenone (as per method G) was repeated 
but with geranyl bromide instead of prenyl bromide. This reaction afforded both O-
geranylated benzophenones (3.85 and 3.86) and benzophenones with a combined O and C-
geranyl groups (3.79 and 3.80). NMR, IR and MS were used to confirm the structures of 
these compounds. 
 














































Scheme 3.43: Geranylation of para-fluorinated benzophenone. 
 
3.4.9.5 Prenylation of (2-fluorophenyl)(2,4,6-trihydroxyphenyl) 
methanone 
As it was explained in Section 3.4.8.2 and Figure 3.9, (2-fluorophenyl)(2,4,6-
trihydroxyphenyl)methanone (3.61) could not be C-prenylated with DBU as a base, unlike 
the other benzophenones. The use of K2CO3 as base as in method G as shown in Scheme 
3.44 was attempted. After the reaction was completed, four new spots were observed by 
TLC. The mixture was separated by chromatography and the compounds analyzed by 
NMR, IR and mass spectrometry. The NMR spectra of these spots (3.87, 3.88, 3.89 and 
3.90) clearly showed that the prenyl group was indeed incorporated in the benzophenone 
structure. 
 





































































Scheme 3.44: Prenylation of (2-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone. 
 
The products obtained in this reaction were different from those obtained from the 3-fluoro 
and 4-fluorobenzophenones. The 1H NMR spectrum of (2-fluorophenyl)[2,4-dihydroxy-6-
(3-methylbut-2-enyloxy)phenyl]methanone (3.87) revealed that only one prenyl group was 
incorporated and that was through the ortho-oxygen atom. The aromatic protons H-3 and 
H-5 appeared as doublets at δH 6.37 at δH 6.45, respectively. The 13C NMR spectrum of 
3.87 revealed that C-3 resonates at δC 97.6 and C-5 at δC 93.4, while the hydroxy-
substituted carbons C-2 and C-4 resonate at δC 163.5 and at δC 157.7, respectively (Plate 
33). 
The diprenylated benzophenones (2-fluorophenyl)[2,6-dihydroxy-3-(3-methylbut-2-enyl)-
4-(3-methylbut-2-enyloxy)phenyl]methanone (3.88) and (2-fluorophenyl)[2,6-dihydroxy-
5-(3-methylbut-2-enyl)-4-(3-methylbut-2-enyloxy)phenyl]methanone (3.89) were also 
produced in this reaction. The elucidation of the structures of these compounds was not so 
easy, as they appeared similar in most analytical aspects such mass, IR and UV spectra. 
Their molecular formulae are the same, which made it impossible to differentiate them 
using mass spectrometry. Their NMR spectra showed the same number of protons and 
carbons but fortunately, the chemical shifts of some protons and carbons were different, 
and this difference was used to elucidate their structure. The 1H NMR spectra of these 
compounds revealed that the aromatic protons (H-3 of 3.89 and H-5 of 3.88) were not 
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resonating in the same region, H-3 is relatively more shielded than H-5 as they resonate at 
δH 6.40 and δH 6.45, respectively. 
K2CO3 was used to achieve the O-prenylation of the benzophenones, but prenylation with 
this base was found to be nonselective as it also does the C-prenylation. Protection of some 
acidic protons in the structure is necessary when using K2CO3 in order to maximize the 
yield of the desired product. 
3.4.10 Attempted synthesis of prenylated pyridinoyl phloroglucinol 
Having successfully synthesized prenylated benzophenones, we decided to explore 
nitrogen-containing analogues such as prenylated pyridinoyl phloroglucinol. The aim of 
this reaction was also to confirm the impact of hydrogen bonding on the prenylation step of 
this synthesis as shown below. The ortho and meta N-substituted pyridinoyl substituents 
were selected for this reaction.147 Due to the cost of pyridinoyl chloride, picolinoyl 
chloride (3.91) and nicotinoyl chloride (3.95) were synthesized from the corresponding 
carboxylic acids by treatment with thionyl chloride (SOCl2) as shown in Schemes 3.45 and 
3.46.148,149 The acyl chloride is more reactive than the corresponding carboxylic acid in the 
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The first step of this reaction was the formation of the acyl chloride. The lone pair of 
electrons of oxygen attacks the thionyl group of SOCl2 to form a protonated acyl 
chlorosulfite intermediate as shown in Scheme 3.47. This highly unstable intermediate 
releases acyl chloride (product) with SO2 and HCl as by-products. The acyl chloride was 




























Scheme 3.46: Attempted synthesis of (pyridine-3-yl)[2,4,6-trihydroxy-3-(3-methyl-2-
butenyl)phenyl]methanone (3.98). 
 
The second step of this reaction involves the Friedel-Crafts acylation reaction as described 
in the previous Sections. This reaction was first tried with 1,3,5-trimethoxybenzene but the 
reaction was unsuccessful. When tried with phloroglucinol in the presence of AlCl3, the 
pyridinoyl phloroglucinols, 3.93 and 3.97 were obtained. Surprisingly, the yield of 3.97 
was one third that of 3.93 and this can be explained in terms of the reactivity of pyridinoyl 
chloride (see below). 
 












































R = Pyridine  
Scheme 3.47: Mechanism for the preparation of acyl chloride. 
 
The last step of this synthesis involved prenylation. (Pyridin-3-yl)(2,4,6-
trihydroxyphenyl)methanone (3.93) was subjected to the reaction in the presence of DBU, 
but this reaction was unsuccessful. This compound forms an intramolecular hydrogen bond 
between the ortho hydroxy proton and carbonyl oxygen which is enhanced by the 
inductive effect caused by the nitrogen (Figure 3.13). This results in the reduction of the 





OH OH  
Figure 3.13: Intramolecular hydrogen bonding of 2-pyridinoyl phloroglucinol (3.93). 
 
AlCl3 was not good enough to activate nicotinoyl chloride (3.95) in the acylation reaction 
and as a result, nicotinoyl phloroglucinol (3.97) was produced in very low yield. In future, 
one might need to alter the reaction conditions to improve the yields of 3.97 as well as 
3.93. One would also need to use K2CO3 or other stronger bases instead of DBU for the 
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prenylation of 3.93 to overcome the intramolecular hydrogen bonding that exist in the 
structure of 3.93 as shown in Figure 3.13. 
3.4.11 Synthesis of dimeric prenylated compounds 
Dimeric phloroglucinols are reported to have interesting biological activities such as 
anticancer,150 anti-HIV,151, 152 antiproliferative and antiplasmodial153 activity. We then 
attempted to synthesize this type of compounds. The prenylated benzophenone 3.54 was 
reacted with paraformaldehyde in the presence of a range of catalysts such as HCl, p-TsCl, 
POCl3 and toluic acid in various solvents, aiming to form dimeric prenylated-
benzophenone 3.101 as shown in Scheme 3.48, but the reaction was unsuccessful. Failing 
with this route, the same reaction was tried with trimethoxybenzophenone (3.32) under the 
same conditions but it was also unsuccessful. Reaction with the trihydroxybenzophenone 
3.33 gave a good yield of 95%. The next step was to prenylate this dimeric benzophenone 
(3.100) under the previously-used conditions (DBU in THF), but the reaction failed. This 















































Prenyl bromide Prenyl bromide
 
Scheme 3.48: Attempted synthesis of dimeric prenylated benzophenone (3.101). 
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This synthesis was also attempted with the system that did not have an electron-
withdrawing group on the phloroglucinol ring. As a result, dimeric prenylated 
phloroglucinol 3.104 was targeted to explore the impact of the electron-withdrawing group 




























Scheme 3.49: Synthesis of dimeric prenylated-phloroglucinol (3.104). 
 
In the first attempt, the prenylation of 1,3,5-trimethoxybenzene using DBU as base did not 
give a product (Scheme 3.49). When the same reaction was applied to phloroglucinol, it 
was successful and a good yield (72%) of biprenylated trihydroxybenzene (3.103) was 
obtained. Two equivalents of compound 3.103 was reacted with 1 equivalent of 
paraformaldehyde in the presence of acid catalyst. After running this reaction for 10 min 
under 100 W power in a microwave, a new spot was observed on the TLC which was the 
desired product (3.104). The success of this reaction (formation of 3.104) clearly shows 
that the presence of the electron-withdrawing group in the trihydroxybenzene ring does 
reduce the nucleophilicity of the ring. As a result, the formation of 3.101 needed a 
microwave of more than 750 W as oppose to the formation of 3.104 which required only 
100 W power. 
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3.5 Activity of benzophenones 
Benzophenones (3.75, 3.77, 3.81, 3.83, 3.87, 3.88, 3.89 and 3.90) were subjected to an in 
vitro cell-base HIV assay in the MINTEK laboratories at a concentration of 10 µg.mL-1, 
but none of these showed any activity. The concentration of 10 µg.mL-1 is a vigorous level 
to consider for activity, but activity at this level is needed for drug discovery. Many of the 
compounds reported in the literature to have anti-HIV activity have IC50 at much higher 
concentrations. Antimicrobial and cytotoxic activities of cell lines are currently under 
investigation. 
3.6 Conclusion 
One of the aims of this project was to synthesize fluorine-containing prenylated 
benzophenones. Friedel-Crafts acylation and electrophilic aromatic substitution reactions 
were the key reactions of this synthesis to achieve these fluorinated prenylated 
benzophenones. Friedel-Crafts acylation reactions were conducted under AlCl3-mediated 
conditions to form a benzophenone scaffold (trihydroxybenzophenones) which were then 
prenylated via carbon or oxygen at the last step of the reaction using DBU and K2CO3. 
3.7 Experimental Procedure 
3.7.1 General Experimental Procedure 
Unless otherwise stated, all reagents (including solvents) were purchased from the 
chemical suppliers Aldrich, Fluka and Merck (the chemical suppliers). For all moisture-
sensitive reactions, the glassware was thoroughly dried in an oven at ca. 140 °C for 12 h 
prior to use, and anhydrous solvents were used under inert conditions. Qualitative thin-
layer chromatography (TLC) was used to monitor reactions and to determine the purity of 
compounds. TLC plates (Merck Kieselgel 60254 aluminum backed) were bought ready for 
use. Visualization of the TLC plates was achieved using an iodine tank and/or fluorescence 
on exposure to short wavelength ultraviolet light (254 nm). For purification, centrifugal 
chromatography was conducted on a Harrison Research Chromatotron model 7924T on 
glass plates coated with Merck silica gel (particle size 0.040 - 0.063 mm), 1 - 4 mm thick. 
Column chromatography was conducted using Merck Kieselgel 60 (230-400 mesh). 
Preparative scale TLC plates were prepared using Merck Kieselgel 60254 which was coated 
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onto 20 x 20 cm glass plates. Silica gel (200 g) was homogeneously suspended in 500 mL 
of water to make up two TLC plates with thickness of 2 mm (silica gel). These plates were 
kept in a draft-free area overnight at room temperature and were subsequently activated 
overnight at 120 ºC. 
Melting points (Mp) were determined using a Stuart melting point apparatus with open-
ended capillary tubes and are uncorrected. Nuclear magnetic resonance (NMR) spectra 
were recorded on a Bruker 400 MHz UltraShield spectrometer at frequencies of 399.995 
MHz and 100.4296 MHz for proton (1H) and carbon (13C), respectively. Chemical shifts 
(δ) are reported in parts per millions (ppm) and coupling constants (J values) were 
measured in hertz (Hz). In all spectra, the residual proton solvent resonance was used as an 
internal reference. The spin multiplicities are given as s (singlet), d (doublet), dd (doublet 
of doublets), dt (doublet of triplets), t (triplet), td (triplets of doublet) q (quartet), br 
(broad), or m (multiplet). Infrared (IR) spectra were recorded on a Perkin Elmer 
spectrometer (FTIR Spectrum 100) as neat solid or liquid samples (the samples were put 
on the IR machine lens). High-resolution mass spectrometry (HRMS) was performed on a 
Waters LCT Premier time-of-flight mass spectrometer. 







A mixture of phloroglucinol (1.0 g, 7.93 mmol), iodomethane (5.0g, 35.2 mmol), and 
anhydrous K2CO3 (4.9 g, 35.2 mmol) in acetone (70 mL) was refluxed for 6 h. The 
resulting mixture was cooled to room temperature and filtered through celite. The solvent 
was removed in vacuo. The crude mixture was purified by silica gel column 
chromatography with 10%, 30% and 50% EtOAc in hexanes as eluent. The solvent was 
removed under reduced pressure to yield a colourless solid (1.36 g, 7.93 mmol, 100%). 
After recrystallization (Hexanes-EtOAc, 1:1), 1,3,5-trimethoxybenzene was obtained as 
colourless crystals, mp 53-54 ºC, TLC Rf 0.16 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, 
CDCl3) 3.75 (9H, s, 1,3,5-OCH3), 6.08 (3H, s, H-2,4,6). 13C NMR (100 MHz, CDCl3) 55.4 
(1,3,5-OCH3), 93.1 (C-2,4,6), 161.7 (C-1,3,5). 
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Benzoyl chloride (0.190 g, 0.2 mL, 1.35 mmol) was added dropwise to an ice-cooled 
stirred mixture of AlCl3 (0.180 g, 1.35 mmol) in DCM (20 mL). After being stirred at 0 ºC 
for 1 h, the reaction mixture was added slowly to a solution of 1,3,5-trimethoxybenzene 
(0.227 g, 1.35 mmol) in DCM (15 mL) at 0 ºC. The reaction mixture was allowed to reach 
room temperature and stirred for a further 12 h. An ice-cooled 6 M HCl (20 mL) was 
poured slowly into the reaction mixture and DCM (20 mL) was also added into the 
mixture. The organic layer was separated and washed with saturated NaHCO3 solution (15 
mL), water (20 mL) and brine (15 mL) and dried over anhydrous MgSO4. The solvent was 
removed in vacuo. The resulting product was purified by silica gel column 
chromatography (hexanes-EtOAc, 7:3) to give 3.32 as a white solid (0.331 g, 1.21 mmol, 
90%). After recrystallization (Hexanes-EtOAc, 1:9), 3.32 was obtained as colourless 
crystals, mp 113-115 ºC (lit.127 113-114 °C), TLC Rf 0.15 (Hexanes-EtOAc, 1:9). 1H NMR 
(400 MHz, CDCl3) 3.66 (6H, s, 2,6-OCH3), 3.84 (3H, s, 4-OCH3), 6.16 (2H, s, H-3,5), 7.39 
(2H, t, J= 7.9 Hz, H-10,12), 7.50 (1H, tt, J = 7.9, 1.3 Hz, H-11), 7.82 (2H, dd, J = 7.9, 1.3 
Hz, H-9,13). 13C NMR (100 MHz, CDCl3) 55.7 (4-OCH3), 56.1 (2,6-OCH3), 91.0 (C-3,5), 
111.3 (C-1), 128.5 (C-10,12), 129.6 (C-9,13), 133.1 (C-11), 138.5 (C-8), 159.0 (C-2,6), 
162.7 (C-4), 195.2 (C-7). [Plate 1]. HRMS (ESI+): Found [M+Na]+ 295.0945, Calc. for 
C16H16NaO4 295.0946. IR (neat) νmax (cm-1) 3053, 2949, 1660, 1599, 1583, 1453, 1123. 








A mixture of phloroglucinol (1.0 g, 7.93 mmol), iodomethane (5.5 mL, 35.2 mmol), and 
anhydrous K2CO3 (12 g, 35.2 mmol) in acetone (70 mL) was refluxed for 12 h. The 
resulting mixture was cooled to room temperature, and filtered through celite. The solvent 
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was removed in vacuo. The crude product was purified by silica gel column 
chromatography with 30% EtOAc in hexanes as eluent. The solvent was removed under 
reduced pressure to yield 3.56 as a colourless amorphous solid (0.9 g, 4.84 mmol, 61%), 
TLC Rf 0.17 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 2.00 (3H, s, CH3), 3.78 
(9H, s, 2,4,6-OCH3), 6.12 (2H, s, H-3,5). 13C NMR (100 MHz, CDCl3) 7.8 (CH3), 55.8 
(2,4,6-OCH3), 90.7 (C-3,5), 106.9 (C-1), 158.8 (C-2,6), 160.0 (C-4). 













Benzoyl chloride (0.190 g, 0.2 mL, 1.35 mmol) was added dropwise to an ice-cold stirred 
mixture of AlCl3 (0.180 g, 1.35 mmol) in DCM (20 mL). After being stirred at 0 ºC for 1 h, 
the reaction mixture was added slowly to a solution of 1,3,5-trimethoxy-2-methylbenzene 
(0.246 g, 1.35 mmol) in DCM (15 mL) at 0 ºC. The reaction mixture was allowed to attain 
room temperature and stirred for a further 12 h. An ice-cooled 6 M HCl (20 mL) was 
poured slowly into the reaction mixture and DCM (20 mL) was also added into the 
mixture. The organic layer was washed with saturated NaHCO3 solution (15 mL), water 
(20 mL) and brine (15 mL) and dried over anhydrous MgSO4. The solvent was removed in 
vacuo. The resulting mixture was purified by silica gel column chromatography (Hexanes-
EtOAc, 3:7) to yield the product as a white solid (0.356 g, 1.24 mmol, 92%). After 
recrystallization (Hexanes-EtOAc, 1:9), 3.57 was obtained as colourless crystals, mp 95-96 
ºC, TLC Rf 0.16 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 2.11 (3H, s, CH3), 
3.62 (3H, s, 2-OCH3) 3.72 (3H, s, 6-OCH3), 3.91 (3H, s, 4-OCH3), 6.34 (1H, s, H-5), 7.43 
(2H, dd, J = 8.0, 7.6, H-10,12), 7.55 (1H, tt, J = 7.6, 1.3, H-11), 7.86 (2H, dd, J = 8.0, 1.3, 
H-9,13). 13C NMR (100 MHz, CDCl3) 8.4 (CH3), 55.7 (4-OCH3), 56.0 (6-OCH3), 62.0 (2-
OCH3), 91.4 (C-5), 112.2 (C-1), 115.9 (C-3), 128.3 (C-10,12), 129.4 (C-9,13), 132.9 (C-
11), 138.3 (C-8), 156 (C-6), 157.0 (C-2), 160.1 (C-4), 195.3 (C-7). [Plate 2]. HRMS 
(ESI+): Found [M+Na]+ 309.1103, Calc. for C17H18NaO4 309.1103. IR (neat) νmax (cm-1) 
3051, 2940, 1655, 1599, 1583, 1450, 1112. 
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2-Fluorobenzoyl chloride (0.715 g, 4.51 mmol) was added dropwise to an ice-cold stirred 
mixture of AlCl3 (0.670 g, 5.03 mmol) in DCM (15 mL). After being stirred at 0 ºC for 1 h, 
the reaction mixture was added slowly to a solution of 1,3,5-trimethoxybenzene (0.759 g, 
4.51 mmol) in DCM (15 mL) at 0 ºC. The reaction mixture was allowed to reach room 
temperature and stirred for a further 12 h. An ice-cooled 6 M HCl (20 mL) was poured 
slowly into the reaction mixture and DCM (20 mL) was also added into the mixture. The 
organic layer was washed with saturated NaHCO3 solution (15 mL), water (20 mL) and 
brine (15 mL) and dried over anhydrous MgSO4. The solvent was removed in vacuo. The 
resulting mixture was purified by silica gel column chromatography (Hexanes-EtOAc, 3:7) 
to yield the product as a white solid (1.23 g, 4.24 mmol, 94%). After recrystallization 
(Hexanes-EtOAc, 1:9), 3.58 was obtained as colourless crystals, mp 127-129 ºC, TLC Rf 
0.21 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 3.67 (6H, s, 2,6-OCH3), 3.83 
(3H, s, 4-OCH3), 6.12 (2H, s, H-3,5), 7.01 (1H, dd, J = 11.4, 8.5, H-10), 7.15 (1H, t, J = 
7.7, H-12), 7.43 (1H, m, H-11), 7.75 (1H, dd, J = 7.7, 7.6, H-13). 13C NMR(100 MHz, 
CDCl3) 55.4 (4-OCH3), 55.9 (2,6-OCH3), 90.8 (C-3,5), 113.1 (C-1), 116.3 (d, J = 22.8, C-
10), 123.8 (d, J = 2.9,C-12), 127.9 (d, J = 9.5,C-8), 131.4 (d, J = 1.4,C-13), 133.8 (d, J = 
9.1, C-11), 159.1 (C-2,6), 161.7 (d, J = 256.5, C-9), 162.7 (C-4), 190.7 (C-7). [Plate 3]. 
HRMS (ESI+): Found [M+Na]+ 313.0849,Calc. for C16H15FNaO4 313.0852.IR (neat) νmax 
(cm-1) 3010, 2949, 1651, 1603, 1583, 1451, 1122. 
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3-Fluorobenzoyl chloride (0.715 g, 4.51 mmol) was added dropwise to an ice-cooled 
stirred mixture of AlCl3 (0.670 g, 5.03 mmol) in DCM (15 mL). After being stirred at 0 ºC 
for 1 h, the reaction mixture was added slowly to a solution of 1,3,5-trimethoxybenzene 
(0.759 g, 4.51 mmol) in DCM (15 mL) at 0 ºC. The reaction mixture was allowed to attain 
room temperature and stirred for a further 12 h. An ice-cooled 6 M HCl (20 mL) was 
poured slowly into the reaction mixture and DCM (20 mL) was also added into the 
mixture. The organic layer was washed with saturated NaHCO3 solution (15 mL), water 
(20 mL) and brine (15 mL) and dried over anhydrous MgSO4. The solvent was removed in 
vacuo. The resulting mixture was purified by silica gel column chromatography (Hexanes-
EtOAc, 3:7) to yield the product as a white solid (1.24 g, 4.28 mmol, 95%). After 
recrystallization (Hexanes-EtOAc, 1:9), 3.59 was obtained as colourless crystals, mp 107-
109 °C, TLC Rf 0.22 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 3.69 (6H, s, 2,6-
OCH3), 3.86 (3H, s, 4-OCH3), 6.17 (2H, s, H-3,5), 7.21 (1H, td, J = 8.2, 2.8, H-12), 7.37 
(1H, m, H-11), 7.51 (1H, dt, J = 9.3, 1.8, H-9), 7.60 (1H, dt, J = 8.2, 1.8, H-13). 13C 
NMR(100 MHz, CDCl3) 55.5 (4-OCH3), 55.8 (2,6-OCH3), 90.8 (C-3,5), 110.4 (C-1), 
115.9 (d, J = 22.4, C-9), 119.7 (d, J = 21.5, C-11), 125.1 (d, J = 2.8, C-13), 129.8 (d, J = 
7.5, C-12), 140.6 (d, J= 6.2, C-8), 158.9 (C-2,6), 162.7 (C-4), 162.8 (d, J = 246.6, C-10), 
193.6 (C-7). [Plate 4]. HRMS (ESI+): Found [M+Na]+ 313.0849, Calc. for C16H15FNaO4 
313.0852.IR (neat) νmax (cm-1) 2947, 2841, 1676, 1583, 1267. 
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4-Fluorobenzoyl chloride (0.715 g, 4.51 mmol) was added dropwise to an ice-cooled 
stirred mixture of AlCl3 (0.670 g, 5.03 mmol) in DCM (15 mL). After being stirred at 0 ºC 
for 1 h, the reaction mixture was added slowly to a solution of 1,3,5-trimethoxybenzene 
(0.759 g, 4.51 mmol) in DCM (15 mL) at 0 ºC. The reaction mixture was allowed to attain 
room temperature and stirred for a further 12 h. An ice-cooled 6 M HCl (20 mL) was 
poured slowly into the reaction mixture and DCM (20 mL) was also added into the 
mixture. The organic layer was washed with saturated NaHCO3 solution (15 mL), water 
(20 mL) and brine (15 mL) and dried over anhydrous MgSO4. The solvent was removed in 
vacuo. The resulting mixture was purified by silica gel column chromatography (Hexanes-
EtOAc, 3:7) to yield the product as a white solid (1.24 g, 4.28 mmol, 95%). After 
recrystallization (1:9 Hexanes-EtOAc), 3.60 was obtained as colourless crystals, mp 155-
157 ºC, TLC Rf 0.22 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 3.69 (6H, s, 2,6-
OCH3), 3.86 (3H, s, 4-OCH3), 6.17 (2H, s, H-3,5), 7.07 (2H, dd, J = 9.2, 8.6, H-10,12), 
7.85 (2H, dd, J = 8.6,5.7, H-9,13). 13C NMR(100 MHz, CDCl3) 55.5 (4-OCH3), 55.8 (2,6-
OCH3), 90.8 (C-3,5), 110.7 (C-1), 115.3 (d, J = 22.0, C-10,12), 132.0 (d, J = 9.4, C-9,13), 
134.9 (C-8), 158.7 (C-2,6), 162.6 (C-4), 165.8 (d, J = 254.8, C-11), 193.3 (C-7). [Plate 5]. 
HRMS (ESI+): Found [M+Na]+ 313.0849, Calc. for C16H15FNaO4 313.0852. IR (neat) νmax 
(cm-1) 3001, 2943, 1658, 1593, 1504, 1272. 











To a stirred solution of phenyl(2,4,6-trimethoxyphenyl)methanone (500 mg, 1.84 mmol) in 
DCM (30 mL) at -78 ºC was added boron tribromide (1 mL). The temperature of the 
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reaction mixture was allowed to reach the room temperature slowly. After being stirred for 
30 h at room temperature, the reaction mixture was cooled to 0 ºC and quenched with 
water. DCM (15 mL) was added into a stirred mixture. A clear liquid was decanted off the 
mixture and the residue was washed with EtOAc. The organic layer was dried over 
anhydrous MgSO4 and the solvent was removed in vacuo. The resulting yellow product 
was purified by silica gel column chromatography with 40% EtOAc in hexanes as eluent 
and 3.33 was obtained as a light yellow crystalline solid (419 mg, 1.82 mmol, 99%), mp 
168-170ºC (lit.125,127 168-170 °C), TLC Rf 0.52 (Hexanes-EtOAc, 1:1). 1H NMR (400 
MHz, DMSO-d6) 5.84 (2H, s, H-3,5), 7.43 (2H, t, J= 7.9, H-10,12), 7.53 (1H, tt, J = 7.9, 
1.3, H-11), 7.62 (2H, dd, J= 7.9, 1.3, H-9,13), 9.82 (1H, bs, 4-OH), 10.08 (2H, bs, 2,6-
OH). 13C NMR (100 MHz, DMSO-d6) 94.8 (C-3,5), 106.0 (C-1), 128.6 (C-10,12), 128.9 
(C-9,13), 132.1 (C-11), 140.2 (C-8), 159.8 (C-2,6), 162.3 (C-4), 196.9 (C-7). [Plate 6]. 
HRMS (ESI-) : Found [M-H]- 229.0497, Calc. for C13H9O4 229.0501. IR (neat) νmax (cm-1): 
3621, 1625, 1598, 1543, 1319. 













To a stirred solution of (2-fluorophenyl)(2,4,6-trimethoxyphenyl)methanone (2.1 g, 7.23 
mmol) in DCM (45 mL) at -78 ºC was added boron tribromide (3.1 mL). The temperature 
of the reaction mixture was allowed to reach the room temperature slowly. After being 
stirred for 30 h at room temperature, the reaction mixture was cooled to 0 ºC and quenched 
with water. DCM (20 mL) was added into a stirred mixture. A clear liquid was decanted 
off the mixture and the residue was washed with EtOAc. The organic layer was dried over 
anhydrous MgSO4 and the solvent was removed in vacuo. The resulting yellow product 
was purified by silica gel column chromatography with 40% EtOAc in hexanes as eluent 
and 3.61 was obtained as a yellow crystalline solid (1.76 g, 7.08 mmol, 98%), mp 125-128 
ºC, TLC Rf 0.49 (Hexanes-EtOAc, 1:1). 1H NMR (400 MHz, DMSO-d6) 5.78 (2H, s, H-
3,5), 7.15-7.25 (2H, m, H-10,12), 7.38 (1H, t, J= 7.5 H-11), 7.46 (1H, m, H-13), 10.52 
(1H, bs, 4-OH), 11.47 (2H, bs, 2,6-OH). 13C NMR (100 MHz, DMSO-d6) 94.7 (C-3,5), 
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105.0 (C-1), 115.5 (d, J = 21.4, C-10), 124.5 (d, J = 8.3, C-13), 128.9 (d, J = 3.5, C-12), 
131.5 (d, J = 16.2, C-8), 131.7 (d, J = 8.3, C-11), 158.8 (d, J = 248.0, C-9), 163.9 (C-2,6), 
166.1 (C-4), 193.9 (C-7). [Plate 7]. HRMS (ESI-): Found [M-H]- 247.0405, Calc. for 
C13H8FO4 247.0407. IR (neat) νmax (cm-1): 3598, 1627, 1596, 1514, 1309. 













To a stirred solution of (3-fluorophenyl)(2,4,6-trimethoxyphenyl)methanone (2.1 g, 7.23 
mmol) in DCM (45 mL) at -78 ºC was added boron tribromide (3.1 mL). The temperature 
of the reaction mixture was allowed to reach the room temperature slowly. After being 
stirred for 30 h at room temperature, the reaction mixture was cooled to 0 ºC and quenched 
with water. DCM (20 mL) was added into a stirred mixture. A clear liquid was decanted 
off the mixture and the residue was washed with EtOAc. The organic layer was dried over 
anhydrous MgSO4 and the solvent was removed in vacuo. The resulting yellow product 
was purified by silica gel column chromatography with 40% EtOAc in hexanes as eluent 
and 3.62 was obtained as a yellow crystalline solid (1.78 g, 7.16 mmol, 99%), mp 172-
174ºC, TLC Rf 0.49 (Hexanes-EtOAc, 1:1). 1H NMR (400 MHz, DMSO-d6) 5.84 (2H, s, 
H-3,5), 7.29-7.53 (4H, m, H-9,11,12,13), 9.92 (1H, bs, 4-OH), 10.22 (2H, bs, 2,6-OH). 13C 
NMR (100 MHz, DMSO-d6) 94.7 (C-3,5), 105.4 (C-1), 114.9 (d, J = 22.0, C-9), 118.8 (d, 
J = 21.4, C-11), 124.9 (d, J = 2.6, C-13), 130.6 (d, J = 7.9, C-12), 142.9 (d, J = 6.5, C-8), 
160.0 (C-2,6), 162.3 (d, J= 244.0, C-10), 162.7 (C-4), 195.3 (C-7). [Plate 8]. HRMS (ESI-) 
: Found [M-H]- 247.0406, Calc. for C13H8FO4 247.0407. IR (neat) νmax (cm-1): 3419, 1635, 
1596, 1513, 1300. 
 
83 | P a g e  
 












To a stirred solution of (4-fluorophenyl)(2,4,6-trimethoxyphenyl)methanone (2.1 g, 7.23 
mmol) in DCM (45 mL) at -78 ºC was added boron tribromide (3.1 mL). The temperature 
of the reaction mixture was allowed to reach room temperature slowly. After being stirred 
for 30 h at room temperature, the reaction mixture was cooled to 0 ºC and quenched with 
water. DCM (20 mL) was added into a stirred mixture. A clear liquid was decanted off the 
mixture and the residue was washed with EtOAc. The organic layer was dried over 
anhydrous MgSO4 and the solvent was removed in vacuo. The resulting yellow product 
was purified by silica gel column chromatography with 40% EtOAc in hexanes as eluent 
and 3.63 was obtained as a yellow crystalline solid (1.78 g, 7.16 mmol, 99%), mp 166-168 
ºC, TLC Rf 0.49 (Hexanes-EtOAc, 1:1). 1H NMR (400 MHz, DMSO-d6) 5.85 (2H, s, H-
3,5), 7.26 (2H, m, H-10,12),7.69 (2H, m, H-9,13), 9.82 (1H, bs, 4-OH), 10.04 (2H, bs, 2,6-
OH). 13C NMR (100 MHz, DMSO-d6) 94.9 (C-3,5), 106.0 (C-1), 115.4 (d, J = 22.0, C-
10,12), 131.7 (d, J = 9.3, C-9,13), 136.8 (d, J = 2.7, C-8), 159.6 (C-2,6), 162.3 (C-4), 164.7 
(d, J = 249.7, C-11), 195.3 (C-7) [Plate 9]. HRMS (ESI-): Found [M-H]- 247.0409, Calc. 
for C13H8FO4 247.0407. IR (neat) νmax (cm-1): 3556, 1641, 1595, 1506, 1288. 
















To a mixture of phenyl(2,4,6-trihydroxyphenyl)methanone (0.276 g, 1.2 mmol) and DBU 
(0.183 g, 1.2 mmol) in dry THF (15 mL) was added prenyl bromide (0.179 g, 1.2 mmol) in 
small increments. The mixture was stirred at room temperature for 24 h. After addition of 2 
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M HCl (30 mL), the mixture was stirred for a further 15 min and extracted with EtOAc (4 
x 20 mL), washed with brine (30 mL) and dried over anhydrous MgSO4. The removal of 
the solvent in vacuo resulted in a light orange product. After purification by silica gel 
column chromatography (Hexanes-EtOAc, 3:7), 3.54 was obtained as a light orange 
semisolid (0.222 g, 0.744 mmol, 62%); TLC Rf 0.44 (Hexanes-EtOAc, 3:7). 1H NMR (400 
MHz, CDCl3) 1.76 (3H, d, J = 1.1, H-4'b), 1.80 (3H, s, H-4b), 3.36 (2H, d, J = 7.0, H-1b), 
5.26 (1H, m, H-2b), 5.93 (2H, s, H-5, 4-OH), 6.15 (1H, bs, 2-OH), 7.51 (2H, dd, J = 8.1, 
7.5, H-10,12), 7.58 (1H, tt, J = 7.5,1.5, H-11), 7.64 (2H, dd, J = 8.1,1.5, H-9,13), 10.29 
(1H, bs, 6-OH). 13C NMR (100 MHz, CDCl3) 17.9 (C-4b), 21.7 (C-1b), 25.8 (C-4'b), 96.2 
(C-5), 104.6 (C-1), 106.6 (C-3), 121.6 (C-2b), 127.8 (C-9,13), 129.2 (C-10,12), 132.2 (C-
11), 135.4 (C-3b), 140.0 (C-8), 159.4 (C-6), 160.8 (C-2), 162.6 (C-4), 197.7 (C-7). [Plate 
10]. HRMS (ESI-): Found [M-H]- 297.1130, Calc. for C18H17O4 297.1127. IR (neat) νmax 
(cm-1): 3523, 3023, 2953, 1652, 1594, 1577, 1420, 1111. 
















To a mixture of phenyl(2,4,6-trihydroxyphenyl)methanone (0.276 g, 1.2 mmol) and DBU 
(0.366 g, 2.4 mmol) in dry THF (15 mL) was added prenyl bromide (0.358 g, 2.4 mmol) in 
small increments. The mixture was stirred at room temperature for 48 h. After addition of 2 
M HCl (30 mL) to the mixture, it was stirred for a further 15 min and extracted with 
EtOAc (4 x 20 mL), washed with brine (30 mL) and dried over anhydrous MgSO4. The 
removal of the solvent in vacuo resulted in a light orange product. After purification by 
silica gel column chromatography (Hexanes-EtOAc, 2:8), 3.67 was obtained as a light 
orange semisolid (0.211 g, 0.576 mmol, 48%); TLC Rf 0.85 (Hexanes-EtOAc, 3:7). 1H 
NMR (400 MHz, CDCl3) 1.74 (6H, d, J = 1.1, H-4'b,4'd), 1.79 (6H, s, H-4b,4d), 3.34 (4H, 
d, J = 7.1, H-1b,1d), 5.22 (2H, m, H-2b,2d), 6.35 (1H, bs, 4-OH), 7.50 (2H, dd, J = 8.0, 
7.7, H-10,12), 7.57 (1H, tt, J = 7.7, 1.5, H-11), 7.64 (2H, dd, J = 8.0, 1.5, H-9,13), 8.91 
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(2H, bs, 2-OH). 13C NMR (100 MHz, CDCl3) 17.6 (C-4b,4d), 21.8 (C-1b,1d), 26.0 (C-
4'b,4'd), 104.6 (C-1), 106.3 (C-3,5), 121.9 (C-2b,2d),127.8 (C-9,13), 129.2 (C-10,12), 
132.2 (C-11), 135.4 (C-3b,3d), 140.0 (C-8), 157.5 (C-2,6), 161.0 (C-4), 198.0 (C-7). [Plate 
13]. HRMS (ESI+): Found [M+Na]+ 389.1723, Calc. for C23H26NaO4 389.1729. IR (neat) 
νmax (cm-1): 3512, 3023, 2942, 1632, 1586, 1566, 1443, 1121. 

















To a mixture of (3-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (0.298 g, 1.2 mmol) 
and DBU (0.183 g, 1.2 mmol) in dry THF (15 mL) was added prenyl bromide (0.179 g, 1.2 
mmol) in small increments. The mixture was stirred at room temperature for 24 h. After 
addition of 2 M HCl (30 mL), the mixture was stirred for a further 15 min and extracted 
with EtOAc (4 x 20 mL), washed with brine (30 mL) and dried over anhydrous MgSO4. 
The removal of the solvent in vacuo resulted in a light orange product. After purification 
by silica gel column chromatography using 30% EtOAc in hexanes, 3.65 was obtained as a 
light orange semisolid (0.231 g, 0.732 mmol, 61%); TLC Rf 0.43 (Hexanes-EtOAc, 3:7). 
1H NMR (400 MHz, CDCl3) 1.76 (3H, d, J= 1.1, H-4'b), 1.80 (3H, s, H-4b), 3.36 (2H, d, J 
= 7.1, H-1b), 5.25 (1H, m, H-2b), 5.91 (1H, s, H-5), 7.24 (1H, t, J = 8.1, H-12), 7.32 (1H, 
m, H-11), 7.38-7.48 (2H, m, H-9,13), 10.16 (1H, bs, 6-OH). 13C NMR (100 MHz, CDCl3) 
17.9 (C-4b), 21.7 (C-1b), 25.8 (C-4'b), 96.2 (C-5), 104.5 (C-1), 106.5 (C-3), 115.1 (d, J = 
22.9, C-9), 118.7 (d, J = 21.1, C-11), 121.3 (C-2b), 130.4 (d, J = 7.6, C-13), 130.4 (d, J = 
7.6, C-12), 135.9 (C-3b), 142.5 (d, J = 6.6, C-8), 159.2 (C-6), 160.9 (C-2), 162.5 (C-4), 
162.6 (d, J = 249.2, C-10), 196.6 (C-7). [Plate 11]. HRMS (ESI+): Found [M+Na]+ 
339.1003, Calc. for C18H17FNaO4 339.1009. IR (neat) νmax (cm-1): 3507, 3061, 2925, 1663, 
1594, 1572, 1446, 1112. 
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To a mixture of (3-phenyl)(2,4,6-trihydroxyphenyl)methanone (0.298 g, 1.2 mmol) and 
DBU (0.366 g, 2.4 mmol) in dry THF (15 mL) was added prenyl bromide (0.358 g, 2.4 
mmol) in small increments. The mixture was stirred at room temperature for 48 h. After 
addition of 2 M HCl (30 mL), the mixture was stirred for a further 15 min and extracted 
with EtOAc (4 x 20 mL), washed with brine (30 mL) and dried over anhydrous MgSO4. 
The removal of the solvent in vacuo resulted in a light orange product. After purification 
by silica gel column chromatography (Hexanes-EtOAc, 3:7), 3.68 was obtained as a light 
orange semisolid (0.212 g, 0.552 mmol, 46%); TLC Rf 0.85 (Hexanes-EtOAc, 3:7). 1H 
NMR (400 MHz, CDCl3) 1.75 (6H, d, J = 1.1, H-4'b,4'd), 1.79 (6H, s, H-4b,4d), 3.35 (4H, 
d, J = 7.1, H-1b,1d), 5.22 (2H, m, H-2b,2d), 6.38 (1H, bs, 4-OH), 7.22 (1H, t, J = 8.1 H-
12), 7.31 (1H, m, H-11), 7.38-7.47 (2H, m, H-9,13), 8.83 (2H, bs, 2,6-OH). 13C NMR (100 
MHz, CDCl3) 17.6 (C-4b,4d), 21.8 (C-1b,1d), 26.1 (C-4'b,4'd), 104.6 (C-1), 106.1 (C-3,5), 
115.2 (d, J = 22.9, C-9), 118.6 (d, J = 21.1, C-11), 121.6 (C-2b,2d), 123.6 (d, J = 3.0, C-
13), 130.3 (d, J = 7.4, C-12), 135.8 (C-3b,3d), 142.9 (d, J = 6.5, C-6), 157.7 (C-2,6), 160.9 
(C-4), 162.5 (d, J = 247.9, C-10), 197.0 (C-7). [Plate 14]. HRMS (ESI+): Found [M+Na]+ 
407.1634, Calc. for C23H25FNaO4 407.1635. IR (neat) νmax (cm-1): 3524, 3035, 2941, 1653, 
1587, 1577, 1431, 1142. 
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To a mixture of (4-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (0.298 g, 1.2 mmol) 
and DBU (0.183 g, 1.2 mmol) in dry THF (15 mL) was added prenyl bromide (0.179 g, 1.2 
mmol) in small increments. The mixture was stirred at room temperature for 24 h. After 
addition of 2 M HCl (30 mL), the mixture was stirred for a further 15 min and extracted 
with EtOAc (4 x 20 mL), washed with brine (30 mL) and dried over anhydrous MgSO4. 
The removal of the solvent in vacuo resulted in a light orange product. After purification 
by silica gel column chromatography (Hexanes-EtOAc, 3:7), 3.66 was obtained as a light 
orange semisolid (0.235 g, 0.744 mmol, 62%); TLC Rf 0.43 (Hexanes-EtOAc, 3:7). 1H 
NMR (400 MHz, CDCl3) 1.76 (3H, d, J = 1.1, H-4'b), 1.80 (3H, s, H-4b), 3.36 (2H, d, J = 
7.1, H-1b), 5.25 (1H, m, H-2b), 5.92 (1H, s, H-5), 6.22 (1H, bs, 4-OH), 7.14 (2H, m, H-
10,12), 6.50 (1H, bs, 2-OH), 7.67 (2H, m, H-9,13), 10.03 (1H, bs, 6-OH). 13C NMR (100 
MHz, CDCl3) 17.9 (C-4b), 21.7 (C-1b), 25.8 (C-4'b), 96.1 (C-5), 104.6 (C-1), 106.5 (C-3), 
115.8 (d, J = 21.9, C-10,12), 121.4 (C-2b), 130.9 (d, J = 9.0, C-9,13), 135.7 (C-3b), 136.4 
(d, J = 3.1, C-8), 160.0 (C-6), 160.6 (C-2), 162.2 (C-4), 165.0 (d, J = 253.6, C-11), 196.6 
(C-7). [Plate 12]. HRMS (ESI-): Found [M-H]- 315.1035, Calc. for C18H16FO4 315.1033. 
IR (neat) νmax (cm-1): 3559, 3055, 2952, 1663, 1596, 1587, 1450, 1143. 
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To a mixture of (4-phenyl)(2,4,6-trihydroxyphenyl)methanone (0.298 g, 1.2 mmol) and 
DBU (0.366 g, 2.4 mmol) in dry THF (15 mL) was added prenyl bromide (0.358 g, 2.4 
mmol) in small increments. The mixture was stirred at room temperature for 48 h. After 
addition of 2 M HCl (30 mL), the mixture was stirred for a further 15 min and extracted 
with EtOAc (4 x 20 mL), washed with brine (30 mL) and dried over anhydrous MgSO4. 
The removal of the solvent in vacuo resulted in a light orange product. After purification 
by silica gel column chromatography (Hexanes-EtOAc, 2:8), 3.69 was obtained as a light 
orange semisolid (0.217 g, 0.564 mmol, 47%); TLC Rf 0.85 (Hexanes-EtOAc, 3:7). 1H 
NMR (400 MHz, CDCl3) 1.75 (6H, d, J = 1.1, H-4'b,4'd), 1.79 (6H, s, H-4b,4d), 3.35 (4H, 
d, J = 7.1, H-1b,1d), 5.22 (2H, m, H-2b,2d), 6.34 (1H, bs, 4-OH), 7.14 (2H, m, H-10,12), 
7.67 (2H, m, H-9,13), 8.75 (2H, bs, 2,6-OH). 13C NMR (100 MHz, CDCl3) 17.9 (C-4b,4d), 
21.9 (C-1b,1d), 25.8 (C-4'b,4'd), 104.7 (C-1), 106.1 (C-3,5), 115.7 (d, J = 21.9, C-10,12), 
121.6 (C-2b,2d), 130.9 (d, J = 9.0, C-9,13), 135.6 (C-3b,3d), 136.7 (d, J = 3.1, C-8), 157.4 
(C-2,6), 160.6 (C-4), 164.9 (d, J = 253.6, C-11), 196.9 (C-7). [Plate 15]. HRMS (ESI-): 
Found [M-H]- 383.1653, Calc. for C23H24O4F 383.1659. IR (neat) νmax (cm-1): 3552, 3046, 
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To a mixture of phenyl(2,4,6-trihydroxyphenyl)methanone (0.276 g, 1.2 mmol) and DBU 
(0.183 g, 1.2 mmol) in dry THF (15 mL) was added geranyl bromide (0.261 g, 1.2 mmol) 
in small increments. The mixture was stirred at room temperature for 24 h. After addition 
of 2 M HCl (30 mL), the mixture was stirred for a further 15 min and extracted with 
EtOAc (4 x 20 mL), washed with brine (30 mL) and dried over anhydrous MgSO4. The 
removal of the solvent in vacuo resulted in a light orange product. After purification by 
silica gel column chromatography (Hexanes-EtOAc, 2:8), 3.8 was obtained as a light 
orange semisolid (0.181 g, 0.51 mmol, 42%); TLC Rf 0.46 (Hexanes-EtOAc, 2:8). 1H 
NMR (400 MHz, CDCl3) 1.59 (3H, d, J = 1.1, H-8'b), 1.66 (3H, s, H-8b), 1.79 (3H, s, H-
4'b), 2.02-2.16 (4H, m, H-4b,5b), 3.37 (2H, d, J = 7.0, H-1b), 5.05 (1H, t, J = 6.6, H-6b), 
5.27 (1H, t, J = 6.8, H-2b), 5.93 (1H, s, H-5), 6.27 (1H, bs, 4-OH), 7.47-7.66 (5H, m, H-
9,10,11,12,13), 10.28 (1H, bs, 6-OH). 13C NMR (100 MHz, CDCl3) 16.2 (C-4'b), 17.7 (C-
8'b), 21.7 (C-1b), 25.7 (C-8b), 26.3 (C-5b), 39.7 (C-4b), 96.3 (C-5), 104.6 (C-1), 106.5 (C-
3), 121.5 (C-2b), 123.7 (C-6b), 127.8 (C-9,13), 129.1 (C-10,12), 123.1 (C-7b), 132.2 (C-
11), 139.3 (C-3b), 140.1 (C-8), 159.4 (C-6), 160.8 (C-2), 162.6 (C-4), 197.8 (C-7). [Plate 
16]. HRMS (ESI+): Found [M+Na]+ 389.1721, Calc. for C23H26NaO4 389.1729. IR (neat) 
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To a mixture of (3-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (0.276 g, 1.2 mmol) 
and DBU (0.183 g, 1.2 mmol) in dry THF (15 mL) was added geranyl bromide (0.261 g, 
1.2 mmol) in small increments. The mixture was stirred at room temperature for 24 h. 
After addition of 2 M HCl (30 mL), the mixture was stirred for a further 15 min and 
extracted with EtOAc (4 x 20 mL), washed with brine (30 mL) and dried over anhydrous 
MgSO4. The removal of the solvent in vacuo resulted in a light orange product. After 
purification by silica gel column chromatography (Hexanes-EtOAc, 2:8), 3.71 was 
obtained as a light orange semisolid (0.18 g, 0.458 mmol, 40%); TLC Rf 0.45 (Hexanes-
EtOAc, 2:8). 1H NMR (400 MHz, CDCl3) 1.58 (3H, s,H-8'b), 1.65 (3H, s, H-8b), 1.79 (3H, 
s, H-4'b), 2.02-2.16 (4H, m, H-4b,5b), 3.38 (2H, d, J = 7.2, H-1b), 5.04 (1H, t, J = 6.8, H-
6b), 5.26 (1H, t, J = 6.9, H-2b), 5.92 (1H, s, H-5), 6.24 (1H, bs, 4-OH), 7.23 (1H, t, J = 8.2 
H-12), 7.32 (1H, m, H-11), 7.38-7.48 (2H, m, H-9,13), 7.54 (1H, bs, 2-OH), 10.13 (1H, bs, 
6-OH). 13C NMR (100 MHz, CDCl3) 16.2 (C-4'b), 17.7 (C-8'b), 21.7 (C-1b), 25.6 (C-8b), 
26.2 (C-5b), 39.7 (C-4b), 96.2 (C-5), 104.5 (C-1), 106.4 (C-3), 115.1 (d, J = 22.8, C-9), 
118.7 (d, J = 21.2, C-11), 121.2 (C-2b), 123.5 (d, J = 3.0, C-13), 123.6 (C-6b), 130.3 (d, J 
= 7.9, C-12), 130.5 (C-7b), 139.9 (C-3b), 142.6 (d, J = 6.6, C-8), 159.3 (C-6), 160.9 (C-2), 
162.7 (C-4), 162.6 (d, J = 248.6, C-10), 197.8 (C-7). [Plate 17]. HRMS (ESI+): Found 
[M+Na]+ 407.1632, Calc. for C23H25FNaO4 407.1635. IR (neat) νmax (cm-1): 3561, 3059, 
2947, 1662, 1598, 1575, 1457, 1133. 
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To a mixture of (3-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (0.276 g, 1.2 mmol) 
and DBU (0.183 g, 1.2 mmol) in dry THF (15 mL) was added geranyl bromide (0.522 g, 
2.4 mmol) in small increments. The mixture was stirred at room temperature for 48 h. 
After addition of 2 M HCl (30 mL), the mixture was stirred for a further 15 min and 
extracted with EtOAc (4 x 20 mL), washed with brine (30 mL) and dried over anhydrous 
MgSO4. The removal of the solvent in vacuo resulted in a light orange product. After 
purification by silica gel column chromatography (Hexanes-EtOAc, 2:8), 3.73 was 
obtained as a light orange oil (0.120 g, 0.192 mmol, 16%); TLC Rf 0.88 (Hexanes-EtOAc, 
2:8). 1H NMR (400 MHz, CDCl3) 1.58 (6H, s, H-8'b,8'd), 1.64 (6H, s, H-8b,8d), 1.78 (6H, 
s, H-4'b,4'd), 2.03-2.15 (8H, m, H-4b,4d,5b,5d), 3.37 (4H, d, J = 6.9, H-1b,1d), 5.03 (2H, t, 
J = 6.8, H-6b,6d), 5.23 (2H, t, J = 6.9, H-2b,2d), 6.42 (1H, bs, 4-OH), 7.20 (1H, m, H-12), 
7.31 (1H, m, H-11), 7.38-7.48 (2H, m, H-9,13), 8.86 (2H, bs, 2,6-OH). 13C NMR (100 
MHz, CDCl3) 16.2 (C-4'b,4'd), 17.7 (C-8'b,8'd), 21.8 (C-1b,1d), 25.6 (C-8b,8d), 26.2 (C-
5b,5d), 39.7 (C-4b,4d), 104.6 (C-1), 106.0 (C-3,5), 115.1 (d, J = 22.8, C-9), 118.4 (d, J = 
21.1, C-11), 121.5 (C-2b,2d), 123.6 (d, J = 3.0, C-13), 123.6 (C-6b,6d), 130.0 (d, J = 7.9, 
C-12), 132.1 (C-7b,7d), 139.7 (C-3b,3d), 143.1 (d, J = 6.6, C-8), 157.8 (C-2,6), 160.9 (C-
4), 162.5 (d, J = 247.8, C-10), 197.2 (C-7). [Plate 19]. HRMS (ESI+): Found [M+Na]+ 
543.2895, Calc. for C33H41FNaO4 543.2887. IR (neat) νmax (cm-1): 3543, 3046, 2936, 1657, 
1594, 1586, 1455, 1145. 
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To a mixture of (4-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (0.276 g, 1.2 mmol) 
and DBU (0.183 g, 1.2 mmol) in dry THF (15 mL) was added geranyl bromide (0.261 g, 
1.2 mmol) in small increments. The mixture was stirred at room temperature for 24 h. 
After addition of 2 M HCl (30 mL), the mixture was stirred for a further 15 min and 
extracted with EtOAc (4 x 20 mL), washed with brine (30 mL) and dried over anhydrous 
MgSO4. The removal of the solvent in vacuo resulted in a light orange product. After 
purification by silica gel column chromatography (Hexanes-EtOAc, 2:8), 3.72 was 
obtained as a light orange semisolid (0.202 g, 0.528 mmol, 44%). TLC Rf 0.45 (Hexanes-
EtOAc, 2:8). 1H NMR (400 MHz, CDCl3) 1.59 (3H, s, H-8'b), 1.65 (3H, s, H-8b), 1.79 
(3H, s, H-4'b), 2.03-2.14 (4H, m, H-4b,5b), 3.38 (2H, d, J = 7.1, H-1b), 5.04 (1H, t, J = 
6.9, H-6b), 5.26 (1H, t, J = 7.0, H-2b), 5.92 (1H, s, H-5), 6.26 (1H, bs, 4-OH), 7.14 (2H, m, 
H-10,12), 7.57 (1H, bs, 2-OH), 7.67 (2H, m, H-9,13), 10.00 (1H, bs, 6-OH). 13C NMR 
(100 MHz, CDCl3) 16.3 (C-4'b), 17.7 (C-8'b), 21.7 (C-1b), 25.6 (C-8b), 26.3 (C-5b), 39.7 
(C-4b), 96.2 (C-5), 104.6 (C-1), 106.4 (C-3), 115.7 (d, J = 21.9, C-10,12), 121.3 (C-2b), 
122.1 (C-6b), 130.9 (d, J = 9.0, C-9,13), 132.1 (C-7b), 136.4 (d, J = 3.4, C-8), 139.6 (C-
3b), 159.0 (C-6), 160.6 (C-2), 162.3 (C-4), 165.0 (d, J = 253.8, C-11), 196.7 (C-7). [Plate 
18]. HRMS (ESI+): Found [M+Na]+ 407.1632, Calc. for C23H25FNaO4 407.1635. IR (neat) 
νmax (cm-1): 3548, 3062, 2946, 1662, 1595, 1572, 1451, 1141. 
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To a mixture of (4-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (0.276 g, 1.2 mmol) 
and geranyl bromide (0.522 g, 2.4 mmol) in dry THF (15 mL) was added DBU (0.183 g, 
1.2 mmol) in small increments. The mixture was stirred at room temperature for 48 h. 
After addition of 2 M HCl (30 mL), the mixture was stirred for a further 15 min and 
extracted with EtOAc (4 x 20 mL), washed with brine (30 mL) and dried over anhydrous 
MgSO4. The removal of the solvent in vacuo resulted in a light orange product. After 
purification by silica gel column chromatography (Hexanes-EtOAc, 2:8), 3.74 was 
obtained as a light orange oil (0.120 g, 0.192 mmol, 16%), TLC Rf 0.88 (Hexanes-EtOAc, 
3:7). 1H NMR (400 MHz, CDCl3) 1.58 (6H, s, H-8'b,8'd), 1.64 (6H, s, H-8b,8d), 1.78 (6H, 
s, H-4'b,4'b), 2.03-2.15 (8H, m, H-4b,4d,5b,5d), 3.37 (4H, d, J = 7.2, H-1b,1d), 5.03 (2H, t, 
J = 6.9, H-6b,6d), 5.23 (2H, t, J = 7.2, H-2b,2d), 6.37 (1H, bs, 4-OH), 7.11 (2H, m, H-
10,12), 7.67 (2H, m, H-9,13), 8.78 (2H, bs, 2,6-OH). 13C NMR (100 MHz, CDCl3) 16.2 
(C-4'b,4'd), 17.7 (C-8'b,8'd), 21.8 (C-1b,1d), 25.6 (C-8b,8d), 26.3 (C-5b,5d), 39.7 (C-
4b,4d), 104.7 (C-1), 106.0 (C-3,5), 115.5 (d, J = 21.9, C-10,12), 121.6 (C-2b,2d), 123.6 
(C-6b,6d), 131.0 (d, J = 8.9, C-9,13), 132.1 (C-7b,7d), 136.9 (d, J = 3.2, C-8), 139.5 (C-
3b,3d), 157.5 (C-2,6), 160.6 (C-4), 164.9 (d, J = 252.5, C-11), 197.1 (C-7). [Plate 20]. 
HRMS (ESI+): Found [M+Na]+ 543.2895, Calc. for C33H41FNaO4 543.2887. IR (neat) νmax 
(cm-1): 3549, 3041, 2929, 1652, 1584, 1589, 1456, 1149. 
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A mixture of (3-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (0.20 g, 0.81 mmol), 
prenyl bromide (0.48 g) and K2CO3 (0.44 g) in dry acetone (10 mL) was refluxed for 6 h. 
The mixture was allowed to cool before being filtered through a sintered funnel. The 
filtrate was washed with a minimal amount of water and extracted with EtOAc. The 
organic layer was dried over anhydrous MgSO4. After the solvent of the mixture was 
reduced in vacuo, the mixture was purified by column chromatography (Hexanes-EtOAc, 
1:4) to obtain 3.82 (36 mg, 10%) as a light orange semisolid, TLC Rf 0.61 (Hexanes-
EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 1.57 (6H, s, H-4a,4e), 1.67 (6H, s, H-4'a,4'e), 
1.79 (3H, s, H-4c), 1.84 (3H, s, H-4'c), 4.42 (4H, d, J = 6.7, H-1a,1e), 4.55 (2H, d, J = 6.8, 
H-1c), 5.20 (2H, t, J = 6.7, H-2a,2e), 5.53 (1H, t, J = 6.8, H-2c), 6.19 (2H, s, H-3,5), 7.21 
(1H, t, J = 7.8, H-11), 7.37 (1H, m, H-12), 7.51 (1H, d, J = 9.5, H-9), 7.61 (1H, d, J = 7.8, 
H-13). 13C NMR (100 MHz, CDCl3) 18.1 (C-4a,4e), 18.2 (C-4c), 25.6 (C-4'a,4'e), 25.8 (C-
4'c), 64.9 (C-1c), 65.6 (C-1a,1e), 92.9 (C-3,5), 111.5 (C-1), 115.9 (d, J = 22.1, C-9), 119.3 
(d, J = 21.3, C-11), 119.3 (C-2c), 119.5 (C-2a,2e), 125.0 (d, J = 2.2, C-13), 129.6 (d, J = 
7.6, C-12), 137.5 (C-3a,3e), 138.6 (C-3c), 141.1 (d, J = 6.2, C-8), 158.2 (C-2,6), 161.6 (C-
4), 162.7 (d, J = 253.0, C-10), 193.7 (C-7). [Plate 24]. HRMS (ESI+): Found [M+Na]+ 
475.2267, Calc. for C28H33FNaO4 475.2261. 
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A mixture of (3-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (0.2 g), prenyl bromide 
(0.48 g) and K2CO3 (0.44 g) in dry acetone (10 mL) was refluxed for 6h. The mixture was 
allowed to cool before being filtered through a sintered funnel. The filtrate was washed 
with a minimal amount of water and extracted with EtOAc. The organic layer was dried 
over MgSO4. After the solvent of the mixture was reduced in vacuo, the mixture was 
purified by column chromatography (Hexanes-EtOAc, 1:4) to obtain 3.81 (62 mg, 20%) as 
a cream white semisolid, TLC Rf 0.70 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 
1.54 (3H, s, H-4e), 1.62 (3H, s, H-4'e), 1.78 (3H, s, H-4c), 1.83 (3H, s, H-4'c), 4.20 (2H, d, 
J = 6.8, H-1e), 4.58 (2H, d, J = 6.8, H-1c), 4.73 (1H, t, J = 6.8, H-2e), 5.50 (1H, t, J = 6.8, 
H-2c), 5.94 (1H, d, J = 2.3, H-3), 6.17 (1H, d, J = 2.3, H-5), 7.10-7.18 (2H, m, H-9,11), 
7.27 (1H, d, J = 7.8, H-13), 7.33 (1H, m, H-12), 12.37 (1H, bs, 2-OH). 13C NMR (100 
MHz, CDCl3) 17.9 (C-4e), 18.2 (C-4c), 25.5 (C-4'e), 25.8 (C-4'c), 65.0 (C-1e), 65.2 (C-1c), 
92.5 (C-3), 94.1 (C-5), 105.4 (C-1), 114.3 (d, J = 22.7, C-9), 116.8 (d, J = 21.7, C-11), 
118.0 (C-2e), 118.6 (C-2c), 122.8 (d, J = 3.0, C-13), 129.2 (d, J = 7.6, C-12), 137.8 (C-3e), 
139.3 (C-3c), 144.5 (d, J = 7.1, C-8), 161.4 (C-6), 162.1 (d, J = 244.0, C-10), 166.2 (C-4), 
166.4 (C-2), 198.0 (d, J = 1.9, C-7). [Plate 23]. HRMS (ESI+): Found [M+Na]+ 407.1642, 
Calc. for C23H25FNaO4 407.1635. 
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A mixture of (3-fluorophenyl)[2,4,6-trihydroxy-3-(3-methyl-2-butenyl)phenyl]methanone 
(0.1 g, 0.32 mmol), prenyl bromide (0.14 g) and K2CO3 (0.17 g) in dry acetone (10 mL) 
was refluxed for 5 h. The mixture was allowed to cool before being filtered through a 
sintered funnel. The filtrate was washed with a minimal amount of water and extracted 
with EtOAc. The organic layer was dried over MgSO4. After the solvent of the mixture 
was reduced in vacuo, the mixture was purified by column chromatography (hexanes-
EtOAc, 1:4) to obtain 3.75 (0.12 g, 85%) as light yellow crystals, mp 108-109 °C, TLC Rf 
0.82 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 1.56 (3H, s, H-4e), 1.63 (3H, s, 
H-4'e), 1.70 (3H, s, H-4b), 1.77 (3H, s, H-4c), 1.79 (3H, s, H-4'b), 1.83 (3H, s, H-4'c), 3.33 
(2H, d, J = 7.1, H-1b), 4.21 (2H, d, J = 6.7, H-1e), 4.60 (2H, d, J = 6.7, H-1c), 4.74 (1H, t, 
J = 6.7, H-2e), 5.26 (1H, t, J = 7.1, H-2b), 5.49 (1H, t, J = 6.8, H-2c), 5.94 (1H, s, H-3), 
7.09-7.19 (2H, m, H-9,11), 7.27 (1H, d, J = 7.8, H-13), 7.33 (1H, m, H-12), 12.21 (1H, bs, 
2-OH). 13C NMR (100 MHz, CDCl3) 17.7 (C-4e), 17.9 (C-4b), 18.3 (C-4c), 21.6 (C-1b), 
25.6 (C-4'e), 25.7 (C-4'b), 25.8 (C-4'c), 65.0 (C-1c), 65.2 (C-1e), 88.7 (C-3), 105.4 (C-1), 
110.1 (C-5), 114.3 (d, J = 23.3, C-9), 116.5 (d, J = 21.2, C-11), 118.3 (C-2e), 119.4 (C-2c), 
122.6 (C-2b), 122.9 (d, J = 2.8, C-13), 129.2 (d, J = 8.0, C-12), 131.3 (C-3b), 137.6 (C-3e), 
138.1 (C-3c), 144.9 (d, J = 7.1, C-8), 160.0 (C-6), 162.3 (d, J = 245.5, C-10), 162.4 (C-2), 
163.5 (C-4), 198.3 (d, J = 1.9, C-7). [Plate 21]. HRMS (ESI+): Found [M+Na]+ 475.2262, 
Calc. for C28 H33FNaO4 475.2261. 
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A mixture of (3-fluorophenyl)[2,4,6-trihydroxy-3,5-bis(3-methyl-2-butenyl)phenyl] 
methanone (0.10 g), prenyl bromide (77 mg) and K2CO3 (90 mg) in dry acetone (10 mL) 
was refluxed for 2 h. The mixture was allowed to cool before being filtered through a 
sintered funnel. The filtrate was washed with a minimal amount of water and extracted 
with EtOAc. The organic layer was dried over anhydrous MgSO4. After the solvent of the 
mixture was reduced in vacuo, the mixture was purified by column chromatography 
(Hexanes-EtOAc, 1:4) to obtain 3.76 (0.13 g, 98%) as a light orange semisolid, TLC Rf 
0.90 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 1.36 (3H, s, H-4e), 1.59 (3H, s, 
H-4'e), 1.69 (3H, s, H-4b), 1.71 (6H, s, H-4c,4'b), 1.73 (3H, s, H-4d), 1.79 (3H, s, H-4'd), 
1.82 (3H, s, H-4'c), 3.31 (2H, d, J = 6.4, H-1b), 3.42 (2H, d, J = 6.4, H-1d), 3.96 (2H, d, J 
= 7.0, H-1e), 4.39 (2H, d, J = 7.0, H-1c), 4.70 (1H, t, J = 7.0, H-2e), 5.16 (1H, t, J = 6.4, 
H-2b), 5.27 (1H, t, J = 6.4, H-2d), 5.58 (1H, t, J = 7.0, H-2c), 7.23 (1H, dd, J = 9.5, 7.8, H-
11), 7.39 (1H, m, H-12), 7.42 (1H, d, J = 9.5, H-9), 7.51 (1H, d, J = 7.8, H-13), 10.88 (1H, 
bs, 2-OH). 13C NMR (100 MHz, CDCl3) 17.7 (C-4e), 17.9 (C-4d), 17.9 (C-4b), 18.0 (C-
4c), 23.3 (C-1d), 23.4 (C-1b), 25.6 (C-4'e), 25.6 (C-4'b), 25.7 (C-4'd), 25.8 (C-4'c), 71.3 
(C-1c), 72.7 (C-1e), 110.0 (C-1), 112.0 (C-5), 116.3 (d, J = 22.8, C-9), 118.8 (d, J = 21.3, 
C-11), 119.5 (C-2e), 120.4 (C-2c), 121.2 (C-3), 122.8 (C-2d), 124.0 (C-2b), 125.3 (d, J = 
2.4, C-13), 129.2 (d, J = 7.6, C-12), 131.3 (C-3b), 132.1 (C-3d), 137.5 (C-3e), 137.5 (C-
3c), 141.9 (d, J = 6.6, C-8), 156.7 (C-6), 169.3 (C-2), 162.1 (d, J = 248.3, C-10), 162.5 (C-
4), 198.1 (C-7). [Plate 22]. HRMS (ESI+): Found [M+Na]+ 543.2882, Calc. for 
C33H41FNaO4 543.2887. 
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A mixture of (4-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (0.20 g), prenyl bromide 
(0.48 g) and K2CO3 (0.44 g) in dry acetone (10 mL) was refluxed for 6 h. The mixture was 
allowed to cool before being filtered through a sintered funnel. The filtrate was washed 
with a minimal amount of water and extracted with EtOAc. The organic layer was dried 
over anhydrous MgSO4. After the solvent of the mixture was reduced in vacuo, the mixture 
was purified by column chromatography (Hexanes-EtOAc, 1:4) to obtain 3.83 (62 mg, 
20%) as cream white crystals, mp 86-90 °C, TLC Rf 0.71 (Hexanes-EtOAc, 1:9). 1H NMR 
(400 MHz, CDCl3) 1.53 (3H, s, H-4e), 1.62 (3H, s, H-4'e), 1.77 (3H, s, H-4c), 1.83 (3H, s, 
H-4'c), 4.21 (2H, d, J = 6.7, H-1e), 4.56 (2H, d, J = 6.7, H-1c), 4.75 (1H, t, J = 6.7, H-2e), 
5.49 (1H, t, J = 6.7, H-2c), 5.94 (1H, d, J = 2.4, H-3), 6.18 (1H, d, J = 2.4, H-5), 7.04 (2H, 
m, H-10,12), 7.51 (2H, m, H-9,13), 12.19 (1H, bs, 2-OH). 13C NMR (100 MHz, CDCl3) 
17.9 (C-4e), 18.2 (C-4c), 25.5 (C-4'e), 25.8 (C-4'c), 65.0 (C-1e), 65.2 (C-1c), 92.5 (C-3), 
94.2 (C-5), 105.6 (C-1), 114.4(d, J = 21.9, C-10,12), 118.2 (C-2e), 118.7 (C-2c), 130.0 (d, 
J = 9.1, C-9,13), 137.6 (C-3e), 138.4 (d, J = 3.0, C-8), 139.3 (C-3c), 161.1 (C-6), 164.2 (d, 
J = 250.0, C-11), 165.8 (C-4), 166.0 (C-2), 198.0 (C-7). [Plate 27]. HRMS (ESI+): Found 
[M+Na]+ 407.1640, Calc. for C23H25FNaO4 407.1635. 
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A mixture of (4-fluorophenyl)[2,4,6-trihydroxy-3-(3-methyl-2-butenyl)phenyl]methanone 
(0.1 g), prenyl bromide (0.14 g) and K2CO3 (0.17 g) in dry acetone (10 mL) was refluxed 
for 5 h. The mixture was allowed to cool before being filtered through a sintered funnel. 
The filtrate was washed with a minimal amount of water and extracted with EtOAc. The 
organic layer was dried over anhydrous MgSO4. After the solvent of the mixture was 
reduced in vacuo, the mixture was purified by column chromatography (Hexanes-EtOAc, 
1:4) to obtain 3.77 (0.12 g, 85%) as light yellow crystals, mp 114-115 °C, TLC Rf 0.67 
(Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 1.56 (3H, s, H-4e), 1.64 (3H, s, H-
4'e), 1.70 (3H, s, H-4b), 1.77 (3H, s, H-4c), 1.79 (3H, s, H-4'b), 1.83 (3H, s, H-4'c), 3.33 
(2H, d, J = 7.2, H-1b), 4.22 (2H, d, J = 6.6, H-1e), 4.60 (2H, d, J = 6.7, H-1c), 4.77 (1H, t, 
J = 6.6, H-2e), 5.26 (1H, t, J = 7.2, H-2b), 5.49 (1H, t, J = 6.7, H-2c), 5.95 (1H, s, H-3), 
7.04 (2H, m, H-10,12), 7.53 (2H, m, H-9,13), 12.08 (1H, bs, 2-OH). 13C NMR (100 MHz, 
CDCl3) 17.7 (C-4e), 17.9 (C-4b), 18.3 (C-4c), 21.6 (C-1b), 25.5(C-4'e), 25.7 (C-4'b), 25.8 
(C-4'c), 65.1 (C-1c), 65.2 (C-1e), 88.9 (C-3), 105.7 (C-1), 110.2 (C-5), 114.4 (d, J = 21.9, 
C-10,12), 118.6 (C-2e), 119.5 (C-2c), 122.7 (C-2b), 130.0 (d, J = 9.1, C-9,13), 131.2 (C-
3b), 137.4 (C-3e), 138.0 (C-3c), 138.7 (d, J = 3.0, C-8), 159.7 (C-6), 162.0 (C-2), 163.1 
(C-4), 164.1 (d, J = 263.9, C-11), 198.3 (C-7). [Plate 25]. HRMS (ESI+): Found [M+Na]+ 
475.2263, Calc. for C28H33FNaO4 475.2261. 
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A mixture of (4-fluorophenyl)[2,4,6-trihydroxy-3,5-bis(3-methyl-2-butenyl)phenyl] 
methanone (0.1 g), prenyl bromide (77 mg) and K2CO3 (90 mg) in dry acetone (10 mL) 
was refluxed for 2 h. The mixture was allowed to cool before being filtered through a 
sintered funnel. The filtrate was washed with a minimal amount of water and extracted 
with EtOAc. The organic layer was dried over anhydrous MgSO4. After the solvent of the 
mixture was reduced in vacuo, the mixture was purified by column chromatography 
(Hexanes-EtOAc, 1:4) to obtain 3.78 (0.13 g, 98%) as a light orange semisolid, TLC Rf 
0.90 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 1.35 (3H, s, H-4e), 1.58 (3H, s, 
H-4'e), 1.67-1.74 (12H, m, H-4b,4c,4'b,4d), 1.79 (3H, s, H-4'd), 1.82 (3H, s, H-4'c), 3.31 
(2H, d, J = 6.3, H-1b), 3.41 (2H, d, J = 6.6, H-1d), 3.94 (2H, d, J = 7.0, H-1e), 4.38 (2H, d, 
J = 6.9, H-1c), 4.70 (1H, t, J = 7.0, H-2e), 5.15 (1H, t, J = 6.3, H-2b), 5.27 (1H, t, J = 6.6, 
H-2d), 5.58 (1H, t, J = 6.9, H-2c), 7.10 (2H, m, H-10,12), 7.78 (2H, m, H-9,13), 10.81 (1H, 
bs, 2-OH). 13C NMR (100 MHz, CDCl3) 17.7 (C-4e), 17.9 (C-4d), 17.9 (C-4b), 18.0 (C-
4c), 23.3 (C-1d), 23.4 (C-1b), 25.6 (C-4'e), 25.6 (C-4'b), 25.7 (C-4'd), 25.8 (C-4'c), 71.3 
(C-1c), 72.5 (C-1e), 112.0 (C-1), 114.7 (d, J = 22.0, C-10,12), 119.4 (C-2e), 119.5 (C-2c), 
120.4 (C-3), 121.1 (C-5), 122.9 (C-2d), 124.1 (C-2b), 131.2 (C-3b), 132.0 (C-3d), 132.3 (d, 
J = 9.0,C-9,13), 135.7 (d, J = 3.0, C-8), 137.5 (C-3e), 137.6 (C-3c), 156.5 (C-6), 159.1 (C-
2), 162.1 (C-4), 165.2 (d, J = 255.0, C-11), 197.9 (C-7). [Plate 26]. HRMS (ESI+): Found 
[M+Na]+ 543.2884, Calc. for C33H41FNaO4 543.2887. 
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A mixture of (4-fluorophenyl)[2,4,6-trihydroxy-3-(3-methyl-2-butenyl)phenyl]methanone 
(0.10 g), prenyl bromide (0.14 g) and K2CO3 (0.17 g) in dry acetone (10 mL) was refluxed 
for 5 h. The mixture was allowed to cool before being filtered through a sintered funnel. 
The filtrate was washed with a minimal amount of water and extracted with EtOAc. A 
combined organic layer was dried over anhydrous MgSO4. After the solvent of the mixture 
was reduced in vacuo, the mixture was purified by column chromatography (Hexanes-
EtOAc, 1:4) to obtain 3.84 (21 mg, 15%) as a light orange semisolid, TLC Rf 0.43 
(Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 1.59 (6H, s, H-4e,4d), 1.67 (3H, s, H-
4'd), 1.68 (3H, s, H-4'e), 1.79 (3H, s, H-4c), 1.83 (3H, s, H-4'c), 3.39-4.46 (4H, m, H-
1e,1d), 4.64 (2H, d, J = 6.6, H-1c), 5.18 (1H, t, J = 6.5, H-2e), 5.33 (1H, t, J = 7.3, H-2d), 
5.53 (1H, t, J = 6.6, H-2c), 6.38 (1H, s, H-3), 7.04 (2H, m, H-10,12), 7.83 (2H, m, H-9,13). 
13C NMR (100 MHz, CDCl3) 17.9 (C-4d), 18.1 (C-4e), 18.4 (C-4c), 25.6 (C-4'e), 25.7 (C-
4'd), 25.8 (C-4'c), 66.0 (C-1e), 66.6 (C-1c), 71.7 (C-1d), 95.7 (C-5), 99.5 (C-1), 115.4 (d, J 
= 22.2, C-10,12), 118.0 (C-3), 119.1 (C-2e), 119.1 (C-2c), 119.5 (C-2d), 132.1 (d, J = 9.6, 
C-9,13), 134.6 (d, J = 3.0, C-8), 138.0 (C-3e), 138.5 (C-3c), 139.1 (C-3d), 155.1 (C-6), 
156.5 (C-2), 157.6 (C-4), 165.8 (d, J = 254.4, C-11), 192.4 (C-7). [Plate 28]. HRMS 
(ESI+): Found [M+Na]+ 475.2265, Calc. for C28H33FNaO4 475.2261. 
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A mixture of (2-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (2.0 g), prenyl bromide 
(1.3 g) and K2CO3 (1.3 g) in dry acetone (15 mL) was refluxed for 1 h. The mixture was 
allowed to cool before being filtered through a sintered funnel. The filtrate was washed 
with a minimal amount of water and extracted with EtOAc. A combined organic layer was 
dried over anhydrous MgSO4. After the solvent of the mixture was reduced in vacuo, the 
mixture was purified by column chromatography (Hexanes-EtOAc, 1:4) to give a light 
yellow solid product (1.8 g, 65%). After recrystallization (1:9 Hexanes-EtOAc), 3.87 was 
obtained as light yellow crystals, mp 138-139 °C. TLC Rf 0.61 (Hexanes-EtOAc, 1:9). 1H 
NMR (400 MHz, CDCl3) 1.78 (3H, s, H-4e), 1.83 (3H, s, H-4'e), 4.62 (2H, d, J = 6.8, H-
1e), 5.51 (1H, t, J = 6.8, H-2e), 6.37 (1H, d, J = 2.2, H-3), 6.45 (1H, d, J = 2.2, H-5), 7.38 
(1H, t, J = 7.6, H-12), 7.44 (1H, dd, J = 8.5, 7.6, H-10), 7.72 (1H, t, J = 7.6, H-11), 8.62 
(1H, d, J = 7.6, H-13), 12.86 (1H, bs, 2-OH). 13C NMR (100 MHz, CDCl3) 18.3 (C-4e), 
25.8 (C-4'e), 65.5 (C-1e), 93.5 (C-5), 97.6 (C-3), 103.6 (C-1), 117.6 (C-10), 118.5 (C-2e), 
120.4(C-8), 123.9 (C-12), 125.9 (C-13), 134.9 (C-11), 139.4 (C-3e), 157.7 (C-6), 157.7 (C-
9), 163.5 (C-2), 166.1 (C-4), 181.5 (C-7). [Plate 33]. HRMS (ESI+): Found [M+Na]+ 
317.3141, Calc. for C18H18FNaO4 317.3161. 
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A mixture of (2-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (2.0 g), prenyl bromide 
(2.6 g) and K2CO3 (2.8 g) in dry acetone (15 mL) was refluxed for 3 h. The mixture was 
allowed to cool before being filtered through a sintered funnel. The filtrate was washed 
with a minimal amount of water and extracted with EtOAc. A combined organic layer was 
dried over anhydrous MgSO4. After the solvent of the mixture was reduced in vacuo, the 
mixture was purified by column chromatography (Hexanes-EtOAc, 1:4) to give a light 
yellow solid product (1.2 g, 38%). After recrystallization (Hexanes-EtOAc, 1:9), 3.89 was 
obtained as a light yellow crystals, mp 98-100 °C, TLC Rf 0.70 (Hexanes-EtOAc, 1:9). 1H 
NMR (400 MHz, CDCl3) 1.68 (3H, s, H-4b), 1.77 (3H, s, H-4e), 1.82 (3H, s, H-4'e), 1.87 
(3H, s, H-4'b), 3.51 (2H, d, J = 7.4, H-1b), 4.63 (2H, d, J = 6.5, H-1e), 5.24 (1H, t, J = 7.4, 
H-2b), 5.50 (1H, t, J = 6.5, H-2e), 6.40 (1H, s, H-5), 7.37 (1H, t, J = 7.6, H-12), 7.46 (1H, 
dd, J = 8.3, 7.6, H-10), 7.71 (1H, t, J = 7.6, H-11), 8.25 (1H, d, J = 7.6, H-13), 12.96 (1H, 
bs, 2-OH). 13C NMR (100 MHz, CDCl3) 17.8 (C-4'b), 18.3 (C-4e), 21.7 (C-1b), 25.7 (C-
4b), 25.8 (C-4'e), 65.5 (C-1e), 95.1 (C-5), 103.6 (C-1), 117.6 (C-10), 119.0 (C-2e), 120.4 
(C-8), 122.2 (C-2b), 123.7 (C-12), 125.8 (C-13), 131.5 (C-3b), 134.8 (C-11), 138.5 (C-3e), 
154.1 (C-4), 156.2 (C-9), 161.9 (C-2), 163.7 (C-6), 181.5 (C-7). [Plate 35]. HRMS (ESI+): 
Found [M+Na]+ 407.1633, Calc. for C23H25FNaO4 407.1635. 
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A mixture of (2-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (2.0 g), prenyl bromide 
(2.6 g) and K2CO3 (2.8 g) in dry acetone (15 mL) was refluxed for 3 h. The mixture was 
allowed to cool before being filtered through a sintered funnel. The filtrate was washed 
with a minimal amount of water and extracted with EtOAc. A combined organic layer was 
dried over anhydrous MgSO4. After the solvent of the mixture was reduced in vacuo, the 
mixture was purified by column chromatography (Hexanes-EtOAc, 1:4) to give a light 
yellow solid product (1.9 g, 60%). After recrystallization (Hexanes-EtOAc, 1:9), 3.88 was 
obtained as light yellow crystals, mp 122-123 °C, TLC Rf 0.74 (Hexanes-EtOAc, 1:9). 1H 
NMR (400 MHz, CDCl3) 1.70 (3H, s, H-4b), 1.79 (3H, s, H-4c), 1.81 (3H, s, H-4'b), 1.84 
(3H, s, H-4'c), 3.39 (2H, d, J = 7.2, H-1b), 4.65 (2H, d, J = 6.6, H-1c), 5.27 (1H, t, J = 7.2, 
H-2b), 5.53 (1H, t, J = 6.6, H-2c), 6.45 (1H, s,H-5), 7.37 (1H, t, J = 7.6, H-12), 7.43 (1H, 
dd, J = 8.5, J = 7.6, H-10), 7.70 (1H, t, J = 7.6, H-11), 8.27 (1H, d, J = 7.6, H-13), 12.92 
(1H, bs, 2-OH). 13C NMR (100 MHz, CDCl3) 17.8 (C-4'b), 18.3 (C-4c), 21.4(C-1b), 25.7 
(C-4d), 25.8 (C-4'c), 65.6 (C-1c), 90.7 (C-5), 103.7 (C-1), 112.2 (C-3), 117.4 (C-10), 119.0 
(C-2c), 120.8 (C-8), 122.1(C-2b), 123.8 (C-12), 125.9 (C-13), 131.7 (C-3b), 134.6 (C-11), 
138.5 (C-3c), 155.9 (C-9), 156.3 (C-6), 159.7 (C-2), 163.8 (C-4), 180.7 (C-7). [Plate 34]. 
HRMS (ESI+): Found [M+Na]+ 407.1630, Calc. for C23H25FNaO4 407.1635. 
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4'd 4d  
A mixture of (2-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (2.0 g), prenyl bromide 
(4.8 g) and K2CO3 (4.5 g) in dry acetone (15 mL) was refluxed for 6 h. The mixture was 
allowed to cool before being filtered through a sintered funnel. The filtrate was washed 
with a minimal amount of water and extracted with EtOAc. A combined organic layer was 
dried over anhydrous MgSO4. After the solvent of the mixture was reduced in vacuo, the 
mixture was purified by column chromatography (Hexanes-EtOAc, 1:4) and 3.90 was 
obtained as a light yellow amorphous solid (2.5 g, 68%), TLC Rf 0.83 (Hexanes-EtOAc, 
1:9). 1H NMR (400 MHz, CDCl3) 1.71 (9H, m, H-4b,4e,4d), 1.81 (3H, s, H-4'b), 1.82 (3H, 
s, H-4e'), 1.89 (3H, s, H-4'd), 3.45 (2H, d, J = 6.6, H-1b), 3.57 (2H, d, J = 6.8, H-1d), 4.65 
(2H, d, J = 7.0, H-1e), 5.25 (1H, t, J = 6.8, H-2d), 5.28 (1H, t, J = 6.6, H-2b), 5.61 (1H, t, J 
= 6.6, H-2e), 7.37 (1H, t, J = 7.6, H-12), 7.47 (1H, dd, J = 8.5, 7.6, H-10), 7.72 (1H, t, J = 
7.6, H-11), 8.28 (1H, d, J = 7.6, H-13), 12.96 (1H, bs, 2-OH). 13C NMR (100 MHz, 
CDCl3) 17.9 (C-4d), 18.0 (C-4b), 18.1 (C-4e), 22.8 (C-1d), 23.0 (C-1b), 25.7 (C-4'b), 25.7 
(C-4'd), 25.8 (C-4'e), 71.8 (C-1e), 106.1 (C-1), 113.4 (C-5), 117.5 (C-3), 117.7 (C-10), 
120.2 (C-2e), 120.4 (C-8), 122.7 (C-2b), 122.9 (C-2d), 123.8 (C-12), 125.9 (C-13), 131.7 
(C-3b), 132.0 (C-3d), 135.0 (C-11), 137.9 (C-3e), 153.2 (C-9), 156.2 (C-6), 159.0 (C-2), 
162.9 (C-4), 181.8 (C-7). [Plate 36]. HRMS (ESI+): Found [M+Na]+ 475.4267, Calc. for 
C28H33FNaO4 475.4261. 
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A mixture of (4-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (1.0 g), geranyl bromide 
(3.5 g) and K2CO3 (2.2 g) in dry acetone (10 mL) was refluxed for 6 h. The mixture was 
allowed to cool before being filtered through a sintered funnel. The filtrate was washed 
with a minimal amount of water and extracted with EtOAc (3 x 20 mL). A combined 
organic layer was dried over anhydrous MgSO4. After the solvent of the mixture was 
removed under reduced pressure, the mixture was purified by column chromatography 
(Hexanes-EtOAc, 1:9), and 3.86 was obtained as a light orange oil (0.32 g, 12%), TLC Rf 
0.57 (Hexanes-EtOAc, 1:10). 1H NMR (400 MHz, CDCl3) 1.58 (6H, s, H-4'a,4'e), 1.58 
(6H, s, H-8a,8e), 1.64 (3H, s, H-8c), 1.66 (6H, s, H-8'a,8'e), 1.70 (3H, s, H-8'c), 1.78 (3H, 
s, H-4'c), 1.81-1.90 (8H, m, H-4a,4e,5a,5e), 1.98-2.06 (4H, m, H-4c,5c), 4.45 (4H, d, J = 
6.3, H-1a,1e), 4.57 (2H, d, J = 6.6, H-1c), 5.03 (2H, t, J = 6.2, H-6a,6e), 5.13 (1H, t, J = 
6.1, H-6c), 5.21 (2H, t, J = 6.3, H-2a,2e), 5.52 (1H, t, J = 6.6, H-2c), 6.19 (2H, s, H-3,5), 
7.06 (2H, m, H-10,12), 7.85 (2H, m, H-9,13). 13C NMR (100 MHz, CDCl3) 16.5 (C-4'c), 
16.7 (C-4'a,4'e), 17.6 (C-8a,8e), 17.7 (C-8c), 25.6 (C-8'a,8'e), 25.7 (C-8'c), 26.2 (C-5a,5e), 
26.3 (C-5c), 39.4 (C-4a,4e), 39.6 (C-4c), 65.0 (C-1c), 65.7 (C-1a,1e), 92.9 (C-3,5), 110.3 
(C-1), 114.1 (d, J = 21.6, C-10,12), 119.1 (C-2c), 119.4 (C-2a,2e), 123.7 (C-6a,6e), 123.7 
(C-6c), 131.7 (C-7a,7e), 131.9 (C-7c), 131.9 (d, J = 9.4, C-9,13), 135.3 (d, J = 2.7, C-8), 
140.5 (C-3a,3e), 141.6 (C-3c), 158.0 (C-2,6), 161.5 (C-4), 166.2 (d, J = 253.3, C-11), 
193.5 (C-7). [Plate 32]. HRMS (ESI+): Found [M+Na]+ 679.4142, Calc. for C43H57FNaO4 
679.4139. 
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A mixture of (4-fluorophenyl)(2,4,6-trihydroxyphenyl)methanone (1.0 g), geranyl bromide 
(3.5 g) and K2CO3 (2.2 g) in dry acetone (10 mL) was refluxed for 6 h. The mixture was 
allowed to cool before being filtered through a sintered funnel. The filtrate was washed 
with a minimal amount of water and extracted with EtOAc (3 x 20 mL). A combined 
organic layer was dried over anhydrous MgSO4. After the solvent of the mixture was 
removed under reduced pressure, the mixture was purified by column chromatography 
(Hexanes-EtOAc, 1:9), and 3.85 was obtained as a light orange oil (0.42 g, 20%), TLC Rf 
0.63 (Hexanes-EtOAc, 1:10). 1H NMR (400 MHz, CDCl3) 1.55 (3H, s, H-4'e), 1.61 (3H, s, 
H-8e), 1.63 (3H, s, H-8c), 1.70 (3H, s, H-8'e), 1.70 (3H, s, H-8'c), 1.77 (3H, s, H-4'c), 1.85-
2.05 (4H, m, H-4e,5e), 2.07-2.20 (4H, m, H-4c,5c), 4.25 (2H, d, J = 6.4, H-1e), 4.60 (2H, 
d, J = 6.6, H-1c), 4.76 (1H, t, J = 6.5, H-2e), 5.04 (2H, t, J = 6.9, H-6e), 5.12 (1H, t, J = 
6.5, H-6c), 5.50 (1H, t, J = 6.6, H-2c), 5.95 (1H, s, H-3), 6.17 (1H, s, H-5), 7.04 (2H, m, H-
10,12), 7.54 (2H, m, H-9,13), 10.18 (1H, bs, 2-OH). 13C NMR (100 MHz, CDCl3) 16.6 (C-
4'e), 16.7 (C-4'c), 17.6 (C-8e), 17.7 (C-8c), 25.7 (C-8'e), 25.7 (C-8'c), 26.1 (C-5e), 26.3 (C-
5c), 39.2 (C-4e), 39.5 (C-4c), 65.2 (C-1e), 65.3 (C-1c), 92.6 (C-3), 94.2 (C-5), 105.6 (C-1), 
114.5 (d, J = 21.3, C-10,12), 117.8 (C-2e), 118.4 (C-2c), 123.7 (C-6e), 123.7 (C-6c), 130.1 
(d, J = 9.1, C-9,13), 131.8 (C-7e), 131.9 (C-7c), 138.4 (d, J = 3.5, C-8), 140.8 (C-3e), 
142.3 (C-3c), 161.1 (C-6), 164.4 (d, J = 250.0, C-11), 168.5 (C-2), 166.0 (C-4), 198.0 (C-
7). [Plate 31]. HRMS (ESI+): Found [M+Na]+ 543.2878, Calc. for C33H41FNaO4 543.2887. 
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8'c 3.79  
A mixture of (4-fluorophenyl)[2,4,6-trihydroxy-3-(3,7-dimethylocta-2,6-dienyl)phenyl] 
methanone (1.0 g), geranyl bromide (1.7 g) and K2CO3 (1.4 g) in dry acetone (10 mL) was 
refluxed for 5 h. The mixture was allowed to cool before being filtered through a sintered 
funnel. The filtrate was washed with a minimal amount of water and extracted with 
EtOAc. A combined organic layer was dried over anhydrous MgSO4. After the solvent of 
the mixture was removed in vacuo, the crude was purified by column chromatography 
(Hexanes-EtOAc, 1:9) to obtain 1.3 g (76%) of 3.79 as a light orange semisolid, TLC Rf 
0.78 (Hexanes-EtOAc, 1:10). 1H NMR (400 MHz, CDCl3) 1.57 (3H, s, H-4'e), 1.60 (3H, s, 
H-8b), 1.61 (3H, s, H-8e), 1.63 (3H, s, H-8c), 1.67 (3H, s, H-8'b), 1.70 (3H, s, H-8'e), 1.70 
(3H, s, H-8'c), 1.76 (3H, s, H-4'c), 1.79 (3H, s, H-4'b), 1.87-2.05 (4H, m, H-4e,5e), 2.04-
2.20 (8H, m, H-4c,4b,5c,5b), 3.35 (2H, d, J = 7.1, H-1b), 4.25 (2H, d, J = 6.4, H-1e), 4.62 
(2H, d, J = 6.4, H-1c), 4.76 (1H, t, J = 6.4, H-2e), 5.05 (2H, t, J = 7.2, H-6e), 5.08-5.17 
(2H, m, H-6c,6b), 5.27 (1H, t, J = 7.1, H-2b), 5.50 (1H, t, J = 6.5, H-2c), 5.96 (1H, s, H-3), 
7.04 (2H, m, H-10,12), 7.55 (2H, m, H-9,13), 12.00 (1H, bs, 2-OH). 13C NMR (100 MHz, 
CDCl3) 16.1(C-4'b), 16.6 (C-4'e), 16.7 (C-4'c), 17.6 (C-8e), 17.6 (C-8c), 17.7 (C-8b), 21.6 
(C-1b), 25.6 (C-8'e), 25.6 (C-8'b), 25.6 (C-8'c), 26.2 (C-5e), 26.3 (C-5c), 26.8 (C-5b), 39.3 
(C-4e), 39.5 (C-4c), 39.9 (C-4b), 65.2 (C-1e), 65.3 (C-1c), 88.9 (C-3), 105.7 (C-1), 110.2 
(C-5), 114.4 (d, J = 21.6, C-10,12), 118.2 (C-2e), 119.3 (C-2c), 122.5 (C-2b), 123.7 (C-6e), 
123.7 (C-6c), 124.5 (C-6b), 130.1 (d, J = 8.5, C-9,13), 131.1 (C-7b), 131.8 (C-7e), 131.9 
(C-7c), 134.7 (C-3b), 138.7 (d, J = 3.0, C-8), 140.6 (C-3e), 141.3 (C-3c), 159.7 (C-6), 
162.0 (C-2), 163.2 (C-4), 164.2 (d, J = 251.9, C-11), 198.3 (C-7). [Plate 29]. HRMS 
(ESI+): Found [M+Na]+ 679.4142, Calc. for C43H57FNaO4 679.4141. 
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3.7.39 Synthesis of (4-fluorophenyl)[2-hydroxy-3,5-bis(3,7-
dimethylocta-2,6-dienyl)-4,6-bis(3,7-dimethylocta-2,6-



























A mixture of (4-fluorophenyl)[2,4,6-trihydroxy-3,5-bis(3,7-dimethylocta-2,6-
dienyl)phenyl]methanone (1.0 g), geranyl bromide (0.90 g) and K2CO3 (0.66 g) in dry 
acetone (10 mL) was refluxed for 2 h. The mixture was allowed to cool before being 
filtered through a sintered funnel. The filtrate was washed with a minimal amount of water 
and extracted with EtOAc (3 x 20 mL). A combined organic layer was dried over 
anhydrous MgSO4. After the solvent of the mixture was removed in vacuo, the mixture 
was purified by column chromatography (Hexanes-EtOAc, 1:9) to give 1.3 g (88%) of 
3.80 as a light yellow semisolid, TLC Rf 0.87 (Hexanes-EtOAc, 1:10). 1H NMR (400 
MHz, CDCl3) 1.35 (3H, s, H-4'e), 1.59 (6H, s, H-8d,8b), 1.60 (3H, s, H-8e), 1.64 (3H, s, 
H-8c), 1.65 (6H, s, H-8'd,8'b), 1.69 (3H, s, H-8'e), 1.69 (3H, s, H-8'c), 1.72 (3H, s, H-4'c), 
1.72 (3H, s, H-4'b), 1.79 (3H, s, H-4'd), 1.82-1.90 (4H, m, H-4e,5e), 1.92-2.20 (12H, m, H-
4b,4c,4d,5b,5c,5d), 3.33 (2H, d, J = 6.2, H-1b), 3.43 (2H, d, J = 6.3, H-1d), 3.97 (2H, d, J 
= 6.9, H-1e), 4.41 (2H, d, J = 6.6, H-1c), 4.70 (1H, t, J = 6.9, H-2e), 5.02 (2H, t, J = 7.0, 
H-6e), 5.05-5.11 (2H, m, H-6d,6b), 5.11-5.22 (2H, m, H-6c,2b), 5.29 (1H, t, J = 6.4, H-
2d), 5.59 (1H, t, J = 6.7, H-2c), 7.09 (2H, m, H-10,12), 7.78 (2H, m, H-9,13), 10.84 (1H, 
bs, 2-OH). 13C NMR (100 MHz, CDCl3) 16.2 (C-4'd), 16.3 (C-4'b), 16.4 (C-4'e), 16.6 (C-
4'c), 17.6 (C-8e), 17.6 (C-8c), 17.6 (C-8b), 17.7 (C-8d), 23.3 (C-1b), 23.4 (C-1d), 25.6 (C-
8'e), 25.6 (C-8'c), 25.7 (C-8'b), 26.2 (C-5e), 26.1 (C-5e), 26.4 (C-5c), 26.7 (C-5b), 26.7 (C-
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5d), 39.4 (C-4e), 39.6 (C-4c), 39.7 (C-4b), 39.7 (C-4d), 71.3 (C-1e), 72.6 (C-1c), 112.0 (C-
1), 114.7 (d, J = 21.9, C-10,12), 119.0 (C-2e), 119.5 (C-2c), 120.2 (C-3), 121.1 (C-5), 
122.8 (C-2d), 123.8 (C-6e), 123.9 (C-6c), 124.0 (C-2b), 124.3 (C-6d), 124.3 (C-6b), 131.2 
(C-7b), 131.3 (C-7d), 131.7 (C-7e), 131.8 (C-7c), 132.4 (d, J = 9.0, C-9,13), 134.8 (C-3b), 
135.6 (C-3d), 135.7 (d, J = 3.0, C-8), 140.7 (C-3e), 140.8 (C-3c), 156.6 (C-6), 159.2 (C-2), 
162.2 (C-4), 165.3 (d, J = 251.9, C-11), 197.9 (C-7). [Plate 30]. HRMS (ESI+): Found 
[M+Na]+ 815.5397, Calc. for C53H73FNaO4 815.5391. 










To a mixture of phloroglucinol (1.0 g, 7.93 mmol) and prenyl bromide (2.36 g, 15.86 
mmol) in dry THF (50 mL) was added DBU (2.42 g, 15.86 mmol) in small increments. 
The mixture was stirred at room temperature for 6 h. After addition of 2 M HCl (20 mL), 
the mixture was stirred for a further 15 min and extracted with EtOAc (4 x 30 mL), washed 
with brine (30 mL) and dried over anhydrous MgSO4. The solvent was removed under 
reduced pressure. The crude was purified by silica gel column chromatography (Hexanes-
EtOAc 1:9) and 3.103 was obtained as a deep orange oil (1.5 g, 5.71 mmol, 72%), TLC Rf 
0.63 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 1.74 (6H, s, H-4',4''), 1.81 (6H, s, 
H-4a',4a''), 3.34 (4H, d, J = 7.1, H-1',1''), 5.24 (2H, m, H-2',2''), 5.97 (1H, s, H-6). 13C 
NMR (400 MHz, CDCl3) 17.8 (C-4a',4a''), 22.4 (C-1',1''), 25.7 (C-4',4''), 96.2 (C-4), 106.5 
(C-2), 122.4 (C-2',2''), 134.8 (C-3',3''), 152.9 (C-3,5), 154.1 (C-1). IR (neat) νmax (cm-1): 
3412, 2916, 1572, 1574, 1423, 1135. 
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4c 4d'  
To a stirred mixture of 2,4-bis(3-methyl-2-butenyl)-1,3,5-benzenetriol (0.05 g, 0.19 mmol) 
and paraformaldehyde (3 mg, 0.1 mmol) in THF (3 mL) was added a mixture of 4 M HCl 
in diethyl ether (2.0 mL). The mixture was heated in a microwave oven (100 W power,  
100 Psi pressure, 50 ºC) for 10 min. After addition of 2 M HCl (5 mL), the mixture was 
stirred for a further 15 min and extracted with EtOAc (3 x 10 mL), washed with brine (6 
mL) and dried over anhydrous MgSO4. The removal of the solvent under vacuum resulted 
in an orange crude product which was purified by silica gel column chromatography 
(Hexanes-EtOAc, 2:8) giving 3.104 as a light orange viscous liquid (0.06 g, 0.12 mmol, 
65%), TLC Rf 0.58 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 1.61 (12H, s, H-
4a,4b,4c,4d), 1.66 (12H, s, H-4a',4b',4c',4d'), 2.36-2.55 (8H, m, H-1a,1b,1c,1d), 3.39 (2H, 
s, H-1), 4.91 (4H, m, H-2a,2b,2c,2d). 13C NMR (100 MHz, CDCl3) 17.9 (C-4a',4b',4c',4d'), 
27.8 (C-4a,4b,4c,4d), 33.5 (C-1a,1b,1c,1d), 67.5 (C-2,2'), 117.8 (C-2a,2b,2c,2d), 134.8 (C-
4,4',6,6'), 136.1 (C-3a,3b,3c,3d), 203.9 (C-3,3',7,7'), 207.3 (C-5,5'). IR (neat) νmax (cm-1): 
3511, 2941, 1589, 1580, 1400, 1115. 

















A mixture of phenyl(2,4,6-trihydroxyphenyl)methanone (0.2 g, 0.87 mmol) and para-
formaldehyde (0.026 g, 0.87 mmol) was stirred in toluene (10 mL) at room temperature for 
2 min. A mixture of 2M HCl (5 mL) in diethyl ether (5 mL) was added to the reaction 
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mixture and was stirred at room temperature for a further 18 h. After addition of 2 M HCl 
(10 mL), the mixture was stirred for a further 15 min and extracted with EtOAc (3 x 20 
mL), washed with brine (10 mL) and dried over anhydrous MgSO4. Removal of the 
solvent under vacuum resulted in a yellow crude product which was purified by silica gel 
column chromatography (Hexanes-EtOAc, 3:7) giving 3.100 as a yellow solid (0.34 g, 
0.722 mmol, 83%), mp 249-252 ºC, TLC Rf 0.41 (Hexanes-EtOAc, 3:7). 1H NMR (400 
MHz, DMSO-d6) 3.62 (2H, s, H-1), 6.01 (2H, s, H-6,6'), 7.44 (4H, t, J = 7.6, H-
11,11',13,13'), 7.54 (2H, t, J = 7.6, H-12,12'), 7.63 (4H, d, J = 7.6, H-10,10',14,14'), 9.70 
(2H, s, 7,7'-OH), 10.14 (2H, bs, 3,3'-OH), 10.58 (2H, bs, 5,5'-OH). 13C NMR (100 MHz, 
DMSO-d6) 16.4 (C-1), 95.2 (C-6,6'), 105.8 (C-2,2'), 107.2 (C-4,4'), 128.5 (C-
11,11',13,13'), 128.9 (C-10,10',14,14'), 132.3 (C-12,12'), 140.1 (C-9,9'), 156.8 (C-5,5'), 
157.3 (C-3,3'), 157.7 (C-7,7'), 196.9 (C-8,8'). IR (neat) νmax (cm-1): 3620, 1637, 1588, 
1551, 1320. 









N,N-Dimethylformamide (1.00 mL, 12.8 mmol) was cooled to 0 °C and freshly distilled 
POCl3 (1.2 mL, 12.8 mmol) was added. The faint orange solution was stirred vigorously 
for approximately 5 min until the mixture solidified. Distilled acetonitrile (10 mL) was 
added until the white solid dissolved. The reaction mixture was stirred for a further 30 min 
at room temperature. A solution of 1,3,5-trimethoxybenzene (1.6 g, 12.8 mmol) in 
acetonitrile (10 mL) was added to the reaction mixture and stirred under reflux for 15 h. 
After the mixture was cooled to room temperature, a solution of methanol-water (2:1, 10 
mL) was added for imine hydrolysis and was stirred for 45 min. The resulting product was 
purified by silica gel column chromatography with 25% EtOAc in hexanes as eluent to 
obtain 3.105 as a cream crystalline solid (1.3 g, 54%), mp 122-124 ºC. 1H NMR (400 
MHz, CDCl3) 3.84 (3H, s, 5-OCH3), 3.85 (6H, s, 3,7-OCH3), 6.04 (2H, s, H-4,6), 10.32 
(1H, s, H-1). 13C NMR (100 MHz, CDCl3) 55.7 (5-OCH3), 56.2 (3,7-OCH3), 90.5 (C-4,6), 
109.1 (C-2), 164.3 (C-3,7), 166.4 (C-5), 187.9 (C-1). IR (neat) νmax (cm-1): 2920, 2796, 
1662, 1596, 1575, 1131. 
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A mixture of 1,3,5-trimethoxybenzene (0.63 g, 5.0 mmol) and para-formaldehyde (0.15 g, 
5.0 mmol) in toluene was stirred at room temperature for 2 h. 2 M HCl in diethyl ether (8.0 
mL) was then added dropwise to the mixture and stirred for a further 48 h. After addition 
of 2 M HCl (10 mL), the mixture was stirred for a further 15 min and extracted with 
EtOAc (3 x 15 mL), washed with brine (10 mL) and dried over anhydrous MgSO4. The 
removal of the solvent under vacuum resulted in a yellow crude product. The crude 
product was purified by silica gel column chromatography (Hexanes-EtOAc, 3:7) giving 
3.99 as colourless-white crystalline solid (1.7 g, 95%), TLC Rf 0.62 (Hexanes-EtOAc, 1:9). 
1H NMR (400 MHz, CDCl3) 3.73 (12H, s, 3,3',7,7'-OCH3), 3.78 (6H, s, 5,5'-OCH3), 3.87 
(2H, s, H-1), 6.12 (4H, s, H-4,4'6,6'). 13C NMR (100 MHz, CDCl3) 16.7 (C-1), 55.2 (5,5'-
OCH3), 56.1 (3,3',7,7'-OCH3), 91.3 (C-2,2'), 112.1 (C-4,4',6,6'), 158.7 (C-5,5'), 159.3 (C-
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CHAPTER 4. 4-PHENYLCOUMARINS 
4.1 Introduction 
Coumarins are a class of phenolic compounds characterized by a benzene ring fused to a 
pyrone ring (4.1) and are structurally diverse. They can roughly be classified into five 
major groups (Figure 4.1), simple coumarins (4.2), pyranocoumarins (4.3), furocoumarins 
(4.4), pyrone-substituted coumarins (4.5) and dimeric coumarins (4.6).154 Coumarins with 
substituents on the benzene ring are named ‘simple’ coumarins. The second group of 
coumarins, pyranocoumarins, contains a linear- or an angular-fused six-membered oxygen 
heterocyclic ring. Furocoumarins are compounds with the coumarin moiety fused to a five-
membered furan ring. Pyrone-substituted coumarins have substituents on the pyrone ring, 
at either position 3 or 4. The last group are dimeric coumarins which are characterized by 
two or more coumarin units linked together. 










NSC 158393 (4.6)  
Figure 4.1: Examples of the different classes of coumarin. 
 
Coumarins constitute one of the big classes of naturally occurring compounds. The first 
coumarin was isolated from tonka bean (Dipteryx odorata) by Vogel and Guibourt in 
1820. Due to their sweet smell, they have been used to make perfumes since 1882. Since 
then, there has been an increase in the number of isolated coumarins that were reported. 
Presently, more than 1300 coumarins were identified from natural sources.22, 24 Sweet 
woodruff (Galium odoratum), mullein (Verbascum spp.), sweet grass (Hierochloe 
odorata), vanilla grass (Anthoxanthum odoratum), cassia cinnamon (Cinnamomum cassia), 
deertongue (Dichanthelium clandestinum) and sweet-clover (Melilotus ssp.) were found to 
have high concentration of coumarins.155 These compounds play an important role in the 
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physiology and biochemistry of the plant as they act as enzyme inhibitors, antioxidants and 
precursors of toxic substances.156 They also are involved in the processes of plant 
photosynthesis, respiration, the action of plant growth hormones and growth regulator as 
well as defense against infections.157 
Coumarins have been reported to play a vital role as food and cosmetics constituents,158 
dye-sensitized solar cells159 and cigarettes additives.160 In addition, coumarins possess 
antibacterial,31 anti-inflammatory,32 anti-oxidant,33 anticoagulant,34 anti-tumor,35 
hepatoprotective, anti-carcinogenic, anti-viral and anti-thrombotic activities.36 The variety 
of uses of these compounds resulted in an increase in demand for large quantities of 
coumarins. Due to an insufficient natural supply of these organic compounds, numerous 
methods for their synthesis have been developed, including using the Pechmann 
condensation,161 Stille coupling reaction, Knoevenagel condensation,27 Heck coupling 
reaction, Perkin reaction,26 Kostanecki reaction, Baylis-Hillman reaction,30 Michael 





Figure 4.2: Skeletal structure of 4-phenylcoumarin (neoflavone). 
 
This chapter will focus on the natural sources, synthesis and biological activities of 4-
phenylcoumarins (neoflavones). The first neoflavone was isolated from Calophyllum 
inophyllum seeds in 1951 and its structure was established in 1957. Several other 4-
phenylcoumarins were isolated from plants of the Mammea and Dalbergia genera in the 
1960’s, and since then neoflavones were recognized as a new group of natural compounds. 
Neoflavones have been isolated from more than 58 plant species of the Clusiaceae, 
Thelypteridaceae, Rubiaceae, Rutaceae, Fabaceae, Asteraceae, and Passifloraceae families. 
The aim of this investigation was to develop and improve the methods for the preparation 
of substituted 4-arylcoumarins. The chapter starts by giving an overview on naturally 
occurring coumarins followed by an overview of the biological activities of 4-
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phenylcoumarins and a summary of different synthetic methods for the synthesis of 4-
phenylcoumarins. The results obtained in the synthesis of 4-phenylcoumarins are discussed 
in the second-last Section of this chapter. The last Section gives detailed experimental 
procedures for all the successful syntheses. 
4.2 Naturally occurring coumarins 
After the isolation of the first coumarin in 1820, a large number of coumarins have been 
reported. For example, (+)-calanolide A (4.7) was first isolated from a Malaysian plant 
Calophyllum lanigerum162 and was identified as a novel non-nucleoside reverse 
transcriptase inhibitor (NNRTI) with potent activity against HIV-1 (Figure 4.3).162,163 To 
meet the demand for 4.7 for preclinical and clinical research, a total synthesis of this 
tetracyclic coumarin was developed.164 
(+)-Inophyllum B (4.8) was also reported to be a highly active inhibitor of HIV-reverse 
transcriptase. This pentacyclic coumarin was isolated by Patil et al. from Calophyllum 
inophyllum.165 Shortly after 4.8 was isolated, its total synthesis was developed to increase 












Figure 4.3: Structure of (+)-calanolide A (4.7) and (+)-inophyllum B (4.8). 
 
Cruz et al. reported the isolation of 4-arylcoumarins 4.9 and 4.10 from the stem of 
Kielmeyera reticulate, a wild shrub belonging to Guttiferae (Clusiaceae) (Figure 4.4).167  
 


















Figure 4.4: Naturally occurring 5,7-dihydroxy-4-phenylcoumarins from Kielmeyera 
reticulate. 
 
5,7-Dimethoxy-4-p-methoxyphenylcoumarin (4.11) and 5,7-dimethoxy-4-phenylcoumarin 
(4.12) were isolated from a microorganism Streptomyces aureofaciens CMUAc130, which 
was isolated from the root tissues of Zingiber officinale Rosc. (Zingiberaceae) (Figure 
4.5).168 These 4-phenylcoumarins tested active against phytopathogenic fungi. These 
secondary metabolites are very useful to plants as they protect plants against attacks by 









Figure 4.5: Naturally occurring 4-phenylcoumarins from Streptomyces aureofaciens. 
 
Mata et al. isolated 5-[β-D-xylopyranosyl-(1→6)-β-D-glucopyranosyloxy]-7,3',4'-
trihydroxy-4-phenylcoumarin (4.13) from the stem bark of Exostema caribaeum (Figure 
4.6). This compound was found to be less toxic relative to the other 4-phenylcoumarins 
isolated from the same plant even at a concentration as high as 5 g/kg.169 
 
















OH 4.13  
Figure 4.6: Naturally occurring 4-arylcoumarin from Exostema caribaeum. 
 
Yu et al. reported the extraction of 4-phenylcoumarin-7-O-β-D-glucopyranoside (4.14) and 
7-hydroxy-4-phenylcoumarin-5-O-β-D-glucopyranoside (4.15) from Polygonum 
multiflorum (Figure 4.7). 4.14 and 4.15 were biosynthesized using transgenic hairy roots of 


















Figure 4.7: 4-Phenylcoumarins from Polygonum multiflorum. 
 
4.3 Biologically active 4-arylcoumarins 
The structure of coumarins is extremely variable, which influences their biological 
activities. Neoflavones (4-phenylcoumarins) have been reported to exhibit several 
biological activities such as anti-HIV, antibacterial, antimalarial, antitumor, antimicrobial, 
anti-diabetic, antiprotozoal and cytotoxicity.171, 172 
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4.3.1 Anti-HIV 4-arylcoumarins 
The human immunodeficiency virus type 1 (HIV-1) belongs to a subfamily of retroviruses 
(Lenti virinae) which causes the acquired immunodeficiency syndrome (AIDS). Currently, 
there are four HIV-1 protease inhibitors that have been approved for the treatment of 















inophyllum A ( 4.17)
 
Figure 4.8: Structure of HIV-1 inhibitors. 
 
Lee et al. reported the synthesis of 3',4'-di-O-(S)-(-)-camphanoyl-4-phenyl-(+)-cis-
khellactone (DCK)  (4.16) which was prompted by the isolation of the suksdorfin from 
Lomatium uksdorfii. DCK (4.16) and derivatives tested positive towards the inhibition of 
HIV-1 replication. The mode of action of these khellactones was proven not to involve 
inhibition of HIV reverse transcriptase (RT), which makes it possible for them to be used 
in combination with RT inhibitors.175 
Inophyllum A (4.17) is one of the 4-phenylcoumarins isolated from Calophyllum genus 
(Guttiferae) and it has been reported that it strongly inhibited the in vitro replication and 
cytopathicity of HIV-1.175 
4.3.2 Antimicrobial 4-arylcoumarins 
Microbes are the main causes of infectious diseases. For example, tuberculosis (TB) is one 
of the infectious diseases caused by the bacillus Mycobacterium tuberculosis (Mtb). 
According to the World Health Organization, this disease is estimated to have infected 
one-third of the world´s population and caused 1.7 million deaths in 2009.176  
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Hung et al.177 reported the synthesis of potentially anti-tubercular 4-arylcoumarins, one of 
which is 5,7-dimethyl-6-phenyl-4-phenylcoumarin (4.18) (Figure 4.9). This class of 
compounds was reported to target the fatty acyl ACP synthetase activity of the FadD32 
enzyme which is essential for Mtb survival because it plays a crucial role in the 
biosynthesis of the unique branched fatty acids (mycolic acids) that make up the Mtb cell 
wall.178-180 Chin et al.181 reported the synthesis of 6-benzoyl-5,7-hydroxy-4-










Figure 4.9: 4-Arylcoumarins with anti-tubercular (4.18) and antibacterial (4.19) 
activities. 
4.3.3 Antimalarial and anticancer 4-arylcoumarins 
Malaria is one of the most important parasitic diseases which causes more than one million 
deaths per year. This disease is a worldwide threat and mostly affects children in Sub-
Saharan countries.182 4-(3,4-Dimethoxyphenyl)-6,7-dimethoxycoumarin (4.20) showed a 
strong antiprotozoal activity against multidrug-resistant strains of Plasmodium falciparum 
and Leishmania donovani and was synthesized by a Suzuki-Miyaura cross-coupling 
reaction (Figure 4.10).183 This 4-phenylcoumarin and derivatives were found to strongly 












Figure 4.10: Structures for the derivatives of neoflavone. 
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Cancer is a class of diseases characterized by abnormal cell growth. Cancer harms the 
body when damaged cells divide uncontrollably to form lumps or masses of tissue called 
tumors. There are over 100 different types of cancer that have been identified and each is 
classified by the type of cells or tissues that are initially affected.184 According to the 
World Health Organization, in 2012, about 14.1 million new cases of cancer occurred and 
about 8.2 million deaths or 14.6% of all human deaths globally were caused by cancer.185 
Beletskaya et al.186 and Bailly et al.187 reported the synthesis of 4-(3-hydroxy-4-
methoxyphenyl)-6,7-dimethoxycoumarin (4.21) by a Suzuki-Miyaura cross-coupling 
reaction. This 4-arylcoumarin was found to be an antimitotic agent that inhibits tubulin 
assembly for the treatment of cancer. 
4.4 Synthetic routes for 4-arylcoumarins 
The variety of the biological uses of coumarins and an insufficient supply from natural 
sources led to the development of synthetic routes for coumarins of which most involve the 
lactone ring closure. Numerous methods have been developed for the synthesis of 
coumarins, including the Pechmann condensation, Perkin reaction, Knoevenagel 
condensation, Reformatsky reaction, Wittig reaction and Baylis-Hillman reaction. 
4.4.1 Transition metal-catalyzed reactions 
Transition metal-catalyzed reactions have become one of the popular reactions to prepare 
4-phenylcoumarins. These reactions are based on the palladium-catalyzed Suzuki coupling, 
Negishi coupling or Stille coupling reactions with the use of organometallic reagents (such 
as organoboron,188 organotin,189 organozinc,190 organobismuth191or organoindium192) and 
phenyl electrophilic reagents (aryl halogen, triflate, phosphonate or tosylate). These 
reactions have been used for the successful C–C bond formation in the past decades and 
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4.4.1.1 Transition metals in direct coupling 
4.4.1.1.1 Suzuki-Miyaura cross-coupling reaction 
Beletskaya et al.186 have reported the synthesis of polymethoxylated 4-
heterophenylcoumarins 4.23 by a Suzuki-Miyaura cross-coupling reaction. They treated 4-
trifluoromethyl-sulfonyloxycoumarins (4.22) with 4-methoxypyridin-3-ylboronic acid 
under Suzuki-Miyaura cross-coupling conditions as shown in Scheme 4.1. These 4-


















Scheme 4.1: Synthesis of 5,7-dimethoxy-4-(4-methoxypyridin-3-yl)coumarin (4.23). 
 
Peyrot et al.193 have applied the Suzuki-Miyaura cross-coupling reaction in the synthesis of 
polymethoxylated neoflavone 4.28 (Scheme 4.2). Debenzylation and boronation of 
bromobenzene 4.24 afforded 3-hydroxy-4-methoxyphenylboronic acid (4.25) which was 
reacted with 4-trifluoromethylsulfonyloxycoumarin (4.27) (prepared from 4-
hydroxycoumarin, 4.26) under Suzuki-Miyaura cross-coupling conditions to yield 
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4.4.1.1.2 Stille coupling reaction 
Bailly and coworkers187 have synthesized 5,6,7-trimethoxy-4-(3,5-dimethoxyphenyl) 
coumarin (4.32) by a Suzuki-Miyaura cross-coupling reaction and 5,6,7-trimethoxy-4-
(3',4'-methylenedioxyphenyl)coumarin (4.34) by a Stille coupling reaction (Scheme 4.3). 
The Suzuki reaction was achieved by C-4 arylation of a trifluorosulfonyl-activated 
coumarin (4.30) with 3,5-dimethoxyphenylboronic acid (4.31) under palladium-copper 
catalysis. The Stille reaction of 4.30 and tributyl-3,4-methylenedioxyphenyltin was 
catalyzed by a palladium-lithium catalyst. Cytotoxicity studies of these polymethoxylated 








































Scheme 4.3: Synthesis of 4-arylcoumaris by the Suzuki and Stille reactions. 
4.4.1.1.3 Heck coupling reaction 
The palladium-catalyzed oxidative Heck coupling reaction has been used for the direct 
synthesis of 6-methoxy-4-phenylcoumarin (4.36) (Scheme 4.4).194 A coumarin proton (at 
C-4) was oxidatively displaced by a phenyl group in a palladium-catalyzed reaction in the 
presence of oxygen gas. 
 














Scheme 4.4: Synthesis of 6-methoxy-4-phenylcoumarin (4.36) by the Heck reaction. 
4.4.1.1.4 Negishi cross-coupling reaction 
Yang and Wu195 have reported the synthesis of 4-(4-methoxyphenyl)coumarin (4.39) by 
the Negishi cross-coupling reaction with the use of a nickel catalyst (Scheme 4.5). They 
activated 4-hydroxycoumarin (4.37) by forming a vinylic phosphate coumarin 4.38 which 
was then reacted with methoxyphenylzinc bromide under nickel-mediated conditions to 












4.37 86%  
Scheme 4.5: Synthesis of 4-(4-methoxyphenyl)coumarin (4.39) via Negishi reaction. 
4.4.1.2 Transition metals in pyrone ring closure 
The Sonogashira coupling reaction is one of the most widely used methods for the 
coupling of vinyl or aryl halides with terminal alkynes to form conjugated enynes or aryl 
alkynes. Hung and coworkers177 have applied the Sonogashira reaction to couple an aryl 
iodide to the terminal alkyne ester 4.42, which was prepared by the esterification of a 
trisubstituted phenol 4.40 with an acetylenic carboxylic acid 4.41, to form an alkyne ester 
intermediate 4.43 (Scheme 4.6). The intramolecular cyclization of 4.43 in the presence of a 
palladium catalyst afforded the substituted neoflavone 4.44. 
 





























Scheme 4.6: Synthesis of polysubstituted 4-arylcoumarin (4.44) by Pd catalysis. 
 
Fujiwara et al.196 have reported the synthesis of trimethoxyneoflavone 4.46 by pyrone ring 
closure (Scheme 4.7). They firstly prepared trimethoxyphenyl phenylpropiolate (4.45) by 
the esterification of phenylpropiolic acid and trimethoxyphenol in the presence of N,N´-
dicyclohexylcarbodiimide. Compound 4.45 undergoes an intramolecular ring cyclization 


















Scheme 4.7: Synthesis of trimethoxy-4-arylcoumarin 4.46 under Pt-catalyzed conditions. 
 
Yamamoto and Kirai197 reported the synthesis of 4-phenylcoumarin 4.50 by copper-
catalyzed hydroarylation (Scheme 4.8). The treatment of MOM-protected salicylaldehyde 
(4.47) with CBr4, Et3N and PPh3 afforded dibromoalkene 4.48 which was treated with 
butyllithium and then with acid to form methyl phenylpropiolate (4.49). Compound 4.49 
was treated with a copper catalyst in the presence of phenylboronic acid to form 
neoflavone 4.50. 
 
























Scheme 4.8: Cu-catalyzed hydroarylation reaction to form neoflavone (4.50). 
 
Kitamura and Oyamada198 have reported the use of platinum and silver catalysts to form 
6,7-dimethyl-4-arylcoumarin (4.53) via hydroarylation of phenylpropiolic acid (4.52) with 
3,4-dimethylphenol (4.51) (Scheme 4.9). They also used platinum and TFA in their 










Scheme 4.9: Pt-Ag couple-catalyzed hydroarylation reaction. 
 
Alper et al.199 have synthesized neoflavone (4.50) via palladium-catalyzed oxidative 
cyclocarbonylation of vinylphenol 4.54 (Scheme 4.10). This oxidative carbonylation 
reaction is an intramolecular reaction which involves the connection of two components 
through a carbonyl group. This reaction was run at low CO/air pressures at 110 °C. 1,4-
Benzoquinone was also used as a substitute for air in the presence of Pd catalyst to form 
the same coumarin. 
 










Scheme 4.10: Pd-catalyzed oxidative cyclocarbonylation reaction. 
4.4.2 Wittig reaction 
The Wittig reaction has also been applied to the synthesis of 4-phenylcoumarin derivatives. 
This approach involves reaction of an aromatic ketone with a triphenyl phosphonium ylide. 
This reaction, discovered in 1954 by Georg Wittig, is widely used in organic synthesis for 
the synthesis of alkenes.200, 201  
Bissel and coworkers202 have developed a synthesis for 7-methoxy-4-arylcoumarin (4.53) 
via the Wittig reaction, i.e. the reaction between 2-hydroxy-4-methoxybenzophenone 
(4.51) and ethyl 2-(triphenylphosphoranylidene)acetate (Scheme 4.11). Similar reactions 
were applied by Gallagher et al.203 and Chen et al.204 to synthesize 6-methyl-4-
arylcoumarin (4.56) from the reaction of 2-hydroxy-5-methylbenzophenone (4.54) and 



















Scheme 4.12: Synthesis of 6-methyl-4-arylcoumarin (4.56). 
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4.4.3 Michael reaction 
The Michael addition is a conjugate addition reaction which involves the nucleophilic 
addition of a nucleophile (normally carbanion) to an α,β-unsaturated carbonyl compound. 
This reaction is one of the most used reactions for the formation of C–C bonds under mild 
conditions.205 
Rizzi et al.206 have reported a novel, mild procedure for the synthesis of 7-methoxy-4-(4-
methoxyphenyl)coumarin (4.59) by a Michael-type reaction (Scheme 4.13). They 
condensed m-methoxyphenol with cinnamic acid (4.57) in the presence of trifluoroacetic 
acid at room temperature to form a 4-phenylcoumarin intermediate (4.58) which was 

















Scheme 4.13: Synthesis of 7-methoxy-4-(4-methoxyphenyl)coumarin (4.59). 
 
Speranza et al.207 on the other hand, have reported a synthetic procedure for 4-aryl-3,4-
dihydrocoumarin (4.61) by a Michael reaction of phloroglucinol with p-substituted N-








R = N N
 
Scheme 4.14: Synthesis of 4-aryl-3,4-dihydrocoumarin (4.61). 
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4.4.4 Kostanecki reaction 
In the Kostanecki acylation, a 4-phenylcoumarin is formed by acylation of an O-
hydroxyaryl ketone with an acid chloride followed by an intramolecular aldol condensation 
cyclization. Lee and coworkers208 have reported the synthesis of a 4-arylcoumarin 4.64 by 
the Kostanecki reaction of trimethylated 2-hydroxybenzophenone (4.62) with phenylacetyl 










4.62 76%  
Scheme 4.15: Synthesis of 5,7-dimethyl-3-phenyl-4-(4-methylphenyl)coumarin (4.64). 
4.4.5 Pechmann reaction 
The Pechmann condensation is one of the most commonly used procedures for the 
preparation of 4-phenylcoumarins and derivatives. This method involves the reaction of a 
β-ketoester with phenol in the presence of a homogeneous acidic catalyst (sulfuric, 
hydrochloric,209 phosphoric or trifluoroacetic acid210 and a Lewis acid such as iron(III) 
chloride, titanium chloride,211 aluminium chloride,212 tin(IV) chloride and zinc chloride213) 
or a heterogeneous catalyst (cation exchange resins, Nafion-H, zeolite-HBEA and other 
solid acids).214 Lately, microwave irradiation,215 ionic liquids216 and ultrasound217 have 
also been applied to this reaction. 
Until now, the Pechmann reaction for the synthesis of 4-arylcoumarins (4.66) has been 
limited to unsubstituted phenyl C-rings (Scheme 4.16), partly because the substituted 
phenyl-β-ketoesters (4.65) are not readily available. 4-Arylcoumarins that are substituted 
on the C-ring have been synthesized but hardly any have been synthesized by the 
Pechmann reaction. Most of these substituted coumarins have been made by transition 
metal-catalyzed reactions and other reactions such as the Michael reaction as shown in the 
previous Sections. 
 












Scheme 4.16: General Pechmann reaction to synthesize 4-arylcoumarin (4.66). 
 
Guilet et al.218 reported the synthesis of 5,7-dihydroxy-6-prenyl-4-phenylcoumarin (4.67) 
by the Pechmann condensation catalyzed by indium(III) chloride (Scheme 4.17). They 
obtained their product by refluxing prenylated phloroglucinol and ethyl benzoylacetate in 














Scheme 4.17: Indium (III) chloride catalyzed reaction. 
 
Karami and co-workers219 synthesized 5,7-dihydroxy-4-phenylcoumarin (4.68) from the 
reaction of ethyl benzoylacetate with phloroglucinol in the presence of ZrOCl2.8H2O/SiO2 













Scheme 4.18: Solvent-free reaction in the presence of ZrOCl2.8H2O/SiO2. 
 
Wang et al.220 reported the synthesis of neoflavone 4.66 by reacting phenol with ethyl 
benzoylacetate in the presence of magnesium bis(trifluoromethane)sulfonamide (Scheme 
4.19). This Pechmann reaction was run under solvent-free conditions to get a maximum 
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Scheme 4.19: Synthesis of neoflavone 4.66. 
 
Ionic liquids have been used as alternative solvents for reactions as well as catalyst for 
various reactions. The use of ionic liquids has gained more attention as a result of green 
chemistry. Shaterian and Aghakhanizadeh221 have used ionic liquids in their synthesis of 
5,7-dihydroxyneoflavone (4.68) (Scheme 4.20). They reacted phloroglucinol with the β-
ketoester under solvent-free conditions, at room temperature, in the presence of Brønsted 
acid ionic liquids such as 2-pyrrolidonium hydrogen sulfate, N-methyl-2-pyrrolidonium 














Scheme 4.20: Pechmann reaction with ionic liquid catalyst. 
4.4.5.1 Synthesis of β-ketoesters 
β-Ketoesters are known to be important intermediates in the synthesis of ceramides, 
degradable polymers and antibiotics (e.g. coumarins, quinolones, etc.).222 Shriner and 
coworkers223 have synthesized ethyl benzoylacetate (4.70) by the acylation of ethyl 
acetoacetate at C-2 in the presence of sodium to form ethyl benzoylacetoacetate (4.69) 
which was further hydrolyzed in the presence of ammonia and ammonium chloride to yield 
β-ketoester 4.70 as shown in Scheme 4.21. 
 
















Scheme 4.21: Synthesis of ethyl benzoylacetate (4.70) from benzoyl chloride. 
 
McElvain and Weber224 have reported the synthesis of ethyl benzoylacetate (4.70) by 
acylating ethyl acetoacetate with ethyl benzoate under sodium-mediated conditions to form 
the sodium enolate 4.71 (Scheme 4.22). This enolate was treated with aqueous sulfuric 















Scheme 4.22: Synthesis of ethyl benzoylacetate (4.70) from ethyl benzoate. 
 
Yuasa and Tsuruta225 have reported the synthesis of methyl benzoylacetate (4.65) using 
barium oxide as catalyst (Scheme 4.23). They acylated methyl acetoacetate (4.73) reacted 
with benzoyl chloride in the presence of BaO catalyst to form an enolate-barium complex 
















Scheme 4.23: Synthesis of methyl benzoylacetate (4.65) using BaO. 
 
Sijbesma et al.226 have reported the synthesis of ethyl 3,4,5-tris((S)-3,7-dimethyloctyloxy) 
benzoylacetate (4.77) from ethyl malonate (4.76) or/and potassium monoethyl malonate 
(4.75). One of their reactions was the acylation of ethyl malonate with acid chloride 4.74 in 
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the presence of butyllithium to form β-ketoester (4.77). The other reaction started by 
forming potassium-malonate salt (4.75) from diethyl malonate, which was then acylated 































Scheme 4.24: Synthesis of ethyl 3,4,5-tris((S)-3,7-dimethyloctyloxy) benzoylacetate 
(4.77). 
 
It is shown in the review above that coumarins are natural compounds and that many are 
biological active. The first neoflavone was isolated from Calophyllum inophyllum seeds in 
1951 and since then several synthetic methods for neoflavones have been developed. 
 
4.5 Results and discussion for 4-arylcoumarins 
4.5.1 Introduction 
The Pechmann reaction (Section 4.4.5) is a general reaction used for the preparation of 4-
substituted coumarins. However, this reaction has received very little attention in the 
synthesis of 4-arylcoumarins with substituents on the phenyl ring, most likely because of 
problems encountered in the preparation of the β-ketoesters. Most substituted 4-
arylcoumarins have been prepared by palladium-catalysed reactions such as the Suzuki 
reaction (Section 4.4.1.1.1). 
 






Figure 4.11: Structure of a ring-C substituted neoflavone. 
 
Our aim was to find new or better methods for synthesizing substituted 4-
phenylcoumarins. In this report, we present a new palladium-free method for constructing 
β-keto esters containing a fluorine-substituted phenyl ring. This has enabled us to 
successfully synthesize ring-C fluorinated neoflavones by the Pechmann reaction. 

















Scheme 4.25: Retrosynthetic analysis for 4-phenylcoumarins. 
 
The retrosynthetic analysis of the target coumarin is based on the condensation of a β-
ketoester with a phenolic compound by the Pechmann reaction. The formation of the aryl-
substituted β-ketoester can be achieved by a benzoylation-deacylation reaction of methyl 
acetoacetate. 
 
135 | P a g e  
 



















MX = MgCl 2 or NaH  
Scheme 4.26: Synthetic scheme of fluorinated 4-phenylcoumarins. 
 
Scheme 4.26 outlines our approach to synthesize fluorinated 4-phenylcoumarins (4.81). 
The key step in this synthesis was the development of an effective procedure for the 
synthesis of fluorinated methyl benzoylacetates (4.80). The final step of this synthesis was 
the application of the Pechmann reaction to yield 4-arylcoumarins (4.81). 
4.5.2 Synthesis of β-keto ester 
4.5.2.1 Synthesis of methyl benzoylacetate (4.65) 
The first step of the reaction was to synthesize a substituted β-keto ester. This was 
accomplished via a novel reaction using readily available reagents and mild condition. 
Methyl acetoacetate was treated with MgCl2 (or NaH), Et3N and n-BuLi in DCM (or THF) 
and then with benzoyl chloride to yield methyl benzoylacetate (4.65). After a series of 
trials of different combinations to optimize the yield, a combination of MgCl2, Et3N and n-
BuLi in DCM was found to give the optimum yield (88%). The use of NaH in DCM gave 
an average yield of 52%. THF was also found not to favour this reaction as the yields were 















Scheme 4.27: Synthesis of methyl benzoylacetate (4.65). 
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This reaction is an acylation-deacylation reaction which takes place under mild conditions 
(0 °C to 25 °C). In combination of MgCl2, Et3N behaves as a much stronger base and is 
more effective in enolizing a β-keto ester than Et3N on its own. This combination has been 
used in a number of interesting reactions, as was summarised by Anwar.227 The proposed 
mechanism for acylation-deacylation reaction is shown in Scheme 4.28. Methyl 
acetoacetate was treated with MgCl2 to form a six membered-ring magnesium complex 
which makes the α-protons (CH2) of methyl acetoacetate even more acidic. The removal of 
an acidic proton with the weak base (Et3N) results in the formation of an enolate 
magnesium-complex chloride salt. This in turn reacts with the acid chloride to form a 
diketoester 4.82. The intermediate 4.82 contains three carbonyl groups (an acetyl, a 
benzoyl and an ester carbonyl). These three carbonyls differ in reactivity towards a 
nucleophile, with the acetyl carbonyl being the most reactive. As a result, the nucleophile 
attacks the acetyl carbonyl causing 4.82 to deacetylate to afford methyl benzoylacetate 


























Scheme 4.28: Proposed mechanism for acylation-deacylation reaction. 
 
The success of the reaction to form methyl benzoylacetate was confirmed by the absence 
of the methyl acyl proton peak in the 1H spectrum (Plate 37). The acetyl group had been 
replaced by a benzoyl group. The phenyl protons were evident at δH 7.50 (t), δH 7.62 (t) 
and δH 7.97 (d). The ortho protons on the phenyl ring are deshielded by the anisotropic 
effect of the carbonyl and as a result, they appeared further downfield (δH 7.97). Two 
singlets upfield at δH 3.77 (3H) and δH 4.03 (2H) were assigned to the methoxy and α-
protons, respectively. 
The 13C NMR spectrum revealed eight signals which correlate with the expected number 
of carbon peaks. Two singlets, assigned to the ketone carbonyl carbon and ester carbonyl 
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carbon, occur at δC 192.4 and δC 167.9. A quaternary singlet appeared downfield (δC 
136.0) relative to the other aromatic carbons. With the aid of DEPT-135 and HSQC 
spectra, the α-carbon (C-2) was assigned to the signal at δC 45.7. This NMR data is in 
agreement with published data.225 
4.5.2.2 Synthesis of fluorinated methyl benzoylacetates (4.84, 4.85 
and 4.86) 
Methyl 2-fluorobenzoylacetate (4.84), methyl 3-fluorobenzoylacetate (4.85) and methyl 4-
fluorobenzoylacetate (4.86) were also synthesized in a similar manner to the synthesis of 
4.65 (Section 4.5.2.1) using 2-fluorobenzoyl chloride, 3-fluorobenzoyl chloride and 4-










































Scheme 4.29: Synthesis of fluorinated methyl benzoylacetates (4.84, 4.85 and 4.86). 
 
The products were characterized by NMR (Plate 38, 39, and 40). The 13C-NMR spectra 
revealed that all the aromatic 13C signals are split into doublets due to coupling with 19F. 
The 13C,19F coupling constant of the ipso carbon is quite large (J ~ 250 Hz), but for the rest 
of the aromatic carbons, the J-values decrease with the increase in the number of bonds to 
the fluorine, for example, the ortho carbons, C-2' and C-4', for 4.85 J = 21.4 Hz and 22.5 
Hz, respectively. The meta- and para- carbons of the same compound have coupling 
constants of 7.5 Hz and 2.0 Hz, respectively. 
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The 1H NMR spectra for these fluorinated β-keto esters revealed that the 1H,19F coupling 
constants are always greater than that of 1H, 1H coupling constants for protons located in 
the same position. For example, in the 1H NMR spectrum of 4.84, the ortho 1H,19F 
coupling constant (3JH-3',F = 12.1 Hz) of H-3'-to-fluorine is significantly larger than the 1H, 
1H coupling constant of the same proton (H-3') to the ortho proton (H-4') (3JH-3',H-4' = 8.5 
Hz). The 1H NMR spectrum of 4.85 showed 3JH-4',F = 9.1 Hz and 3JH-4',H-5' = 8.0 Hz which 











Scheme 4.30: Keto-enol tautomerism of methyl benzoylacetate. 
 
The NMR spectra for all β-keto esters synthesized suggest that these organic molecules 
exist as a mixture of keto-enol tautomers (Scheme 4.30). The keto form (4.65) is more 
favourable than the enol form (4.65A). For example, 4.65 and 4.86 exist at a keto-enol 
ratio of 6:1 as shown by the peak integrals (Table 4.1). The 2-fluoro (4.84) and 3-fluoro 
(4.85) β-keto ester derivatives have keto-enol ratios that are more than 50% less than that 
of 4.65 and 4.86.  
Table 4.1: Keto-enol ratio from methoxy protons of β-keto esters. 
Compound Tautomeric form Integration of 
methoxy protons 
Integral ratio 
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4.5.3 Pechmann reaction 
The Pechmann reaction is commonly used to synthesize coumarins. This involves 
cyclization of a β-keto ester with phenol in the presence of a catalyst. The second step of 
our reaction involves the application of the Pechmann reaction to synthesize fluorinated 4-
phenylcoumarins (neoflavones).  
4.5.3.1 Synthesis of 7-hydroxy-4-phenylcoumarin (4.87) 
7-Hydroxy-4-phenylcoumarin (4.87) was synthesized by the Pechmann reaction. The 
treatment of methyl benzoylacetate (4.65) and resorcinol (4.79) with H2SO4 at 35 °C 
produced 4.87 in a yield of 96% (Scheme 4.31). The product 4.87 was isolated as a yellow 
solid and its structure was verified by NMR, mass spectrometry and the melting point 












Scheme 4.31: Synthesis of 7-hydroxy-4-phenylcoumarin (4.87). 
 
A mechanism for the Pechmann reaction is proposed in Scheme 4.32. The acid catalyses 
the transesterification process to form a reactive β-keto ester which readily converts to the 
enol tautomer. An intramolecular Michael addition forms the coumarin skeleton. 
Subsequent acid-induced dehydration and dehydrogenation lead to the coumarin. 
 





































Scheme 4.32: A proposed mechanism for the Pechmann reaction. 
 
The structure of 4.87 was confirmed by the 1H NMR spectrum which revealed an olefinic 
α-proton peak (H-3) as a singlet at δH 6.41 and three proton peaks of the phenolic aromatic 
ring (H-6, H-8 and H-5) resonating at δH 6.78, δH 6.80 and δH 7.27, respectively (Plate 41). 
H-6 appeared as doublet of doublets due to ortho- and meta-coupling with H-5 (J = 8.7 Hz) 
and H-8 (J = 2.4 Hz), respectively. H-8 appeared as a doublet due to meta-coupling with 
H-6 (J = 2.4 Hz) and H-5 with ortho-coupling to H-6 (J = 8.7 Hz). This coupling pattern 
was confirmed by the COSY spectrum which showed a correlation between H-5 and H-6, 
and further correlation between H-6 and H-8. Two multiplets (for the phenyl moiety) 
which integrate to two protons (δH 7.50) and three protons (δH 7.55) were assigned to the 
ortho protons (H-2', H-6') and meta and para protons (H-3', H-4', H-5'), respectively. A 
broad hydroxy proton peak appeared downfield at δH 10.64. 
The 13C NMR spectrum also confirmed the structure 4.87 by showing the expected thirteen 
signals (Plate 41). HSQC, HMBC and DEPT-135 NMR spectra were used to assign each 
of these thirteen peaks. The phenolic and carbonyl carbons were most deshielded as they 
resonate at δC 161.9 and δC 160.6, respectively. The non-protonated aromatic carbons (H-
8a, H-4 and H-1') were also deshielded as they appeared downfield at δC 156.0, δC 155.9 
and δC 135.7, respectively. The rest of the aromatic carbons were assigned based on the 
HSQC NMR spectra. 
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4.5.3.2 Synthesis of fluorinated 7-hydroxy-4-phenylcoumarins (4.88, 

































Scheme 4.33: Synthesis of fluorinated 4-arylcoumarins (4.88, 4.89 and 4.90). 
 
Having successfully synthesized 4-arylcoumarin (4.87) by the Pechmann condensation, the 
reaction was also applied in the synthesis of fluorinated 4-phenylcoumarins (Scheme 4.33). 
Resorcinol (4.79) was reacted with ortho-, meta- and para-fluorinated aryl β-keto esters to 
yield the corresponding fluorinated 4-phenylcoumarins, (4.88, 4.89 and 4.90), respectively. 
The reaction conditions for these reactions were similar to that for the synthesis of 4.87 
and fluorinated coumarins (4.88, 4.89 and 4.90) were obtained in good yields (91% - 
98%). The chemical structures of the fluorinated coumarins were confirmed by NMR 
spectroscopy (Plate 42, 43 and 44) and mass spectrometry. 
4.5.3.3 Synthesis of 5,7-dihydroxy-4-phenylcoumarin (4.83) 
The synthesis of coumarins by the Pechmann condensation was also investigated with 
phloroglucinol instead of resorcinol (4.79) as a starting material. The reaction of the 3-
phenyl β-keto ester with phloroglucinol in acid medium afforded 5,7-dihydroxy-4-
phenylcoumarin (4.83) in good yield. The structure of 4.83 was confirmed by NMR 
spectroscopy, mass spectrometry and melting point. 
 















Scheme 4.34: Synthesis of 5,7-dihydroxy-4-phenylcoumarin (4.83). 
 
The structure of 4.83 was characterized by the presence of two deshielded singlet peaks at 
δH 10.10 and δH 10.38 in the 1H NMR spectrum (Plate 45) assigned to 7-OH and 5-OH, 
respectively. The aromatic protons of the phenyl group are more deshielded than the 
aromatic protons of the coumarin ring (H-6 and H-8) as they resonate at δH 7.30-7.38 while 
H-6 and H-8 appear at δH 6.16 and δH 6.26, respectively. The 13C NMR spectrum also 
confirmed the structure of 4.83 by showing thirteen carbon peaks. Two phenolic carbons 
(C-5 and C-7) and a carbonyl carbon resonate at δC 157.6, δC 162.2 and δC 160.4, 
respectively. The spectrum also showed the presence of four non-protonated carbons (C-1', 
C-4, C-4a and C-8a). 
4.5.3.4 Synthesis of fluorinated 5,7-dihydroxy-4-phenylcoumarins 
(4.91, 4.92 and 4.93) 
Fluorinated 5,7-dihydroxy-4-phenylcoumarins (4.91, 4.92 and 4.93) were also synthesized 
by the same manner as 4.83. Ortho-, meta- and para-fluorinated 4-aryl β-keto esters (4.84, 
4.85 and 4.86, respectively) were used in this reaction to yield the corresponding 
fluorinated 5,7-dihydroxy-4-phenylcoumarins as shown in Scheme 4.35. The formation of 
these compounds was confirmed by NMR spectroscopy (Plates 46, 47 and 48) and mass 
spectrometry. 
 





































Scheme 4.35: Synthesis of fluorinated dihydroxy-4-arylcoumarins (4.91, 4.92 and 4.93). 
 
4.5.3.5 Synthesis of 4-methylcoumarins 
4-Methylcoumarins (4.94, 4.95 and 4.96) were also synthesized by Pechmann 
condensation. Methyl acetoacetate was reacted with resorcinol, phloroglucinol and 4-
hydroxyphenol separately to yield 7-hydroxy-4-methylcoumarin (4.94), 5,7-dihydroxy-4-
methylcoumarin (4.95) and 6-hydroxy-4-methylcoumarin (4.96), respectively. These acid-
mediated reactions were run at low temperatures (less than 50 °C, except for the reaction 
of 4-hydroxyphenol) to yield 4-methylcoumarins and their structures were confirmed by 
NMR, mass spectra and melting points. 
 































Scheme 4.36: Synthesis of 4-methylcoumarins by Pechmann reaction. 
 
The 4-methylcoumarins were characterized by the presence of an allylic methyl resonance 
(CH3) in the upfield region (δH 2.35 – 2.48) in their 1H NMR spectra (Plates 49, 50 and 
51). This allylic peak appears as a doublet due to long-range coupling with the vinylic 
proton (3-H) with an average coupling constant of 1.1 Hz. The vinylic proton also 
appeared as a doublet at about δH 6. 13C NMR revealed ten carbon peaks which correspond 
to the number of carbons in the structure. The carbonyl and phenolic carbons were 
deshielded as they appeared downfield followed by the non-protonated carbons. The 
structures of these compounds were also confirmed by mass spectrometry. 
4.6 Activity of coumarins 
Coumarins (4.83, 4.87, 4.88, 4.89, 4.90, 4.91, 4.92 and 4.93) were subjected to an in vitro 
cell-base HIV assay in the MINTEK laboratories at a concentration of 10 µg.mL-1, but 
none of these showed any activity. The concentration of 10 µg.mL-1 is too low to consider 
for activity, but we are arranging to repeat the tests at higher concentrations. Antimicrobial 
and cytotoxic activities of cell lines are currently under investigation. 
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4.7 Conclusion 
The objective of this study was to investigate the application of the Pechmann reaction in 
the synthesis of 4-phenylcoumarins (neoflavones) with substituents in the 4-phenyl ring. 
Fluorine-substituted 4-aryl β-ketoesters (the precursors for the fluorine-substituted 
neoflavones) were synthesized by a new method which gave good yields (81%-88%). 
Fluorine-substituted neoflavones were successfully synthesized by the Pechmann reaction 
for the first time (reaction of fluorinated β-ketoesters with different phenols) and were 
isolated in good yields of more than 91%. 
4.8 Experimental Procedure 
General experimental procedures are given in Section 3.7.1. 








To a stirred mixture of MgCl2 (2.0 g, 21 mmol) and Et3N (2.1 g, 21 mmol) in dry DCM (15 
mL) at room temperature, methyl acetoacetate, (2.0 g, 17 mmol) was added slowly. The 
mixture was stirred for 30 min before the temperature was reduced to 0 °C. n-BuLi (20 mL 
of a 1.6 M in hexane, 32 mmol) was added slowly into the mixture and the mixture was 
stirred for a further 30 min. Benzoyl chloride (2.4 g, 17 mmol) was added dropwise into 
the mixture and the mixture was stirred for 15 min. The reaction mixture was allowed to 
reach room temperature and was stirred overnight. To the reaction was added 5 M HCl (8 
mL) and distilled water (10 mL) and the mixture was extracted with DCM (3 x 30 mL). 
The organic layer was dried over anhydrous MgSO4 and the solvent was removed in 
vacuo. The resulting yellow product was purified by silica gel column chromatography 
with 10% EtOAc in hexanes as eluent and 4.65 was obtained as a light orange viscous 
liquid (2.6 g, 88%), TLC Rf 0.45 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 3.77 
(3H, s, H-4), 4.03 (2H, s, H-2), 7.50 (2H, t, J = 7.8, H-3',5'), 7.62 (1H, t, J = 7.8, H-4'), 
7.97 (2H, d, J = 7.8, H-2',6'). 13C NMR (100 MHz, CDCl3) 45.7 (C-2), 52.5 (C-4), 128.5 
(C-2',6'), 128.8 (C-3',5'), 133.8 (C-4'), 136.0 (C-1'), 167.9 (C-3), 192.4 (C-1). [Plate 37]. 
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To a stirred mixture of MgCl2 (2.0 g, 21 mmol) and Et3N (2.1 g, 21 mmol) in dry DCM (15 
mL) at room temperature, methyl acetoacetate (2.0 g, 17 mmol) was added slowly. The 
mixture was stirred for 30 min before the temperature was reduced to 0 °C. n-BuLi (20 mL 
of a 1.6 M in hexane, 32 mmol) was added slowly into the mixture and the mixture was 
stirred for a further 30 min. 2-Fluorobenzoyl chloride (2.7 g, 17 mmol) was added 
dropwise into the mixture and the mixture was stirred for 15 min. The reaction mixture 
was allowed to reach room temperature and was stirred overnight. To the reaction was 
added 5 M HCl (8 mL) and distilled water (10 mL) and the mixture was extracted with 
DCM (3 x 30 mL).The organic layer was dried over anhydrous MgSO4 and the solvent was 
removed in vacuo. The resulting yellow product was purified by silica gel column 
chromatography with 10% EtOAc in hexanes as eluent and 4.84 was obtained as a light 
orange viscous liquid (2.7 g, 81%), TLC Rf 0.50 (Hexanes-EtOAc, 1:9). 1H NMR (400 
MHz, CDCl3) 3.76 (3H, s, H-4), 4.01 (2H, s, H-2), 7.15 (1H, ddd, J = 12.1, 8.5, 1.0, H-3'), 
7.26 (1H, t, J = 7.5, H-5'), 7.57 (1H, m, H-4'), 7.95 (2H, td, J = 7.6, 1.9, H-6'). 13C NMR 
(100 MHz, CDCl3) 49.6 (d, J = 8.1, C-2), 52.3 (C-4), 116.7 (d, J = 24.1, C-3'), 124.7 (d, J 
= 2.9, C-6'), 129.3 (d, J = 21.7, C-1'), 131.0 (d, J = 2.3, C-5'), 135.5 (d, J = 9.6, C-4'), 
162.2 (d, J = 254.3, C-2’), 167.8 (d, J = 3.0, C-3), 190.1 (d, J = 3.7, C-1). [Plate 38]. 









To a stirred mixture of MgCl2 (2.0 g, 21 mmol) and Et3N (2.1 g, 21 mmol) in dry DCM (15 
mL) at room temperature, methyl acetoacetate (2.0 g, 17 mmol) was added slowly. The 
mixture was stirred for 30 min before the temperature was reduced to 0 °C. n-BuLi (20 mL 
of a 1.6 M in hexane, 32 mmol) was added slowly into the mixture and the mixture was 
stirred for a further 30 min. 3-Fluorobenzoyl chloride (2.7 g, 17 mmol) was added 
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dropwise into the mixture and the mixture was stirred for 15 min. The reaction mixture 
was allowed to reach room temperature and was stirred overnight. To the reaction was 
added 5 M HCl (8 mL) and distilled water (10 mL) and the mixture was extracted with 
DCM (3 x 30 mL). The organic layer was dried over anhydrous MgSO4 and the solvent 
was removed in vacuo. The resulting yellow product was purified by silica gel column 
chromatography with 10% EtOAc in hexanes as eluent and 4.85 was obtained as a light 
orange viscous liquid (2.9 g, 86%), TLC Rf 0.48 (Hexanes-EtOAc, 1:9). 1H NMR (400 
MHz, CDCl3) 3.77 (3H, s, H-4), 4.00 (2H, s, H-2), 7.31 (1H, dddd, J = 8.5, 8.0, 2.5, 1.0, 
H-4'), 7.48 (1H, m, H-5'), 7.46 (1H, ddd, J = 9.3, 2.5, 1.0, H-2'), 7.73 (1H, dt, J = 7.7, 1.0, 
H-6'). 13C NMR (100 MHz, CDCl3) 45.7 (C-2), 52.5 (C-4), 115.2 (d, J = 22.5, C-4'), 120.8 
(d, J = 21.4, C-2'), 124.3 (d, J = 2.0, C-6'), 130.5 (d, J = 7.5, C-5'), 138.0 (d, J = 6.6, C-1'), 
162.8 (d, J = 246.3, C-3'), 167.5 (C-3), 191.1 (C-1). [Plate 39]. 







F 4.86  
To a stirred mixture of MgCl2 (2.0 g, 21 mmol) and Et3N (2.1 g, 21 mmol) in dry DCM (15 
mL) at room temperature, methyl acetoacetate (2.0 g, 17 mmol) was added slowly. The 
mixture was stirred for 30 min before the temperature was reduced to 0 °C. n-BuLi (20 mL 
of a 1.6 M in hexane, 32 mmol) was added slowly into the mixture and the mixture was 
stirred for a further 30 min. 4-Fluorobenzoyl chloride (2.7 g, 17 mmol) was added 
dropwise into the mixture which was stirred for 15 min. The reaction mixture was allowed 
to reach room temperature and was stirred overnight. To the reaction was added 5 M HCl 
(8 mL) and distilled water (10 mL) and the mixture was extracted with DCM (3 x 30 mL). 
The organic layer was dried over anhydrous MgSO4 and the solvent was removed in 
vacuo. The resulting yellow product was purified by silica gel column chromatography 
with 10% EtOAc in hexanes as eluent and 4.86 was obtained as a light orange viscous 
liquid (2.9 g, 86%), TLC Rf 0.48 (Hexanes-EtOAc, 1:9). 1H NMR (400 MHz, CDCl3) 3.76 
(3H, s, H-4), 3.98 (2H, s, H-2), 7.16 (2H, m, H-3',5'), 7.98 (2H, m, H-2',6'). 13C NMR (100 
MHz, CDCl3) 45.6 (C-2), 52.5 (C-4), 116.0 (d, J = 22.0, C-3',5'), 131.3 (d, J = 9.6, C-2', 
6'), 132.5 (d, J = 3.0, C-1'), 166.1 (d, J = 243.1, C-4'), 167.7 (C-3), 190.7 (C-1). [Plate 40]. 
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To a mixture of resorcinol (2.0 g, 18 mmol) and methyl benzoylacetate (3.2 g, 18 mmol) 
was added conc. H2SO4 (8 mL, 75%). The temperature of the stirred mixture was increased 
to 35 °C. After stirring for 5 h, the mixture was poured into crushed ice and neutralized 
with a NaOH solution. The mixture was filtered under vacuum and the residue was washed 
with plenty of water. The resulting product was purified by silica gel column 
chromatography with 70% EtOAc in hexanes as eluent and 4.87 was obtained as a yellow 
solid (4.1 g, 96%), mp 247-249 °C (lit.228 247-248 ºC), TLC Rf 0.48 (Hexanes-EtOAc, 
3:2). 1H NMR (400 MHz, DMSO-d6) 6.14 (1H, s, H-3), 6.78 (1H, dd, J = 8.7, 2.4, H-6), 
6.80 (1H, d, J = 2.4, H-8), 7.27 (1H, d, J = 8.7, H-5), 7.50 (2H, m, H-2',6'), 7.55 (3H, m, 
H-3',4',5'), 10.64 (1H, s, OH). 13C NMR (100 MHz, DMSO-d6) 103.2 (C-8), 110.8 (C-3), 
111.2 (C-6), 113.7 (C-4a), 128.6 (C-5), 128.8 (C-2',6'), 129.0 (C-4'), 129.3 (C-3',5'), 135.7 
(C-1'), 155.9 (C-4), 156.0 (C-8a), 160.6 (C-2), 161.9 (C-7). [Plate 41]. HRMS (ESI+): 
Found [M+Na]+ 261.0531, Calc. for C15H10NaO3 261.0528. 









To a mixture of phloroglucinol (2.3 g, 18 mmol) and methyl benzoylacetate (3.2 g, 18 
mmol) was added conc. H2SO4 (8 mL, 75%). The temperature of a stirred mixture was 
increased to 35 °C. After stirring for 5 h, the mixture was poured into crushed ice and 
neutralized with a NaOH solution. The mixture was filtered under vacuum and the residue 
was washed with plenty of water. The resulting product was purified by silica gel column 
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chromatography with 70% EtOAc in hexanes as eluent and 4.83 was obtained as a light 
orange solid (4.4 g, 96%), mp 240-242 °C (lit.220 241-242 ºC), TLC Rf 0.48 (Hexanes-
EtOAc, 3:2). 1H NMR (400 MHz, DMSO-d6) 5.73 (1H, s, H-3), 6.16 (1H, d, J = 2.3, H-6), 
6.26 (1H, d, J = 2.3, H-8), 7.30-7.34 (2H, m, H-2',6'), 7.35-7.38 (3H, m, H-3',4',5'), 10.10 
(1H, s, 7-OH), 10.38 (1H, s, 5-OH). 13C NMR (100 MHz, DMSO-d6) 95.1 (C-8), 99.6 (C-
6), 101.1 (C-4a), 110.6 (C-3), 127.7 (C-2',6'), 127.8 (C-3',5'), 128.2 (C-4'), 140.0 (C-1'), 
156.5 (C-4), 157.2 (C-8a), 157.6 (C-5), 160.4 (C-2), 162.2 (C-7). [Plate 45]. HRMS 
(ESI+): Found [M+Na]+ 277.0480, Calc. for C15H10NaO4 277.0477. 








To a mixture of resorcinol (2.0 g, 18 mmol) and methyl 2-fluorobenzoylacetate (3.5 g, 18 
mmol) was added conc. H2SO4 (8 mL, 75%). The temperature of a stirred mixture was 
increased to 35 °C. After stirring for 5 h, the mixture was poured into crushed ice and 
neutralized with a NaOH solution. The mixture was filtered under vacuum and the residue 
was washed with plenty of water. The resulting product was purified by silica gel column 
chromatography with 70% EtOAc in hexanes as eluent and 4.88 was obtained as a light 
yellow solid (4.2 g, 91%), mp 204-207 °C, TLC Rf 0.45 (Hexanes-EtOAc, 3:2). 1H NMR 
(400 MHz, DMSO-d6) 6.24 (1H, s, H-3), 6.77 (1H, dd, J = 8.6, 2.4, H-6), 6.81 (1H, d, J = 
2.4, H-8), 7.03 (1H, dd, J = 8.6, 2.6, H-5), 7.37-7.45 (2H, m, H-3',6'), 7.50 (1H, td, J = 7.5, 
1.8, H-5'), 7.61 (1H, m, H-4'), 10.67 (1H, s, OH). 13C NMR (100 MHz, DMSO-d6) 102.6 
(C-8), 110.7 (C-4a), 112.1 (C-3), 113.4 (C-6), 116.1 (d, J = 21.3, C-3'), 122.7 (d, J = 15.3, 
C-1'), 125.2 (d, J = 3.6, C-6'), 127.9 (d, J = 1.6, C-5), 130.8 (d, J = 2.9, C-5'), 132.0 (d, J = 
8.2, C-4'), 150.3 (C-4), 155.2 (C-8a), 158.6 (d, J = 248.6, C-2'), 160.0 (C-2), 161.6 (C-7). 
[Plate 42]. HRMS (ESI+): Found [M+Na]+ 279.0437, Calc. for C15H9FNaO3 279.0433. 
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To a mixture of phloroglucinol (2.3 g, 18 mmol) and methyl 2-fluorobenzoylacetate (3.5 g, 
18 mmol) was added conc. H2SO4 (8 mL, 75%). The temperature of a stirred mixture was 
increased to 35 °C. After stirring for 5 h, the mixture was poured into crushed ice and 
neutralized with a NaOH solution. The mixture was filtered under vacuum and the residue 
was washed with plenty of water. The resulting product was purified by silica gel column 
chromatography with 70% EtOAc in hexanes as eluent and 4.91 was obtained as an orange 
solid (4.7 g, 96%), mp 168-171 °C, TLC Rf 0.42 (Hexanes-EtOAc, 3:2). 1H NMR (400 
MHz, DMSO-d6) 5.84 (1H, s, H-3), 6.14 (1H, d, J = 2.3, H-6), 6.26 (1H, d, J = 2.3, H-8), 
7.16-7.24 (2H, m, H-3',6'), 7.35 (1H, td, J = 7.6, 1.9, H-5'), 7.42 (1H, m, H-4'), 10.19 (1H, 
s, 7-OH). 13C NMR (100 MHz, DMSO-d6) 95.0 (C-8), 99.5 (C-6), 101.4 (C-4a), 111.1 (C-
3), 114.9 (d, J = 21.1, C-3'), 124.3 (d, J = 3.3, C-6'), 128.1 (d, J = 16.0, C-1'), 129.6 (d, J = 
3.5, C-5'), 130.6 (d, J = 8.2, C-4'), 150.5 (C-4), 156.8 (C-8a), 157.6 (C-5), 159.2 (d, J = 
245.9, C-2'), 160.2 (C-2), 162.3 (C-7). [Plate 46]. HRMS (ESI+): Found [M+Na]+ 
295.0391, Calc. for C15H9FNaO4 295.0383. 









To a mixture of resorcinol (2.0 g, 18 mmol) and methyl 3-fluorobenzoylacetate (3.5 g, 18 
mmol) was added conc. H2SO4 (8 mL, 75%). The temperature of a stirred mixture was 
increased to 35 °C. After stirring for 5 h, the mixture was poured into crushed ice and 
neutralized with a NaOH solution. The mixture was filtered under vacuum and the residue 
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was washed with plenty of water. The resulting product was purified by silica gel column 
chromatography with 70% EtOAc in hexanes as eluent and 4.89 was obtained as a yellow 
solid (4.5 g, 97%), mp 208-211 °C, TLC Rf 0.45 (Hexanes-EtOAc, 3:2). 1H NMR (400 
MHz, DMSO-d6) 6.19 (1H, s, H-3), 6.79 (1H, dd, J = 8.6, 2.4, H-6), 6.81 (1H, d, J = 2.4, 
H-8), 7.26 (1H, d, J = 8.6, H-5), 7.35 (1H, dt, J = 7.7, 1.1, H-6'), 7.36-7.42 (2H, m, H-
2',4'), 7.60 (1H, m, H-5'), 10.66 (1H, s, OH). 13C NMR (100 MHz, DMSO-d6) 102.8 (C-8), 
110.5 (C-6), 110.9 (C-3), 113.4 (C-4a), 115.6 (d, J = 22.6, C-4'), 116.5 (d, J = 20.4, C-2'), 
124.7 (d, J = 2.9, C-6'), 128.1 (C-5), 131.0 (d, J = 8.1, C-5'), 137.4 (d, J = 8.0, C-1'), 154.1 
(d, J = 2.3, C-4), 155.6 (C-8a), 160.1 (C-2), 161.6 (C-7), 162.2 (d, J = 245.2, C-3'). [Plate 
43]. HRMS (ESI+): Found [M+Na]+ 279.0435, Calc. for C15H9FNaO3 279.0433. 












To a mixture of phloroglucinol (2.3 g, 18 mmol) and methyl 3-fluorobenzoylacetate (3.5 g, 
18 mmol) was added conc. H2SO4 (8 mL, 75%). The temperature of a stirred mixture was 
increased to 35 °C. After stirring for 5 h, the mixture was poured into crushed ice and 
neutralized with a NaOH solution. The mixture was filtered under vacuum and the residue 
was washed with plenty of water. The resulting product was purified by silica gel column 
chromatography with 70% EtOAc in hexanes as eluent and 4.92 was obtained as a light 
brown solid (4.7 g, 96%), mp 267-269 °C, TLC Rf 0.44 (Hexanes-EtOAc, 3:2). 1H NMR 
(400 MHz, DMSO-d6) 5.79 (1H, s, H-3), 6.16 (1H, d, J = 2.3, H-6), 6.27 (1H, d, J = 2.3, 
H-8), 7.14-7.23 (3H, m, H-3',4',6'), 7.40 (1H, m, H-5'), 10.18 (1H, s, 7-OH), 10.42 (1H, s, 
5-OH). 13C NMR (100 MHz, DMSO-d6) 95.2 (C-8), 99.6 (C-6), 100.9 (C-4a), 110.7 (C-3), 
114.9 (d, J = 20.8, C-2'), 115.1 (d, J = 22.9, C-4'), 124.0 (d, J = 2.8, C-6'), 129.8 (d, J = 
8.7, C-5'), 142.2 (d, J = 8.2, H-1'), 154.9 (d, J = 1.6, H-4), 157.1 (C-8a), 157.4 (C-5), 160.2 
(C-2), 161.7 (d, J = 242.2, C-3'), 162.3 (C-7). [Plate 47]. HRMS (ESI+): Found [M+Na]+ 
295.0388, Calc. for C15H9FNaO4 295.0383. 
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To a mixture of resorcinol (2.0 g, 18 mmol) and methyl 4-fluorobenzoylacetate (3.5 g, 18 
mmol) was added conc. H2SO4 (8 mL, 75%). The temperature of a stirred mixture was 
increased to 35 °C. After stirring for 5 h, the mixture was poured into crushed ice and 
neutralized with a NaOH solution. The mixture was filtered under vacuum and the residue 
was washed with plenty of water. The resulting product was purified by silica gel column 
chromatography with 70% EtOAc in hexanes as eluent and 4.90 was obtained as a light 
orange solid (4.5 g, 98%), mp 279-283 °C, TLC Rf 0.46 (Hexanes-EtOAc, 3:2). 1H NMR 
(400 MHz, DMSO-d6) 6.13 (1H, s, H-3), 6.76 (1H, dd, J = 8.7, 2.4, H-6), 6.78 (1H, d, J = 
2.4, H-8), 7.25 (1H, d, J = 8.7, H-5), 7.38 (2H, m, H-3',5'), 7.57 (2H, m, H-2',6'). 13C NMR 
(100 MHz, DMSO-d6) 103.2 (C-8), 110.8 (C-3), 110.9 (C-6), 113.9 (C-4a), 116.3 (d, J = 
22.1, C-3',5'), 123.5 (C-5), 131.2 (d, J = 8.2, C-2',6'), 132.0 (d, J = 2.9, C-1'), 154.9 (C-4), 
156.0 (C-8a), 160.6 (C-2), 161.1 (d, J = 245.8, C-4'), 162.0 (C-7). [Plate 44]. HRMS 
(ESI+): Found [M+Na]+ 279.0434, Calc. for C15H9FNaO3 279.0433. 











To a mixture of phloroglucinol (2.3 g, 18 mmol) and methyl 4-fluorobenzoylacetate (3.5 g, 
18 mmol) was added conc. H2SO4 (8 mL, 75%). The temperature of a stirred mixture was 
increased to 35 °C. After stirring for 5 h, the mixture was poured into crushed ice and 
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neutralized with a NaOH solution. The mixture was filtered under vacuum and the residue 
was washed with plenty of water. The resulting product was purified by silica gel column 
chromatography with 70% EtOAc in hexanes as eluent and 4.93 was obtained as a light 
brown solid (4.7 g, 97%), mp 266-266 °C, TLC Rf 0.45 (Hexanes-EtOAc, 3:2). 1H NMR 
(400 MHz, DMSO-d6) 5.76 (1H, s, H-3), 6.16 (1H, d, J = 2.3, H-6), 6.26 (1H, d, J = 2.3, 
H-8), 7.18 (2H, m, H-3',5'), 7.37 (2H, m, H-2',6'), 10.18 (1H, s, 7-OH), 10.44 (1H, s, 5-
OH). 13C NMR (100 MHz, DMSO-d6) 95.2 (C-8), 99.6 (C-6), 101.0 (C-4a), 110.8 (C-3), 
114.6 (d, J = 22.1, C-3',5'), 130.1 (d, J = 8.6, C-2',6'), 136.2 (d, J = 2.8, C-1'), 155.4 (C-4), 
157.2 (C-8a), 157.5 (C-5), 160.3 (C-2), 162.2 (C-7), 162.4 (d, J = 243.5, C-4'). [Plate 48]. 
HRMS (ESI+): Found [M+Na]+ 295.0386, Calc. for C15H9FNaO4 295.0383. 







To a mixture of resorcinol (4.0 g, 36 mmol) and ethyl acetoacetate (4.7 g, 36 mmol) was 
added conc. H2SO4 (10 mL, 75%). The temperature of a stirred mixture was increased to 
50 °C. After stirring for 2 h, the mixture was poured into crushed ice and neutralized with a 
NaOH solution. The mixture was filtered under vacuum and the residue was washed with 
plenty of water. The resulting product was purified by silica gel column chromatography 
with 70% EtOAc in hexanes as eluent and 4.94 was obtained as a light yellow solid (5.8 g, 
92%), mp 184-186 °C (lit.229 182-184 ºC), TLC Rf 0.46 (Hexanes-EtOAc, 3:2). 1H NMR 
(400 MHz, DMSO-d6) 2.35 (3H, d, J = 1.1, CH3), 6.10 (1H, d, J = 1.1, H-3), 6.69 (1H, d, J 
= 2.3, H-8), 6.79 (1H, dd, J = 8.6, 2.3, H-6), 7.57 (1H, d, J = 8.6, H-5). 13C NMR (100 
MHz, DMSO-d6) 18.3 (CH3), 102.4 (C-8), 110.4 (C-3), 112.2 (C-6), 113.1 (C-4a), 126.8 
(C-5), 153.8 (C-4), 155.1 (C-8a), 160.6 (C-2), 161.4 (C-7). [Plate 49]. HRMS (ESI+): 
Found [M+Na]+ 199.0368, Calc. for C10H8NaO3 199.0371. 
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To a mixture of phloroglucinol (4.5 g, 36 mmol) and ethyl acetoacetate (4.7 g, 36 mmol) 
was added conc. H2SO4 (10 mL, 75%). The temperature of a stirred mixture was increased 
to 50 °C. After stirring for 3 h, the mixture was poured into crushed ice and neutralized 
with a NaOH solution. The mixture was filtered under vacuum and the residue was washed 
with plenty of water. The resulting product was purified by silica gel column 
chromatography with 70% EtOAc in hexanes as eluent and 4.95 was obtained as a cream-
white solid (6.8 g, 98%), mp 290-293 °C (lit.230 286-288 ºC), TLC Rf 0.38 (Hexanes-
EtOAc, 3:2). 1H NMR (400 MHz, DMSO-d6) 2.48 (3H, d, J = 1.1, CH3), 5.83 (1H, d, J = 
1.1, H-3), 6.16 (1H, d, J = 2.3, H-6), 6.25 (1H, d, J = 2.3, H-8), 10.36 (1H, bs, 7-OH), 
10.47 (1H, bs, 5-OH). 13C NMR (100 MHz, DMSO-d6) 23.9 (CH3), 95.0 (C-8), 99.6 (C-3), 
102.6 (C-4a), 109.3 (C-6), 155.5 (C-4), 156.9 (C-8a), 158.4 (C-5), 160.6 (C-2), 161.5 (C-
7). [Plate 51]. HRMS (ESI+): Found [M+Na]+ 215.0321, Calc. for C10H8NaO4 215.0320. 







To a mixture of 4-hydroxyphenol (4.0 g, 36 mmol) and ethyl acetoacetate (4.7 g, 36 mmol) 
was added conc. H2SO4 (10 mL, 75%). The temperature of a stirred mixture was increased 
to 95 °C. After stirring for 2 h, the mixture was poured into crushed ice and neutralized 
with a NaOH solution. The mixture was filtered under vacuum and the residue was washed 
with plenty of water. The resulting product was purified by silica gel column 
chromatography with 70% EtOAc in hexanes as eluent and 4.96 was obtained as a grey 
solid (4.6 g, 72%), mp 222-225 °C, TLC Rf 0.40 (Hexanes-EtOAc, 3:2). 1H NMR (400 
MHz, DMSO-d6) 2.37 (3H, d, J = 1.2, CH3), 6.34 (1H, d, J = 1.2, H-3), 7.02 (1H, d, J = 
2.7, H-5), 7.04 (1H, dd, J = 9.6, 2.7, H-7), 7.23 (1H, d, J = 9.6, H-8), 9.76 (1H, s, 4-OH). 
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13C NMR (100 MHz, DMSO-d6) 18.5 (CH3), 110.0 (C-4a), 110.1 (C-5), 114.9 (C-3), 117.8 
(C-8), 120.2 (C-7), 146.7 (C-8a), 153.3 (C-4), 154.4 (C-6), 160.5 (C-2). [Plate 50]. HRMS 
(ESI+): Found [M+Na]+ 199.0372, Calc. for C10H8NaO3 199.0371. 
 
 
CHAPTER 5.  CONCLUSION 
 
The aim of this research was to develop methods to prepare fluorine-containing natural 
products. A library of fluorine-containing prenylated benzophenones and fluorine-
substituted 4-phenylcoumarins were successfully synthesized in this research. 
The structures of the targeted benzophenones that were synthesized were based on 
bioactive benzophenones isolated from South African Hypericum species, viz. geranyl-
2,4,6-trihydroxybenzophenone (3.8). Friedel-Crafts acylation and electrophilic aromatic 
substitution reactions were the key reactions in this synthesis to achieve the targeted 
fluorinated prenylated benzophenones and 27 prenylated benzophenones were successfully 
synthesized in this study.  The compounds prepared include four monoprenyl-, seven 
diprenyl-, five triprenyl-, two tetraprenyl-, three monogeranyl-, three digeranyl-, two 
trigeranyl- and one tetrageranyl benzophenone. 
The Friedel-Crafts acylation of phloroglucinol is a reaction with low selectivity and thus 
protection of the hydroxy groups was essential to obtain the acylated product in high yield. 
The reactivities of benzoyl chloride and 2-, 3- of 4-fluorobenzoyl chloride in the Friedel-
Crafts reactions were similar and almost quantitative yields were observed. In the 
prenylation step, the 2-fluorobenzophenone derivative was less reactive than the other 
substrates and this is most likely a result of increased electron-withdrawing effect the 2-
fluoro derivative on the adjacent aromatic ring. 
In general C-prenylation of the benzophenones was obtained with DBU as a base, whereas 
the use of K2CO3 as a base resulted in O-prenylation. 
Fluorine-substituted 4-phenylcoumarins were synthesized by the application of the 
Pechmann reaction (a palladium-free method). In the first step of this reaction, fluorine-
substituted 4-aryl β-ketoesters (the precursors) were synthesized by a new method which 
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gave good yields. Fluorine-substituted neoflavones were successfully synthesized by the 
Pechmann reaction using fluorine-substituted 4-aryl β-ketoesters. A total of 11 coumarins 
(four monohydroxy- and four dihydroxy- neoflavones and three 4-methylcoumarins) were 
synthesized by our newly developed method. 
Some of the benzophenones (3.75, 3.77, 3.81, 3.83, 3.87, 3.88, 3.89 and 3.90) and 
coumarins (4.83, 4.87, 4.88, 4.89, 4.90, 4.91, 4.92 and 4.93) were assayed for HIV activity 
in the MINTEK laboratories at a concentration of 10 µg.mL-1 but none of them show any 
activity at this concentration. Antimicrobial and cytotoxic activities of the compounds are 
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Plate 51. 1H and 13C NMR spectra of 5,7-dihydroxy-4-methylcoumarin (4.95). 
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